Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 1.5.1.3 - dihydrofolate reductase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acquired Immunodeficiency Syndrome
2,4-Diaminothieno[2,3-d]pyrimidine analogues of trimetrexate and piritrexim as potential inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
6-Substituted 2,4-diaminopyrido[3,2-d]pyrimidine analogues of piritrexim as inhibitors of dihydrofolate reductase from rat liver, Pneumocystis carinii, and Toxoplasma gondii and as antitumor agents.
Application of DNA amplification to pneumocystosis: presence of serum Pneumocystis carinii DNA during human and experimentally induced Pneumocystis carinii pneumonia.
Computer modeling studies of the structural role of NADPH binding to active site mutants of human dihydrofolate reductase in complex with piritrexim.
Conformationally restricted analogues of trimethoprim: 2,6-diamino-8-substituted purines as potential dihydrofolate reductase inhibitors from Pneumocystis carinii and Toxoplasma gondii.
Correlations of Inhibitor Kinetics for Pneumocystis jirovecii and Human Dihydrofolate Reductase with Structural Data for Human Active Site Mutant Enzyme Complexes (dagger) (double dagger).
Design, synthesis, and biological evaluation of 2,4-diamino-5-methyl-6-substituted-pyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors.
Diagnosis of Pneumocystis carinii pneumonia in AIDS patients by using polymerase chain reactions on serum specimens.
Exploring novel strategies for AIDS protozoal pathogens: ?-helix mimetics targeting a key allosteric protein-protein interaction in C. hominis TS-DHFR.
Further studies on 2,4-diamino-5-(2',5'-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three major opportunistic pathogens of AIDS.
Lipophilic antifolate trimetrexate is a potent inhibitor of Trypanosoma cruzi: prospect for chemotherapy of Chagas' disease.
New 2,4-diamino-5-(2',5'-substituted benzyl)pyrimidines as potential drugs against opportunistic infections of AIDS and other immune disorders. Synthesis and species-dependent antifolate activity.
Potential antifolate resistance determinants and genotypic variation in the bifunctional dihydrofolate reductase-thymidylate synthase gene from human and bovine isolates of Cryptosporidium parvum.
Primary structure of the dihydrofolate reductase-thymidylate synthase gene from Toxoplasma gondii.
Salvage trial of trimetrexate-leucovorin for the treatment of cerebral toxoplasmosis in patients with AIDS.
Structure-based design of selective inhibitors of dihydrofolate reductase: synthesis and antiparasitic activity of 2, 4-diaminopteridine analogues with a bridged diarylamine side chain.
Synthesis and antiparasitic and antitumor activity of 2, 4-diamino-6-(arylmethyl)-5,6,7,8-tetrahydroquinazoline analogues of piritrexim.
Synthesis and dihydrofolate reductase inhibitory activities of 2,4-diamino-5-deaza and 2,4-diamino-5,10-dideaza lipophilic antifolates.
Synthesis of 2,4-diamino-6-[2'-O-(omega-carboxyalkyl)oxydibenz[b,f]azepin-5-yl]methylpteridines as potent and selective inhibitors of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductase.
Synthesis of new 2,4-Diaminopyrido[2,3-d]pyrimidine and 2,4-Diaminopyrrolo[2,3-d]pyrimidine inhibitors of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductase.
Wnt/?-catenin aids in regulating the proliferation of hepG2 cells mediated by thy-1.
[Acute pancytopenia induced by pyrimethamine during treatment of cerebral toxoplasmosis associated with AIDS. Role of dihydrofolate reductase inhibitors]
Acute Kidney Injury
Commiphora molmol protects against methotrexate-induced nephrotoxicity by up-regulating Nrf2/ARE/HO-1 signaling.
Adenocarcinoma
Permissivity for methotrexate-induced DHFR gene amplification correlates with the metastatic potential of rat adenocarcinoma cells.
Thy-1 antigen on normal and neoplastic rat mammary tissues: changes in location and amount of antigen during differentiation of cultured stem cells.
X-aptamers targeting Thy-1 membrane glycoprotein in pancreatic ductal adenocarcinoma.
Adenocarcinoma of Lung
Thy-1(+) Cancer-associated Fibroblasts Adversely Impact Lung Cancer Prognosis.
TS expression predicts postoperative recurrence in adenocarcinoma of the lung.
Adenomatous Polyps
Gene-Nutrient Interaction between Folate and Dihydrofolate Reductase in Risk for Adenomatous Polyp Occurrence: A Preliminary Report.
Adenoviridae Infections
Control of cellular gene expression during adenovirus infection: induction and shut-off of dihydrofolate reductase gene expression by adenovirus type 2.
Posttranscriptional control of DHFR gene expression during adenovirus 2 infection.
Adrenoleukodystrophy
Genetic variants of methionine metabolism and X-ALD phenotype generation: results of a new study sample.
AIDS-Related Opportunistic Infections
Exploring novel strategies for AIDS protozoal pathogens: ?-helix mimetics targeting a key allosteric protein-protein interaction in C. hominis TS-DHFR.
Albuminuria
Chronic anti-Thy-1 nephritis is aggravated in the nonclipped but not in the clipped kidney of Goldblatt hypertensive rats.
Alveolitis, Extrinsic Allergic
Absence of Thy-1 results in TGF-? induced MMP-9 expression and confers a profibrotic phenotype to human lung fibroblasts.
Alzheimer Disease
Molecular cloning of human cDNA with a sequence highly similar to that of the dihydrofolate reductase gene in brain libraries derived from Alzheimer's disease patients.
Neuropeptide alterations in the hippocampal formation and cortex of transgenic mice overexpressing beta-amyloid precursor protein (APP) with the Swedish double mutation (APP23).
Regional brain cytochrome oxidase activity in beta-amyloid precursor protein transgenic mice with the Swedish mutation.
Thy-1 in hippocampus: normal anatomy and neuritic growth in Alzheimer's disease.
Amebiasis
Pharmacokinetic justification of antiprotozoal therapy. A US perspective.
Amnesia
Inhibition of long-term memory formation in the chicken by anti chick Thy-1 antibody.
Inhibition of memory in the chick using a monoclonal anti-Thy-1 antibody.
Purified antichick Thy-1 IgG abolishes intermediate and long-term memory.
Amyloidosis
Neuropeptide alterations in the hippocampal formation and cortex of transgenic mice overexpressing beta-amyloid precursor protein (APP) with the Swedish double mutation (APP23).
Anemia
Anemia in a line of transgenic mice carrying a mutant dihydrofolate reductase gene.
Identification and characterization of an inborn error of metabolism caused by dihydrofolate reductase deficiency.
Plasmodium falciparum dihydrofolate reductase alleles and pyrimethamine use in pregnant Ghanaian women.
Anemia, Megaloblastic
Congenital errors of folate metabolism.
Dihydrofolate reductase deficiency causing megaloblastic anemia in two families.
Dihydrofolate reductase deficiency due to a homozygous DHFR mutation causes megaloblastic anemia and cerebral folate deficiency leading to severe neurologic disease.
Dihydrofolate reductase mutations-associated megaloblastic anemia and cerebral folate deficiency.
Drug-induced anaemias.
Hereditary dihydrofolate reductase deficiency with megaloblastic anemia.
Identification and characterization of an inborn error of metabolism caused by dihydrofolate reductase deficiency.
Update and new concepts in vitamin responsive disorders of folate transport and metabolism.
Anemia, Refractory
Flow cytometric analysis of Thy-1 expression in myelodysplastic syndrome.
Anemia, Refractory, with Excess of Blasts
Flow cytometric analysis of Thy-1 expression in myelodysplastic syndrome.
Anencephaly
Impaired retinal vascular development in anencephalic human fetus.
Maternal association and influence of DHFR 19?bp deletion variant predisposes foetus to anencephaly susceptibility: a family-based triad study.
Aneurysm
Targeting feed-forward signaling of TGF?/NOX4/DHFR/eNOS uncoupling/TGF? axis with anti-TGF? and folic acid attenuates formation of aortic aneurysms: Novel mechanisms and therapeutics.
Anthrax
Crystal structure of the anthrax drug target, Bacillus anthracis dihydrofolate reductase.
Using molecular docking, 3D-QSAR, and cluster analysis for screening structurally diverse data sets of pharmacological interest.
X-ray structure of the ternary MTX.NADPH complex of the anthrax dihydrofolate reductase: a pharmacophore for dual-site inhibitor design.
Aortic Aneurysm, Abdominal
Knockout of dihydrofolate reductase in mice induces hypertension and abdominal aortic aneurysm via mitochondrial dysfunction.
Targeting MicroRNA-192-5p, a Downstream Effector of NOXs (NADPH Oxidases), Reverses Endothelial DHFR (Dihydrofolate Reductase) Deficiency to Attenuate Abdominal Aortic Aneurysm Formation.
Arthritis
Characterization of monoclonal antibodies against a human chondrocyte surface antigen.
Methotrexate in rheumatoid arthritis: studies with animal models.
Structure of macrophage migration inhibitory factor in complex with methotrexate.
Arthritis, Juvenile
Light activates reduction of methotrexate by NADPH in the ternary complex with Escherichia coli dihydrofolate reductase.
Arthritis, Rheumatoid
677C>T and 1298A>C MTHFR polymorphisms affect methotrexate treatment outcome in rheumatoid arthritis.
Antifolates in rheumatoid arthritis: a hypothetical mechanism of action.
Association of 63/91 length polymorphism in the DHFR gene major promoter with toxicity of methotrexate in patients with rheumatoid arthritis.
Association of C35T polymorphism in dihydrofolate reductase gene with toxicity of methotrexate in rheumatoid arthritis patients.
Association of dihydrofolate reductase (DHFR) -317AA genotype with poor response to methotrexate in patients with rheumatoid arthritis.
Detection of human soluble Thy-1 in serum by ELISA. Fibroblasts and activated endothelial cells are a possible source of soluble Thy-1 in serum.
Dihydrofolate reductase gene intronic 19-bp deletion polymorphisms in a Japanese population.
Effect of the GPI anchor of human Thy-1 on antibody recognition and function.
Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients.
Increase of dihydrofolate reductase in peripheral blood lymphocytes of rheumatoid arthritis patients treated with low-dose oral methotrexate.
Methotrexate impacts conserved pathways in diverse human gut bacteria leading to decreased host immune activation.
miRNA-24 Gene Sequence, DHFR -829C-T Genotypes, and Methotrexate Response in Mexican Patients with Rheumatoid Arthritis.
Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis.
[A Case of Crohn's Disease Showing Favorable Response to Induction and Maintenance Therapy with Methotrexate after Failure of Anti-tumor Necrosis Factor Therapy].
Astrocytoma
Activated lymphoid cells in human gliomas: morphofunctional and cytochemical evidence.
Differential expression of cell surface antigens and glial fibrillary acidic protein in human astrocytoma subsets.
Asymptomatic Infections
Carriage of Mutant Dihydrofolate Reductase and Dihydropteroate Synthase Genes among Plasmodium falciparum Isolates Recovered from Pregnant Women with Asymptomatic Infection in Lagos, Nigeria.
High prevalence of sulphadoxine-pyrimethamine resistance-associated mutations in Plasmodium falciparum field isolates from pregnant women in Brazzaville, Republic of Congo.
Impact of trimethoprim-sulfamethoxazole prophylaxis on falciparum malaria infection and disease.
Molecular determination of point mutation haplotypes in the dihydrofolate reductase and dihydropteroate synthase of Plasmodium falciparum in three districts of northern Tanzania.
Ataxia
Similarities between human ataxia fibroblasts and murine SCID cells: high sensitivity to gamma rays and high frequency of methotrexate-induced DHFR gene amplification, but normal radiosensitivity to densely ionizing alpha particles.
Ataxia Telangiectasia
DHFR gene amplification in cultured skin fibroblasts of ataxia telangiectasia patients after methotrexate selection.
Investigations into the molecular effects of single nucleotide polymorphism.
Mice lacking the cell adhesion molecule Thy-1 fail to use socially transmitted cues to direct their choice of food.
Radiation-induced gene amplification in rodent and human cells.
Similarities between human ataxia fibroblasts and murine SCID cells: high sensitivity to gamma rays and high frequency of methotrexate-induced DHFR gene amplification, but normal radiosensitivity to densely ionizing alpha particles.
Atherosclerosis
Regulation of endothelial cell tetrahydrobiopterin pathophysiological and therapeutic implications.
Tetrahydrobiopterin prevents chronic ischemia-related lower urinary tract dysfunction through the maintenance of nitric oxide bioavailability.
Autoimmune Diseases
Enhanced degradation of dihydrofolate reductase through inhibition of NAD kinase by nicotinamide analogs.
Evaluation of ototoxicity of intratympanic administration of Methotrexate in rats.
Much more than you expected: The non-DHFR-mediated effects of methotrexate.
Phase II trial of methotrexate in myasthenia gravis.
Simple and Reliable HPLC Method for the Monitoring of Methotrexate in Osteosarcoma Patients.
The keratan sulfate disaccharide Gal(6S03) beta1,4-GlcNAc(6S03) modulates interleukin 12 production by macrophages in murine Thy-1 type autoimmune disease.
The Transgenic Zebrafish Display Fluorescence Reflecting the Expressional Dynamics of Dihydrofolate Reductase.
Vitamin B17 Ameliorates Methotrexate-Induced Reproductive Toxicity, Oxidative Stress, and Testicular Injury in Male Rats.
Babesiosis
Inhibitor-bound complexes of dihydrofolate reductase-thymidylate synthase from Babesia bovis.
Bacterial Infections
3-Methyl-imidazo[2,1-b]thiazole derivatives as a new class of antifolates: Synthesis, in vitro/in vivo bio-evaluation and molecular modeling simulations.
Analysis of Coxiela burnetti dihydrofolate reductase via in silico docking with inhibitors and molecular dynamics simulation.
Dihydrofolate reductase inhibitors for use as antimicrobial agents.
Identification of novel Mycobacterium tuberculosis dihydrofolate reductase inhibitors through rational drug design.
Inhibitors of dihydrofolate reductase in Leishmania and trypanosomes.
Kinetic and structural characterization of dihydrofolate reductase from Streptococcus pneumoniae.
Mutational 'hot-spots' in mammalian, bacterial and protozoal dihydrofolate reductases associated with antifolate resistance: sequence and structural comparison.
Structural comparison of chromosomal and exogenous dihydrofolate reductase from Staphylococcus aureus in complex with the potent inhibitor trimethoprim.
Structural studies provide clues for analog design of specific inhibitors of Cryptosporidium hominis thymidylate synthase-dihydrofolate reductase.
Structure-based design of new DHFR-based antibacterial agents: 7-aryl-2,4-diaminoquinazolines.
Biliary Atresia
Isolation of Hepatic Progenitor Cells From Human Liver With Cirrhosis Secondary to Biliary Atresia Using EpCAM or Thy-1 Markers.
Blast Crisis
Characterization of Thy-1 (CDw90) expression in CD34+ acute leukemia.
Histochemical demonstration of tetrahydrofolate dehydrogenase in blast crisis of chronic myeloid leukaemia.
Blister
Human pharmacokinetics and skin blister levels of sulfonamides and dihydrofolate reductase inhibitors.
Bone Resorption
Thy-1 Deficiency Augments Bone Loss in Obesity by Affecting Bone Formation and Resorption.
Brain Diseases
Decreased cell surface prion protein in mouse models of prion disease.
Brain Neoplasms
Dihydrofolate reductase activity in primary brain tumors in children.
Dihydrofolate reductase in primary brain tumors, cell cultures of central nervous system origin, and normal brain during fetal and neonatal growth.
Inhibition of DHFR targets the self-renewing potential of brain tumor initiating cells.
Natural resistance to methotrexate in human melanomas.
Breast Neoplasms
5' Nucleotide sequences influence serum-modulated expression of a human dihydrofolate reductase minigene.
A functional 19-base pair deletion polymorphism of dihydrofolate reductase (DHFR) and risk of breast cancer in multivitamin users.
A-to-I RNA Editing Up-regulates Human Dihydrofolate Reductase in Breast Cancer.
Association between HIC1 and RASSF1A promoter hypermethylation with MTHFD1 G1958A polymorphism and clinicopathological features of breast cancer in Iranian patients.
Chapter 4 molecular mechanisms of adaptation to folate deficiency.
CODING POLYPURINE HAIRPINS CAUSE TARGET-INDUCED CELL DEATH IN BREAST CANCER CELLS.
Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells.
Design, synthesis of methotrexate-diosgenin conjugates and biological evaluation of their effect on methotrexate transport-resistant cells.
Development and effects of immunoliposomes carrying an antisense oligonucleotide against DHFR RNA and directed toward human breast cancer cells overexpressing HER2.
Dihydrofolate reductase (DHRF) 19-bp intron-1 deletion and methylenetetrahydrofolate reductase (MTHFR) C677T polymorphisms in breast cancer.
Dihydrofolate reductase gene amplification and possible rearrangement in estrogen-responsive methotrexate-resistant human breast cancer cells.
Effects of estrogen and tamoxifen on the regulation of dihydrofolate reductase gene expression in a human breast cancer cell line.
Effects on dihydrofolate reductase of methotrexate metabolites and intracellular folates formed following methotrexate exposure of human breast cancer cells.
Evaluation of UDP-glucuronosyltransferase 2B17 (UGT2B17) and dihydrofolate reductase (DHFR) genes deletion and the expression level of NGX6 mRNA in breast cancer.
Expression of the adhesion molecules CD49d and CD49e on G-CSF-mobilized CD34+ cells of patients with solid tumors or non-Hodgkin's and Hodgkin's lymphoma and of healthy donors is inversely correlated with the amount of mobilized CD34+ cells.
Insulin effects on methotrexate polyglutamate synthesis and enzyme binding in cultured human breast cancer cells.
Interaction of methotrexate polyglutamates and dihydrofolate during leucovorin rescue in a human breast cancer cell line (MCF-7).
Intracellular pharmacokinetics of methotrexate polyglutamates in human breast cancer cells. Selective retention and less dissociable binding of 4-NH2-10-CH3-pteroylglutamate4 and 4-NH2-10-CH3-pteroylglutamate5 to dihydrofolate reductase.
Liposomal M-V-05: formulation development and activity testing of a novel dihydrofolate reductase inhibitor for breast cancer therapy.
Mithramycin inhibits SP1 binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo.
Multi-Targeted Anticancer Activity of Imidazolate Phosphane Gold(I) Compounds by Inhibition of DHFR and TrxR in Breast Cancer Cells.
Pemetrexed: translational research in breast cancer.
Plasma B-vitamins and one-carbon metabolites and the risk of breast cancer in younger women.
Polypurine hairpins directed against the template strand of DNA knock down the expression of mammalian genes.
Preferential platination of an activated cellular promoter by cis-diamminedichloroplatinum.
Regulation of dihydrofolate reductase in human breast cancer cells and in mutant hamster cells transfected with a human dihydrofolate reductase minigene.
Sanguinarine suppresses basal-like breast cancer growth through dihydrofolate reductase inhibition.
Schedule-dependent synergism of taxol or taxotere with edatrexate against human breast cancer cells in vitro.
Synthesis and biological activity of N omega-hemiphthaloyl-alpha,omega- diaminoalkanoic acid analogues of aminopterin and 3',5-dichloroaminopterin.
Synthesis, antifolate, and antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines.
Synthesis, binding and intracellular retention of methotrexate polyglutamates by cultured human breast cancer cells.
The effect of folate-related SNPs on clinicopathological features, response to neoadjuvant treatment and survival in pre- and postmenopausal breast cancer patients.
Thy-1 (CD90)-Induced Metastatic Cancer Cell Migration and Invasion Are ?3 Integrin-Dependent and Involve a Ca2+/P2X7 Receptor Signaling Axis.
Translational research with pemetrexed in breast cancer.
Burkitt Lymphoma
Histone deacetylase inhibition enhances the therapeutic effects of methotrexate on primary central nervous system lymphoma.
Carcinogenesis
A polycistronic transcript in transformed cells encodes the dihydrofolate reductase of herpesvirus saimiri.
Acetylshikonin isolated from Lithospermum erythrorhizon roots inhibits dihydrofolate reductase and hampers autochthonous mammary carcinogenesis in ?16HER2 transgenic mice.
Restoration of gap-junctional intercellular communication in a communication-deficient rat liver cell mutant by transfection with connexin 43 cDNA.
Up-regulation of thy-1 promotes invasion and metastasis of hepatocarcinomas.
Carcinoma
A comparison of dihydrofolate reductase activity in intact leukemia cells and squamous cell carcinoma.
A comparison of the effects of antitumor agents upon normal human epidermal keratinocytes and human squamous cell carcinoma.
A second target of benzamide riboside: Dihydrofolate reductase.
A Tribute to Bruce Chabner.
Amplification of a polymorphic dihydrofolate reductase gene expressing an enzyme with decreased binding to methotrexate in a human colon carcinoma cell line, HCT-8R4, resistant to this drug.
Applying the designed multiple ligands approach to inhibit dihydrofolate reductase and thioredoxin reductase for anti-proliferative activity.
Characterization of the metabolism of perinecrotic cells in solid tumors by enzyme histochemistry.
Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells.
Developmental pattern of Thy-1 immunoreactivity in the human kidney and the application to pediatric renal neoplasms.
Differential alterations of dihydrofolate reductase gene in human leukemia cell lines made resistant to various folate analogues.
Differential expression of the human Thy-1 gene in rodent-human somatic cell hybrids [corrected]
Dihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates: correlates of cytotoxicity toward methotrexate-sensitive and -resistant human head and neck squamous carcinoma cells.
Effect of bridge region variation on antifolate and antitumor activity of classical 5-substituted 2,4-diaminofuro[2,3-d]pyrimidines.
Expression of Thy-1 antigen on human melanoma cells.
Histoenzymological study on desquamative cervico-vaginal cells.
INTERACTION OF ORGANIC MERCURIAL COMPOUNDS WITH DIHYDROFOLATE REDUCTASE FROM EHRLICH ASCITES CARCINOMA CELLS.
Mechanisms for cisplatin-FUra synergism and cisplatin resistance in human ovarian carcinoma cells both in vitro and in vivo.
Methotrexate analogues. 25. Chemical and biological studies on the gamma-tert-butyl esters of methotrexate and aminopterin.
Procion dyes as affinity ligands and reporter groups for dihydrofolate reductase from Walker 256 carcinoma.
PURIFICATION AND PROPERTIES OF DIHYDROFOLATE REDUCTASE FROM EHRLICH ASCITES CARCINOMA CELLS.
Resistance mechanisms and their regulation in lung cancer.
Synergy between the NAMPT inhibitor GMX1777(8) and pemetrexed in non-small cell lung cancer cells is mediated by PARP activation and enhanced NAD consumption.
Synthesis and antitumor activity of pyrrolo[2,3-d]pyrimidine antifolates with a bridge chain containing a nitrogen atom.
Synthesis and biological activity of N omega-hemiphthaloyl-alpha,omega- diaminoalkanoic acid analogues of aminopterin and 3',5-dichloroaminopterin.
Synthesis, antifolate, and antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines.
THY-1 induction is associated with up-regulation of fibronectin and thrombospondin-1 in human ovarian cancer.
Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: The association with treatment efficacy of pemetrexed.
TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed.
Carcinoma, Ehrlich Tumor
Rapid formation of poly-gamma-glutamyl derivatives of methotrexate and their association with dihydrofolate reductase as assessed by high pressure liquid chromatography in the Ehrlich ascites tumor cell in vitro.
Role of methotrexate polyglutamylation and cellular energy metabolism in inhibition of methotrexate binding to dihydrofolate reductase by 5-formyltetrahydrofolate in Ehrlich ascites tumor cells in vitro.
Role of the cellular oxidation-reduction state in methotrexate binding to dihydrofolate reductase and dissociation induced by reduced folates.
Carcinoma, Embryonal
Differential expression of the mouse and human Thy-1 gene in embryonal carcinoma cells.
The Thy-1 glycoprotein is expressed in mouse embryonal carcinoma cells P19.
Carcinoma, Hepatocellular
A study of chromosomal changes associated with amplified dihydrofolate reductase genes in rat hepatoma cells and their dedifferentiated variants.
Antifolate drug interactions: enhancement of growth inhibition due to the antipurine 5,10-dideazatetrahydrofolic acid by the lipophilic dihydrofolate reductase inhibitors metoprine and trimetrexate.
Biochemical and biological studies on 2-desamino-2-methylaminopterin, an antifolate the polyglutamates of which are more potent than the monoglutamate against three key enzymes of folate metabolism.
Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells.
Biological activity of a novel rationally designed lipophilic thymidylate synthase inhibitor.
Depletion of 5,10-methylenetetrahydrofolate and 10-formyltetrahydrofolate by methotrexate in cultured hepatoma cells.
Effects of anti-sense oligonucleotides directed toward dihydrofolate reductase RNA in mammalian cultured cells.
Heterologous antiserum to chemically induced rat non-T, non-B leukemia and its application to characterization of rat leukemias.
Interaction between Gambogic acid and dihydrofolate reductase and synergistic lethal effects with methotrexate on hepatoma cells.
Methotrexate analogues. 23. Synthesis, dihydrofolate reductase affinity, cytotoxicity, and in vivo antitumor activity of some putative degradation products of methotrexate-poly(L-lysine) conjugates.
Polyglutamylation of the dihydrofolate reductase inhibitor gamma-methylene-10-deazaaminopterin is not essential for antitumor activity.
Purification and characterization of a major glycoprotein in rat hepatoma plasma membranes. One of the membrane proteins released by phosphatidylinositol-specific phospholipase C.
Role of substrate depletion in the inhibition of thymidylate biosynthesis by the dihydrofolate reductase inhibitor trimetrexate in cultured hepatoma cells.
The characteristics and consequences of folate depletion in hepatoma cells in vitro by inhibition of dihydrofolate reductase.
The enhancement of the activity of 10-propargyl-5,8-dideazafolate and 5,10-dideazatetrahydrofolate by inhibitors of dihydrofolate reductase.
The properties of the secreted gamma-glutamyl hydrolases from H35 hepatoma cells.
The role of cellular folates in the enhancement of activity of the thymidylate synthase inhibitor 10-propargyl-5,8-dideazafolate against hepatoma cells in vitro by inhibitors of dihydrofolate reductase.
[Cytochemical study of cells of primary and disseminated ascite Yoshida tumor cells]
Carcinoma, Non-Small-Cell Lung
Association between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancer.
Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer.
MicroRNA-1301-3p promotes the progression of non-small cell lung cancer by targeting Thy-1 and predicts poor prognosis of patients.
Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma.
Plasma thymidylate synthase and dihydrofolate reductase mRNA levels as potential predictive biomarkers of pemetrexed sensitivity in patients with advanced non-small cell lung cancer.
Synergy between the NAMPT inhibitor GMX1777(8) and pemetrexed in non-small cell lung cancer cells is mediated by PARP activation and enhanced NAD consumption.
Synthesis and antitumor activity of pyrrolo[2,3-d]pyrimidine antifolates with a bridge chain containing a nitrogen atom.
Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: The association with treatment efficacy of pemetrexed.
[Abnormal expression of Thy-1 as a novel tumor marker in lung cancer and its prognostic significance]
Carcinoma, Ovarian Epithelial
Dihydrofolate reductase as a predictor for poor response to platinum-based chemotherapy in epithelial ovarian cancer.
Thy-1 predicts poor prognosis and is associated with self-renewal in ovarian cancer.
[Cisplatin resistant effects of dihydrofolate reductase gene expression up-regulation in epithelial ovarian cancer].
Carcinoma, Renal Cell
Developmental pattern of Thy-1 immunoreactivity in the human kidney and the application to pediatric renal neoplasms.
Carcinoma, Squamous Cell
A comparison of dihydrofolate reductase activity in intact leukemia cells and squamous cell carcinoma.
A comparison of the effects of antitumor agents upon normal human epidermal keratinocytes and human squamous cell carcinoma.
Dihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates: correlates of cytotoxicity toward methotrexate-sensitive and -resistant human head and neck squamous carcinoma cells.
Effect of bridge region variation on antifolate and antitumor activity of classical 5-substituted 2,4-diaminofuro[2,3-d]pyrimidines.
Methotrexate analogues. 25. Chemical and biological studies on the gamma-tert-butyl esters of methotrexate and aminopterin.
Synthesis and antitumor activity of pyrrolo[2,3-d]pyrimidine antifolates with a bridge chain containing a nitrogen atom.
Synthesis and biological activity of N omega-hemiphthaloyl-alpha,omega- diaminoalkanoic acid analogues of aminopterin and 3',5-dichloroaminopterin.
Synthesis, antifolate, and antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines.
Carcinosarcoma
Evaluation of 1-(3,4-dichlorophenyl)-4-dimethylaminomethyl-1-nonen-3-one hydrochloride effect on nucleic acid and protein syntheses using murine leukemia L-1210 cells.
Procion dyes as affinity ligands and reporter groups for dihydrofolate reductase from Walker 256 carcinoma.
Purification and characterization of dihydrofolate reductase from Walker 256 carcinosarcoma.
Synthesis and antitumor activity of 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine.
Cardiovascular Diseases
Dihydrofolate reductase and biopterin recycling in cardiovascular disease.
Cataract
The enzymatic activities of GTP cyclohydrolase, sepiapterin reductase, dihydropteridine reductase and dihydrofolate reductase; and tetrahydrobiopterin content in mammalian ocular tissues and in human senile cataracts.
Chagas Disease
Acute Trypanosoma cruzi infection differentially affects CD3 and Thy-1 mediated T cell activation.
Crystallization and preliminary crystallographic studies of dihydrofolate reductase-thymidylate synthase from Trypanosoma cruzi, the Chagas disease pathogen.
Novel inhibitors of Trypanosoma cruzi dihydrofolate reductase.
Synthesis and characterization of potent inhibitors of Trypanosoma cruzi dihydrofolate reductase.
Cholera
Control of Thy-1 glycoprotein expression in cultures of PC12 cells.
Glycosylphosphatidyl inositol-anchored proteins and fyn kinase assemble in noncaveolar plasma membrane microdomains defined by reggie-1 and -2.
Increased intracellular cyclic AMP differentially modulates nerve growth factor induction of three neuronal recognition molecules involved in neurite outgrowth.
Independent mobility of cholera toxin binding sites and Thy-1 alloantigen on mouse thymocytes.
Lipid domain structure of the plasma membrane revealed by patching of membrane components.
Mechanism of catecholamine-mediated destabilization of messenger RNA encoding Thy-1 protein in T-lineage cells.
The relationship between cholera toxin receptor and the Thy-1 antigen determinants.
Chondroma
Roles Of EAAT1, DHFR, And Fetuin-A In The Pathogenesis, Progression And Prognosis Of Chondrosarcoma.
Chondrosarcoma
Roles Of EAAT1, DHFR, And Fetuin-A In The Pathogenesis, Progression And Prognosis Of Chondrosarcoma.
Choriocarcinoma
Dihydrofolate reductase transcript level is not suitable for methotrexate-resistance prediction in choriocarcinoma cell line.
Methotrexate-induced resistance to dactinomycin in choriocarcinoma.
[Fundamental and clinical study of chemotherapy of refractory choriocarcinoma]
[Mechanisms of development of resistance to methotrexate in choriocarcinoma cells]
Choroidal Neovascularization
Influence of verteporfin photodynamic therapy on inflammation in human choroidal neovascular membranes secondary to age-related macular degeneration.
Thy-1 Regulates VEGF-Mediated Choroidal Endothelial Cell Activation and Migration: Implications in Neovascular Age-Related Macular Degeneration.
Cleft Lip
Common polymorphism in the glycine N-methyltransferase gene as a novel risk factor for cleft lip with or without cleft palate.
Evidence of the involvement of the DHFR gene in nonsyndromic cleft lip with or without cleft palate.
The 19-bp deletion polymorphism of dihydrofolate reductase (DHFR) and nonsyndromic cleft lip with or without cleft palate: evidence for a protective role.
Cleft Palate
Common polymorphism in the glycine N-methyltransferase gene as a novel risk factor for cleft lip with or without cleft palate.
Evidence of the involvement of the DHFR gene in nonsyndromic cleft lip with or without cleft palate.
The 19-bp deletion polymorphism of dihydrofolate reductase (DHFR) and nonsyndromic cleft lip with or without cleft palate: evidence for a protective role.
Coinfection
High resolution melting: a useful field-deployable method to measure dhfr and dhps drug resistance in both highly and lowly endemic Plasmodium populations.
Plasmodium falciparum DHFR and DHPS Mutations Are Associated With HIV-1 Co-Infection and a Novel DHPS Mutation I504T Is Identified in Western Kenya.
Colitis
Design and synthesis of dihydrofolate reductase inhibitors encompassing a bridging ester group. Evaluation in a mouse colitis model.
Colonic Neoplasms
Antitumor Therapy Based on Cellular Competition.
Association of MTHFR, MTR, MTRR, RFC1, and DHFR Gene Polymorphisms with Susceptibility to Sporadic Colon Cancer.
Cells exposed to antifolates show increased cellular levels of proteins fused to dihydrofolate reductase: a method to modulate gene expression.
Characterization of a cis-acting regulatory element in the protein-coding region of human dihydrofolate reductase mRNA.
Dihydrofolate reductase amplification and sensitization to methotrexate of methotrexate-resistant colon cancer cells.
Effects of 5,8-dideazaisopteroylglutamate and its possible tri-gamma-glutamyl metabolite (5,8-dideazaisoPteGlu3) on colon adenocarcinoma, and the folate dependent enzymes thymidylate synthase and dihydrofolate reductase.
Genomic and transcriptomic analyses reveal a tandem amplification unit of 11 genes and mutations in mismatch repair genes in methotrexate-resistant HT-29 cells.
Human dihydrofolate reductase and thymidylate synthase form a complex in vitro and co-localize in normal and cancer cells.
Novel role for non-homologous end joining in the formation of double minutes in methotrexate-resistant colon cancer cells.
Colorectal Neoplasms
A candidate gene study of folate-associated one carbon metabolism genes and colorectal cancer risk.
Antiproliferative effect of a lectin- and anti-Thy-1.2 antibody-targeted HPMA copolymer-bound doxorubicin on primary and metastatic human colorectal carcinoma and on human colorectal carcinoma transfected with the mouse Thy-1.2 gene.
Early disease relapse in a patient with colorectal cancer who harbors genetic variants of DPYD, TYMS, MTHFR and DHFR after treatment with 5-fluorouracil-based chemotherapy.
Imaging of dihydrofolate reductase fusion gene expression in xenografts of human liver metastases of colorectal cancer in living rats.
Mismatch repair deficiency in ovarian cancer -- molecular characteristics and clinical implications.
mRNA expression levels of E2F transcription factors correlate with dihydrofolate reductase, reduced folate carrier, and thymidylate synthase mRNA expression in osteosarcoma.
New agents for colon and breast cancer.
Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer.
Selective killing of contaminating human fibroblasts in epithelial cultures derived from colorectal tumours using an anti Thy-1 antibody-ricin conjugate.
Communicable Diseases
Analysis of Coxiela burnetti dihydrofolate reductase via in silico docking with inhibitors and molecular dynamics simulation.
Antifolate agents: a patent review (2010 - 2013).
Dihydrofolate reductase as a therapeutic target for infectious diseases: opportunities and challenges.
Enhanced degradation of dihydrofolate reductase through inhibition of NAD kinase by nicotinamide analogs.
Inhibitors of dihydrofolic acid reductase in the therapy of infectious diseases.
Pharmacoinformatic Study on the Selective Inhibition of the Protozoan Dihydrofolate Reductase Enzymes.
Repositioning of DHFR Inhibitors.
Using a Fragment-Based Approach to Identify Alternative Chemical Scaffolds Targeting Dihydrofolate Reductase from Mycobacterium tuberculosis.
Community-Acquired Infections
Structural comparison of chromosomal and exogenous dihydrofolate reductase from Staphylococcus aureus in complex with the potent inhibitor trimethoprim.
Confusion
Expression of the Thy-1 gene in human T lymphoid cell lines.
Congenital Abnormalities
Chemical teratogenesis in humans: biochemical and molecular mechanisms.
Folic acid antagonist use before and during pregnancy and risk for selected birth defects.
Methotrexate-resistant form of dihydrofolate reductase protects transgenic murine embryos from teratogenic effects of methotrexate.
Crohn Disease
Design and synthesis of dihydrofolate reductase inhibitors encompassing a bridging ester group. Evaluation in a mouse colitis model.
Cryptosporidiosis
Highly efficient ligands for dihydrofolate reductase from Cryptosporidium hominis and Toxoplasma gondii inspired by structural analysis.
Potential antifolate resistance determinants and genotypic variation in the bifunctional dihydrofolate reductase-thymidylate synthase gene from human and bovine isolates of Cryptosporidium parvum.
Targeting DHFR in parasitic protozoa.
Cysts
Culture of tissue-cyst forming strain of Toxoplasma gondii and the effect of cyclic AMP and pyrimidine salvage inhibitors.
Synergistic combinations of Ro 11-8958 and other dihydrofolate reductase inhibitors with sulfamethoxazole and dapsone for therapy of experimental pneumocystosis.
Cytomegalovirus Infections
Downregulation of the cellular adhesion molecule Thy-1 (CD90) by cytomegalovirus infection of human fibroblasts.
E2F mediates dihydrofolate reductase promoter activation and multiprotein complex formation in human cytomegalovirus infection.
THY-1 Cell Surface Antigen (CD90) Has an Important Role in the Initial Stage of Human Cytomegalovirus Infection.
Dehydration
Plasticity of neurohypophysial terminals with increased hormonal release during dehydration: ultrastructural and biochemical analyses.
Demyelinating Diseases
A novel approach to 32-channel peripheral nervous system myelin imaging in vivo, with single axon resolution.
Acute leukoencephalopathy due to pyrimethamine. An insight into methotrexate neurotoxicity?
Dermatitis
[The role of immunity on the development of dermatitis in NC mice]
Dermatitis, Contact
Changes in expression of Ia, Thy-1, and Ly-5 antigens in epidermal cells during delayed contact sensitivity reactions in mice: flow cytometric analysis.
Diabetes Mellitus, Type 1
High-resolution linkage mapping for susceptibility genes in human polygenic disease: insulin-dependent diabetes mellitus and chromosome 11q.
Non-HLA genetic factors and insulin dependent diabetes mellitus in the Japanese: TCRA, TCRB and TCRG, INS, THY1, CD3D and ETS1.
dihydrofolate reductase deficiency
Conditional dihydrofolate reductase deficiency due to transposon Tn5tac1 insertion downstream from the folA gene in Escherichia coli.
Congenital errors of folate metabolism.
Construction of a dihydrofolate reductase-deficient mutant of Escherichia coli by gene replacement.
Dihydrofolate reductase deficiency causing megaloblastic anemia in two families.
Dihydrofolate reductase deficiency due to a homozygous DHFR mutation causes megaloblastic anemia and cerebral folate deficiency leading to severe neurologic disease.
Dihydrofolate reductase mutations-associated megaloblastic anemia and cerebral folate deficiency.
Expression and amplification of engineered mouse dihydrofolate reductase minigenes.
Hereditary abnormal transcobalamin II previously diagnosed as congenital dihydrofolate reductase deficiency.
Hereditary dihydrofolate reductase deficiency with megaloblastic anemia.
Identification and characterization of an inborn error of metabolism caused by dihydrofolate reductase deficiency.
Identification of Cryptosporidium parvum dihydrofolate reductase inhibitors by complementation in Saccharomyces cerevisiae.
Loss of Thy-1 inhibits alveolar development in the newborn mouse lung.
Supplementation of serum free media with HT is not sufficient to restore growth properties of DHFR(-/-) cells in fed-batch processes - Implications for designing novel CHO-based expression platforms.
Thy-1 (CD90) promotes bone formation and protects against obesity.
Thy-1 Deficiency Augments Bone Loss in Obesity by Affecting Bone Formation and Resorption.
Update and new concepts in vitamin responsive disorders of folate transport and metabolism.
Diphtheria
Ability of methotrexate to inhibit translocation to the cytosol of dihydrofolate reductase fused to diphtheria toxin.
Characterization of membrane translocation by anthrax protective antigen.
Human dihydrofolate reductase gene is located in chromosome 5 and is unlinked to the related pseudogenes.
Distemper
Immunohistochemical analysis of the lymphoid organs of dogs naturally infected with canine distemper virus.
Down Syndrome
19-base pair deletion polymorphism of the dihydrofolate reductase (DHFR) gene: maternal risk of Down syndrome and folate metabolism.
DHFR 19-bp Deletion and SHMT C1420T Polymorphisms and Metabolite Concentrations of the Folate Pathway in Individuals with Down Syndrome.
Dihydrofolate Reductase (DHFR) del19bp Polymorphism and Down Syndrome Offspring.
Drug-Related Side Effects and Adverse Reactions
Methotrexate accumulates to similar levels in animals transplanted with normal versus drug-resistant transgenic marrow.
Dysentery, Bacillary
Phytochemical constituents of Inula britannica as potential inhibitors of dihydrofolate reductase: A strategic approach against shigellosis.
Elephantiasis, Filarial
Exploration of 2, 4-diaminopyrimidine and 2, 4-diamino-s-triazine derivatives as potential antifilarial agents.
Targeting folate metabolism for therapeutic option: A bioinformatics approach.
Encephalomyelitis
Homing of T cells to the central nervous system throughout the course of relapsing experimental autoimmune encephalomyelitis in Thy-1 congenic mice.
Encephalomyelitis, Autoimmune, Experimental
Experimental allergic encephalomyelitis. T cell trafficking to the central nervous system in a resistant Thy-1 congenic mouse strain.
Homing of T cells to the central nervous system throughout the course of relapsing experimental autoimmune encephalomyelitis in Thy-1 congenic mice.
Escherichia coli Infections
Peritoneal gamma delta T cells induced by Escherichia coli infection in mice. Correlation between Thy-1 phenotype and host minor lymphocyte-stimulating phenotype.
Fanconi Anemia
Deficient gene specific repair of cisplatin-induced lesions in Xeroderma pigmentosum and Fanconi's anemia cell lines.
Repair of 8-methoxypsoralen + UVA-induced damage in specific sequences in chromosomal and episomal DNA in human cells.
Fasciculation
Morphology and growth of embryonic, human dorsal root ganglion explants in long-term culture: expression of cell type-specific markers during early differentiation.
Fetal Diseases
Methotrexate-resistant form of dihydrofolate reductase protects transgenic murine embryos from teratogenic effects of methotrexate.
Fibrosarcoma
Non-glutamate type pyrrolo[2,3-d]pyrimidine antifolates. I: Synthesis and biological properties of pyrrolo[2,3-d]pyrimidine antifolates containing tetrazole congener of glutamic acid.
Non-glutamate type pyrrolo[2,3-d]pyrimidine antifolates. II. Synthesis and antitumor activity of N5-substituted glutamine analogs.
Non-glutamate type pyrrolo[2,3-d]pyrimidine antifolates. III. Synthesis and biological properties of N(omega)-masked ornithine analogs.
Satellite DNA sequences flank amplified DHFR domains in marker chromosomes of mouse fibrosarcoma cells.
The antileukemic efficacy of an immunotoxin composed of a monoclonal anti-Thy-1 antibody disulfide linked to the ribosome-inactivating protein gelonin.
Filariasis
Expression, purification, and inhibition profile of dihydrofolate reductase from the filarial nematode Wuchereria bancrofti.
In vitro biological evaluation of biguanides and dihydrotriazines against Brugia malayi and folate reversal studies.
Gastrointestinal Stromal Tumors
Thy-1 as a potential novel diagnostic marker for gastrointestinal stromal tumors.
Gaucher Disease
In vivo methotrexate selection of murine hemopoietic cells transduced with a retroviral vector for Gaucher disease.
Glioma
A conjugate of adriamycin and monoclonal antibodies to Thy-1 antigen inhibits human neuroblastoma cells in vitro.
Definition of a Thy-1 determinant on human neuroblastoma, glioma, sarcoma, and teratoma cells with a monoclonal antibody.
Demonstration of complex antigenic heterogeneity in a human glioma cell line and eight derived clones by specific monoclonal antibodies.
DHFR/TYMS are positive regulators of glioma cell growth and modulate chemo-sensitivity to temozolomide.
Dihydrofolate reductase activity in primary brain tumors in children.
Dihydrofolate reductase in primary brain tumors, cell cultures of central nervous system origin, and normal brain during fetal and neonatal growth.
Evaluation of methotrexate-conjugated gadolinium(III) for cancer diagnosis and treatment.
Genomic changes in progression of low-grade gliomas.
Inhibition of DHFR targets the self-renewing potential of brain tumor initiating cells.
Glomerulonephritis
A specific Thy-1 molecular epitope expressed on rat mesangial cells.
Anti-inflammatory role of DPP-4 inhibitors in a non-diabetic model of glomerular injury.
C5a Induces the Synthesis of IL-6 and TNF-? in Rat Glomerular Mesangial Cells through MAPK Signaling Pathways.
Chronic anti-Thy-1 nephritis is aggravated in the nonclipped but not in the clipped kidney of Goldblatt hypertensive rats.
Contrasting effects of steroids and mizoribine on macrophage activation and glomerular lesions in rat thy-1 mesangial proliferative glomerulonephritis.
Induction of renal cell apoptosis by antibodies and complement.
Inhibition of Inducible Nitric Oxide Synthase Alters Thy-1 Glomeruonephritis in Rats.
KLF6 Acetylation Promotes Sublytic C5b-9-Induced Production of MCP-1 and RANTES in Experimental Mesangial Proliferative Glomerulonephritis.
Nitric oxide inhibition enhances platelet aggregation in experimental anti-Thy-1 nephritis.
Participation of the matrix metalloproteinase inhibitor in Thy-1 nephritis.
Platelets mediate glomerular cell proliferation in immune complex nephritis induced by anti-mesangial cell antibodies in the rat.
Renoprotective effect of epoetin beta pegol by the prevention of M2 macrophage recruitment in Thy-1 rats.
Selective expression of TGF-beta2 and TGF-beta3 isoforms in early mesangioproliferative glomerulonephritis.
Sublytic C5b-9 complexes induce apoptosis of glomerular mesangial cells in rats with Thy-1 nephritis through role of interferon regulatory factor-1-dependent caspase 8 activation.
Sublytic C5b-9 complexes induce proliferative changes of glomerular mesangial cells in rat Thy-1 nephritis through TRAF6-mediated PI3K-dependent Akt1 activation.
Sublytic C5b-9 Induces Glomerular Mesangial Cell Apoptosis through the Cascade Pathway of MEKK2-p38 MAPK-IRF-1-TRADD-Caspase 8 in Rat Thy-1 Nephritis.
Sublytic C5b-9 induces glomerular mesangial cell proliferation via ERK1/2-dependent SOX9 phosphorylation and acetylation by enhancing Cyclin D1 in rat Thy-1 nephritis.
Sublytic C5b-9 Induces IL-23 and IL-36a Production by Glomerular Mesangial Cells via PCAF-Mediated KLF4 Acetylation in Rat Thy-1 Nephritis.
Sublytic C5b-9 triggers glomerular mesangial cell apoptosis via XAF1 gene activation mediated by p300-dependent IRF-1 acetylation.
Sublytic C5b-9 triggers glomerular mesangial cell proliferation via enhancing FGF1 and PDGF? gene transcription mediated by GCN5-dependent SOX9 acetylation in rat Thy-1 nephritis.
The characterization of a specific Thy-1 molecular epitope expressed on rat mesangial cells.
The complement C5b-9 complexes induced injury of glomerular mesangial cells in rats with Thy-1 nephritis by increasing nitric oxide synthesis.
Transient expression of type I collagen in glomeruli with anti-Thy-1 antibody-induced mesangial proliferative lesions.
TSP-1 promotes glomerular mesangial cell proliferation and extracellular matrix secretion in Thy-1 nephritis rats.
[VEGF is an essential molecule for glomerular endothelial cells and its excretion in urine might be a unique marker of glomerular injury]
Glomerulonephritis, Membranoproliferative
Gene expression profile and overexpression of apoptosis-related genes (NGFI-B and Gadd 45 gamma) in early phase of Thy-1 nephritis model.
Graft vs Host Disease
Antilymphocytic antibodies and bone marrow transplantation. XI. Evidence that reduced Thy-1 expression in Thy-1.1 mice prevents suppression of graft-versus-host disease with anti-Thy-1 monoclonal antibodies.
Antilymphocytic antibodies and marrow transplantation. VII. Two of nine monoclonal anti-Thy-1 antibodies used for pretreatment of donor marrow suppressed graft-versus-host reactions without added complement.
Cyclosporine and methotrexate-related pharmacogenomic predictors of acute graft-versus-host disease.
Graves Ophthalmopathy
Orbital fibroblasts from patients with thyroid-associated ophthalmopathy overexpress CD40: CD154 hyperinduces IL-6, IL-8, and MCP-1.
Head and Neck Neoplasms
A second target of benzamide riboside: Dihydrofolate reductase.
Gene Polymorphisms Involved in Folate Metabolism and DNA Methylation with the Risk of Head and Neck Cancer.
Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck.
Healthcare-Associated Pneumonia
An Updated Review of Iclaprim: A Potent and Rapidly Bactericidal Antibiotic for the Treatment of Skin and Skin Structure Infections and Nosocomial Pneumonia Caused by Gram-Positive Including Multidrug-Resistant Bacteria.
Hematologic Neoplasms
Loss of Thy-1 (CD90) antigen expression on mesenchymal stromal cells from hematologic malignancies is induced by in vitro angiogenic stimuli and is associated with peculiar functional and phenotypic characteristics.
Hepatitis
Up-regulation of thy-1 promotes invasion and metastasis of hepatocarcinomas.
Hepatitis B
A recombinant Chinese hamster ovary cell line containing a 300-fold amplified tetramer of the hepatitis B genome together with a double selection marker expresses high levels of viral protein.
Amplification of expression of hepatitis B surface antigen in 3T3 cells cotransfected with a dominant-acting gene and cloned viral DNA.
Characterization of chimeric antibody producing CHO cells in the course of dihydrofolate reductase-mediated gene amplification and their stability in the absence of selective pressure.
Key determinants in the occurrence of clonal variation in humanized antibody expression of cho cells during dihydrofolate reductase mediated gene amplification.
Murine cells carrying integrated tandem genomes of hepatitis B virus DNA transcribe RNAs from endogenous promoters on both viral strands and express middle and major viral envelope proteins.
Synthesis in animal cells of hepatitis B surface antigen particles carrying a receptor for polymerized human serum albumin.
Ultrastructural studies of fibroblasts transfected with hepatitis B virus DNA.
[Application of dhfr gene negative Chinese hamster ovary cell line to express hepatitis B virus surface antigen]
Hepatitis C
Substrate requirements of hepatitis C virus serine proteinase for intermolecular polypeptide cleavage in Escherichia coli.
Hernias, Diaphragmatic, Congenital
Disruption of THY-1 signaling in alveolar lipofibroblasts in experimentally induced congenital diaphragmatic hernia.
Herpes Simplex
A gene for dihydrofolate reductase in a herpesvirus.
Co-expression of the herpes simplex virus thymidine kinase gene potentiates methotrexate resistance conferred by transfer of a mutated dihydrofolate reductase gene.
Expression and regulation of glycoprotein C gene of herpes simplex virus 1 resident in a clonal L-cell line.
Induction and persistence of a cytotoxic T lymphocyte (CTL) response against a herpes simplex virus-specific CTL epitope expressed in a cellular protein.
Insertion of new genes into bone marrow cells of mice.
Protection from herpes simplex virus type 1 lethal and latent infections by secreted recombinant glycoprotein B constitutively expressed in human cells with a BK virus episomal vector.
Second gene expression in bicistronic constructs using short synthetic intercistrons and viral IRES sequences.
Synthesis of dihydrofolate reductase and metabolism of related RNA in a methotrexate resistant human cell line infected with herpes simplex virus type 2.
Thy-1 tk transgenic mice with a conditional lymphocyte deficiency.
Towards the application of Tc toxins as a universal protein translocation system.
Use of recombinant vectors derived from herpes simplex virus 1 mutant tsK for short-term expression of transgenes encoding cytoplasmic and membrane anchored proteins in postmitotic polarized cortical neurons and glial cells in vitro.
Hirschsprung Disease
Impaired expression of neural cell adhesion molecule L1 in the extrinsic nerve fibers in Hirschsprung's disease.
Histiocytic Sarcoma
Multifocal cutaneous histiocytic sarcoma in a young dog and review of histiocytic cell immunophenotyping.
HIV Infections
Further studies on 2,4-diamino-5-(2',5'-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three major opportunistic pathogens of AIDS.
Hodgkin Disease
Expression of the adhesion molecules CD49d and CD49e on G-CSF-mobilized CD34+ cells of patients with solid tumors or non-Hodgkin's and Hodgkin's lymphoma and of healthy donors is inversely correlated with the amount of mobilized CD34+ cells.
Huntington Disease
MSH3 modifies somatic instability and disease severity in Huntington's and myotonic dystrophy type 1.
Hyperlipidemias
Oxidant stress in hyperlipidemia-induced renal damage.
Hypersensitivity
Conditional dihydrofolate reductase deficiency due to transposon Tn5tac1 insertion downstream from the folA gene in Escherichia coli.
Differential sensitivity to acute cholesterol lowering of activation mediated via the high-affinity IgE receptor and Thy-1 glycoprotein.
Expression of collateral sensitivity to cisplatin, methotrexate, and fluorouracil in a human ovarian carcinoma cell line following exposure to fractionated x-irradiation in vitro.
Functional heterogeneity of Thy-1 membrane microdomains in rat basophilic leukemia cells.
Genetic control of contract hypersensitivity. II. Suppressor cells induced by intravenous injection of DNP-coupled syngeneic spleen cells possessing thy-1 antigen, I-J determinant, Lyt-2+, 3+ antigen, FcR- and DNP-membrane binding receptor on their surfaces.
Hypersensitivity to low level cytotoxic stress in mouse cells with high levels of DHFR gene amplification.
Nucleotide sequence and nuclease hypersensitivity of the Chinese hamster dihydrofolate reductase gene promoter region.
Only the promoter region of the constitutively expressed normal and amplified human dihydrofolate reductase gene is DNase I hypersensitive and undermethylated.
Presence of negative torsional tension in the promoter region of the transcriptionally poised dihydrofolate reductase gene in vivo.
Similarities between human ataxia fibroblasts and murine SCID cells: high sensitivity to gamma rays and high frequency of methotrexate-induced DHFR gene amplification, but normal radiosensitivity to densely ionizing alpha particles.
Hypertension
Chronic anti-Thy-1 nephritis is aggravated in the nonclipped but not in the clipped kidney of Goldblatt hypertensive rats.
Endothelium-specific sepiapterin reductase deficiency in DOCA-salt hypertension.
Glomerular damage in experimental proliferative glomerulonephritis under glomerular capillary hypertension.
Hypermethylation of dihydrofolate reductase promoter increases the risk of hypertension in Chinese.
Knockout of dihydrofolate reductase in mice induces hypertension and abdominal aortic aneurysm via mitochondrial dysfunction.
Novel Treatment of Hypertension by Specifically Targeting E2F for Restoration of Endothelial Dihydrofolate Reductase and eNOS Function Under Oxidative Stress.
Regulation of endothelial cell tetrahydrobiopterin pathophysiological and therapeutic implications.
Significant association between DHFR promoter methylation and ischemic stroke in a Chinese hypertensive population.
Tubulointerstitial injury of Thy-1 nephritis in uninephrectomized stroke-prone spontaneously hypertensive rats.
Hypertension, Renovascular
Chronic anti-Thy-1 nephritis is aggravated in the nonclipped but not in the clipped kidney of Goldblatt hypertensive rats.
Ichthyosis
In vitro colonization of thymic primordia by adult bone marrow cells: light scatter profile and separation by flow cytometry.
Idiopathic Pulmonary Fibrosis
Absence of Thy-1 results in TGF-? induced MMP-9 expression and confers a profibrotic phenotype to human lung fibroblasts.
Conformational coupling of integrin and Thy-1 regulates Fyn priming and fibroblast mechanotransduction.
Epigenetic Regulation of Thy-1 by Histone Deacetylase Inhibitor in Rat Lung Fibroblasts.
Hypoxia-induced dna hypermethylation in human pulmonary fibroblasts is ssociated with thy-1 promoter methylation and the development of a pro-fibrotic Phenotype.
Idiopathic pulmonary fibrosis is strongly associated with productive infection by herpesvirus saimiri.
Loss of fibroblast Thy-1 expression correlates with lung fibrogenesis.
Thy-1 attenuates TNF-alpha-activated gene expression in mouse embryonic fibroblasts via Src family kinase.
Immune System Diseases
Structure-based design of selective inhibitors of dihydrofolate reductase: synthesis and antiparasitic activity of 2, 4-diaminopteridine analogues with a bridged diarylamine side chain.
Using a Fragment-Based Approach to Identify Alternative Chemical Scaffolds Targeting Dihydrofolate Reductase from Mycobacterium tuberculosis.
Infarction, Middle Cerebral Artery
Local hemodynamics dictate long-term dendritic plasticity in peri-infarct cortex.
Infections
A molecular epidemiologic study of point mutations for pyrimethamine-sulfadoxine resistance of Plasmodium falciparum isolates from Lao PDR.
A multiplex ligase detection reaction-fluorescent microsphere assay for simultaneous detection of single nucleotide polymorphisms associated with Plasmodium falciparum drug resistance.
A new reporter system for detection of retroviral infection.
Activity of lipid-soluble inhibitors of dihydrofolate reductase against Pneumocystis carinii in culture and in a rat model of infection.
Acute Trypanosoma cruzi infection differentially affects CD3 and Thy-1 mediated T cell activation.
An Updated Review of Iclaprim: A Potent and Rapidly Bactericidal Antibiotic for the Treatment of Skin and Skin Structure Infections and Nosocomial Pneumonia Caused by Gram-Positive Including Multidrug-Resistant Bacteria.
Antimalarial pharmacodynamics and pharmacokinetics of a third-generation antifolate JPC2056 in cynomolgus monkeys using an in vivo in vitro model.
Antimicrobial treatment of nosocomial meticillin-resistant Staphylococcus aureus (MRSA) pneumonia: current and future options.
Antiparasitic effect of in-feed inhibitors of folic acid synthesis and dihydrofolate reductase against ciliate Cryptocaryon irritans infection in the red sea bream Pagrus major and against ciliate Ichthyophthirius multifiliis infection in black pop-eyed goldfish Carassius auratus
Artesunate-dapsone-proguanil treatment of falciparum malaria: genotypic determinants of therapeutic response.
Bacteriophage T4-coded dihydrofolate reductase: synthesis, turnover, and location of the virion protein.
Can pretreatment screening for dhps and dhfr point mutations in Plasmodium falciparum infections be used to predict sulfadoxine-pyrimethamine treatment failure?
CCAAT box-dependent activation of the TATA-less human DNA polymerase alpha promoter by the human cytomegalovirus 72-kilodalton major immediate-early protein.
Cell Surface THY-1 Contributes to Human Cytomegalovirus Entry via a Macropinocytosis-like Process.
Change in mutation patterns of Plasmodium vivax dihydrofolate reductase (Pvdhfr) and dihydropteroate synthase (Pvdhps) in P. vivax isolates from malaria endemic areas of Thailand.
Characterization of trimethoprim resistant E. coli dihydrofolate reductase mutants by mass spectrometry and inhibition by propargyl-linked antifolates.
Combination of PS-15, epiroprim, or pyrimethamine with dapsone in prophylaxis of Toxoplasma gondii and Pneumocystis carinii dual infection in a rat model.
Comparative activity and properties of lactate dehydrogenase, xanthine dehydrogenase, and dihydrofolate reductase in normal and Brugia pagangi-infected Aedes aegypti.
Comparison of two nested PCR methods for the detection of human malaria.
Computational analysis of binding between malarial dihydrofolate reductases and anti-folates.
Computer modeling studies of the structural role of NADPH binding to active site mutants of human dihydrofolate reductase in complex with piritrexim.
Contribution of Thy-1-CD4+ T cells to the disorganization of lymphoid follicles in retrovirus-induced immunodeficiency syndrome, MAIDS.
Control of cellular gene expression during adenovirus infection: induction and shut-off of dihydrofolate reductase gene expression by adenovirus type 2.
Development of a retroviral construct containing a human mutated dihydrofolate reductase cDNA for hematopoietic stem cell transduction.
Development of substituted pyrido[3,2-d]pyrimidines as potent and selective dihydrofolate reductase inhibitors for pneumocystis pneumonia infection.
DHFR and DHPS genotypes of Plasmodium falciparum isolates from Gabon correlate with in vitro activity of pyrimethamine and cycloguanil, but not with sulfadoxine-pyrimethamine treatment efficacy.
Dihydrofolate reductase as a target for chemotherapy in parasites.
Dihydrofolate Reductase Is a Valid Target for Antifungal Development in the Human Pathogen Candida albicans.
Discovery of traditional Chinese medicine derived compounds as wild type and mutant Plasmodium falciparum dihydrofolate reductase inhibitors: Induced fit docking and ADME studies.
Downregulation of the cellular adhesion molecule Thy-1 (CD90) by cytomegalovirus infection of human fibroblasts.
Effect of the tripartite leader on synthesis of a non-viral protein in an adenovirus 5 recombinant.
Efficacy of epiroprim (Ro11-8958), a new dihydrofolate reductase inhibitor, in the treatment of acute Toxoplasma infection in mice.
Epidemiology of malaria in the forest-savannah transitional zone of Ghana.
Escalating Plasmodium falciparum antifolate drug resistance mutations in Macha, rural Zambia.
Evaluation of antigen detection tests, microscopy, and polymerase chain reaction for diagnosis of malaria in peripheral blood in asymptomatic pregnant women in nanoro, burkina faso.
Evidence that sulfisoxazole, an antibacterial sulfonamide, can adversely affect the development of Brugia pahangi in Aedes aegypti mosquitoes.
Expression of dihydrofolate reductase, and of the adjacent EIb region, in an Ad5-dihydrofolate reductase recombinant virus.
First Three-Dimensional Structure of Toxoplasma gondii Thymidylate Synthase-Dihydrofolate Reductase: Insights for Catalysis, Interdomain Interactions, and Substrate Channeling.
Function of T4D structural dihydrofolate reductase in bacteriophage infection.
Functions of baseplate components in bacteriophage T4 infection. I. Dihydrofolate reductase and dihydropteroylhexaglutamate.
Genetics of drug-resistant Plasmodium falciparum malaria in the Venezuelan state of Bolivar.
Geographic distribution of amino acid mutations in DHFR and DHPS in Plasmodium vivax isolates from Lao PDR, India and Colombia.
High frequency of Plasmodium falciparum CICNI/SGEAA and CVIET haplotypes without association with resistance to sulfadoxine/pyrimethamine and chloroquine combination in the Daraweesh area, in Sudan.
High prevalence of quintuple mutant dhps/dhfr genes in Plasmodium falciparum infections seven years after introduction of sulfadoxine and pyrimethamine as first line treatment in Malawi.
High prevalence of sulphadoxine-pyrimethamine resistance-associated mutations in Plasmodium falciparum field isolates from pregnant women in Brazzaville, Republic of Congo.
Historical trends and new surveillance of Plasmodium falciparum drug resistance markers in Angola.
Human cytomegalovirus stimulates cellular dihydrofolate reductase activity in quiescent cells.
Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections.
Iclaprim: a novel dihydrofolate reductase inhibitor for skin and soft tissue infections.
Identification of novel Mycobacterium tuberculosis dihydrofolate reductase inhibitors through rational drug design.
Inhibition of Stenotrophomonas maltophilia dihydrofolate reductase by methotrexate: a single slow-binding process.
Investigational antimicrobial drugs for bloodstream infections.
Isolation of specific antigen-reactive T-cell clones from nude (nu/nu) mice infected with Mesocestoides corti.
Lethal vaccinia infection in cyclophosphamide-suppressed mice is associated with decreased expression of Thy-1, Lyt-2 and L3T4 and diminished IL-2 production in surviving T cells.
Lipophilic antifolate trimetrexate is a potent inhibitor of Trypanosoma cruzi: prospect for chemotherapy of Chagas' disease.
Low infectivity of Plasmodium falciparum gametocytes to Anopheles gambiae following treatment with sulfadoxine-pyrimethamine in Mali.
Low prevalence of dihydro folate reductase (dhfr) and dihydropteroate synthase (dhps) quadruple and quintuple mutant alleles associated with SP resistance in Plasmodium vivax isolates of West Bengal, India.
Molecular assessment of drug resistance in Plasmodium falciparum from Bahr El Gazal province, Sudan.
Molecular determinants of sulfadoxine-pyrimethamine resistance in Plasmodium falciparum in Nigeria and the regional emergence of dhps 431V.
Molecular determination of point mutation haplotypes in the dihydrofolate reductase and dihydropteroate synthase of Plasmodium falciparum in three districts of northern Tanzania.
Molecular epidemiology of malaria in Yaounde, Cameroon. VI. Sequence variations in the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene and in vitro resistance to pyrimethamine and cycloguanil.
Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria.
Molecular surveillance for drug-resistant Plasmodiumfalciparum malaria in Malawi.
Murine cytomegalovirus induces expression and enzyme activity of cellular dihydrofolate reductase in quiescent cells.
Mutations in dhfr in Plasmodium falciparum infections selected by chlorproguanil-dapsone treatment.
Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase of isolates from the Amazon region of Brazil.
Novel gene-sequence markers for isolate tracking within Monilinia fructicola lesions.
Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase.
Peritoneal gamma delta T cells induced by Escherichia coli infection in mice. Correlation between Thy-1 phenotype and host minor lymphocyte-stimulating phenotype.
Pharmacokinetic and Pharmacodynamic Analyses To Determine the Optimal Fixed Dosing Regimen of Iclaprim for Treatment of Patients with Serious Infections Caused by Gram-Positive Pathogens.
Plasmodium falciparum infection dynamics and transmission potential following treatment with sulfadoxine-pyrimethamine.
Pneumocystis jirovecii infection and the associated dihydropteroate synthase (DHPS) and dihydrofolate reductase (DHFR) mutations in HIV-positive individuals from Pune, India.
Polyclonal Plasmodium falciparum malaria in travelers and selection of antifolate mutations after proguanil prophylaxis.
Polyoma virus and cyclic AMP-mediated control of dihydrofolate reductase mRNA abundance in methotrexate-resistant mouse fibroblasts.
Population-based validation of dihydrofolate reductase gene mutations for the prediction of sulfadoxine-pyrimethamine resistance in Uganda.
Posttranscriptional control of DHFR gene expression during adenovirus 2 infection.
Potent in vitro and in vivo antitoxoplasma activity of the lipid-soluble antifolate trimetrexate.
Presence of novel triple mutations in the pvdhfr from Plasmodium vivax in Mangaluru city area in the southwestern coastal region of India.
Principal role of dihydropteroate synthase mutations in mediating resistance to sulfadoxine-pyrimethamine in single-drug and combination therapy of uncomplicated malaria in Uganda.
Productive murine leukemia virus (MuLV) infection of EL4 T-lymphoblastoid cells: selective elevation of H-2 surface expression and possible association of Thy-1 antigen with viruses.
Pyrimethamine-sulfadoxine efficacy and selection for mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase in Mali.
QSAR analysis of 2,4-diaminopyrido[2,3-d]pyrimidines and 2,4-diaminopyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors.
Rapid selection of Plasmodium falciparum dihydrofolate reductase mutants by pyrimethamine prophylaxis.
Response of Plasmodium falciparum to cotrimoxazole therapy: relationship with plasma drug concentrations and dihydrofolate reductase and dihydropteroate synthase genotypes.
Role of adenovirus type 2 early region 4 in the early-to-late switch during productive infection.
Selection of antifolate-resistant Plasmodium falciparum by sulfadoxine-pyrimethamine treatment and infectivity to anopheles mosquitoes.
Selective peptide inhibitors of bifunctional thymidylate synthase-dihydrofolate reductase from Toxoplasma gondii provide insights into domain-domain communication and allosteric regulation.
Stages in development of mink cell focus-inducing (MCF) virus-accelerated leukemia in AKR mice.
Structural comparison of chromosomal and exogenous dihydrofolate reductase from Staphylococcus aureus in complex with the potent inhibitor trimethoprim.
Structure-based analysis of Bacilli and plasmid dihydrofolate reductase evolution.
Submicroscopic gametocytes and the transmission of antifolate-resistant Plasmodium falciparum in Western Kenya.
Sulfadoxine-pyrimethamine efficacy and selection of Plasmodium falciparum DHFR mutations in Burkina Faso before its introduction as intermittent preventive treatment for pregnant women.
Sulfadoxine/pyrimethamine intermittent preventive treatment for malaria during pregnancy.
Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents.
Synthesis of dihydrofolate reductase and metabolism of related RNA in a methotrexate resistant human cell line infected with herpes simplex virus type 2.
Synthesis, antifolate, and antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines.
Targeting species specific amino acid residues: Design, synthesis and biological evaluation of 6-substituted pyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors and potential anti-opportunistic infection agents.
The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo.
The drug sensitivity and transmission dynamics of human malaria on Nias Island, North Sumatra, Indonesia.
The effect of 5-alkyl modification on the biological activity of pyrrolo[2,3-d]pyrimidine containing classical and nonclassical antifolates as inhibitors of dihydrofolate reductase and as antitumor and/or antiopportunistic infection agents.
The effect of polyoma virus, serum factors, and dibutyryl cyclic AMP on dihydrofolate reductase synthesis, and the entry of quiescent cells into S phase.
The implication of dihydrofolate reductase and dihydropteroate synthetase gene mutations in modification of Plasmodium falciparum characteristics.
The Transgenic Zebrafish Display Fluorescence Reflecting the Expressional Dynamics of Dihydrofolate Reductase.
THY-1 Cell Surface Antigen (CD90) Has an Important Role in the Initial Stage of Human Cytomegalovirus Infection.
Travel and the emergence of high-level drug resistance in Plasmodium falciparum in southwest Uganda: results from a population-based study.
Trimethoprim and other nonclassical antifolates an excellent template for searching modifications of dihydrofolate reductase enzyme inhibitors.
Using a Fragment-Based Approach to Identify Alternative Chemical Scaffolds Targeting Dihydrofolate Reductase from Mycobacterium tuberculosis.
Virtual screening reveals allosteric inhibitors of the Toxoplasma gondii thymidylate synthase-dihydrofolate reductase.
Influenza, Human
Comparative behavior of membrane protein-antibody complexes on motile fibroblasts: implications for a mechanism of capping.
Functional expression of influenza A viral nucleoprotein in cells transformed with cloned DNA.
Glycosylation: heterogeneity and the 3D structure of proteins.
Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
Lipid domain structure of the plasma membrane revealed by patching of membrane components.
Synthesis, biological evaluation and molecular modeling of novel azaspiro dihydrotriazines as influenza virus inhibitors targeting the host factor dihydrofolate reductase (DHFR).
Intellectual Disability
Mice lacking the cell adhesion molecule Thy-1 fail to use socially transmitted cues to direct their choice of food.
Intracranial Aneurysm
Polymorphisms of homocysteine metabolism are associated with intracranial aneurysms.
Iron Deficiencies
Effects of chronic alcohol consumption and iron deficiency on maternal folate status and reproductive outcome in mice.
Ischemic Stroke
Significant association between DHFR promoter methylation and ischemic stroke in a Chinese hypertensive population.
Isosporiasis
Refractory isosporiasis.
Kidney Neoplasms
Developmental pattern of Thy-1 immunoreactivity in the human kidney and the application to pediatric renal neoplasms.
Synthesis of methotrexate-antibody conjugates by regiospecific coupling and assessment of drug and antitumor activities.
Laryngeal Neoplasms
Alterations in the expression pattern of MTHFR, DHFR, TYMS, and SLC19A1 genes after treatment of laryngeal cancer cells with high and low doses of methotrexate.
Leiomyosarcoma
A conjugate of adriamycin and monoclonal antibodies to Thy-1 antigen inhibits human neuroblastoma cells in vitro.
Leishmaniasis
Exploring the ability of dihydropyrimidine-5-carboxamide and 5-benzyl-2,4-diaminopyrimidine-based analogues for the selective inhibition of L. major dihydrofolate reductase.
Homology modelling of the dihydrofolate reductase-thymidylate synthase bifunctional enzyme of Leishmania major, a potential target for rational drug design in leishmaniasis.
Identification of Selective Inhibitors of LdDHFR Enzyme Using Pharmacoinformatic Methods.
Identification of selective LdDHFR inhibitors using quantum chemical and molecular modeling approach.
Pharmacokinetic justification of antiprotozoal therapy. A US perspective.
Probing the structure of Leishmania major DHFR TS and structure based virtual screening of peptide library for the identification of anti-leishmanial leads.
Structure based designing of benzimidazole/benzoxazole derivatives as anti-leishmanial agents.
Targeting pteridine reductase 1 and dihydrofolate reductase: the old is a new trend for leishmaniasis drug discovery.
Leishmaniasis, Cutaneous
Effect of dihydrofolate reductase inhibitors on experimental cutaneous leishmaniasis, with especial emphasis on Leishmania isolates from Latin-America.
Leishmaniasis, Visceral
Probing the structure of Leishmania donovani chagasi DHFR-TS: comparative protein modeling and protein-ligand interaction studies.
Leukemia
A comparison of dihydrofolate reductase activity in intact leukemia cells and squamous cell carcinoma.
A comparison of the inhibition of bovine and murine leukemia dihydrofolate reductase by 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(3-X-phenyl)-s-triazines.
A direct ligand-binding radioassay for the measurement of methotrexate in tissues and biological fluids.
A Drug-Tunable Gene Therapy for Broad-Spectrum Protection against Retinal Degeneration.
A histochemical study on the dihydrofolate reductase activity in leukemia.
A new myeloblastic leukemia cell line with double minute chromosomes. Induction of methotrexate resistance and dihydrofolate reductase gene amplification.
A nonfunctional protein in human leukemia cells reacts with antiserum to dihydrofolate reductase from L1210 leukemia cells.
A second target of benzamide riboside: Dihydrofolate reductase.
A unified framework for using neural networks to build QSARs.
Activity of free and carrier-bound methotrexate against transport-deficient and high dihydrofolate dehydrogenase-containing methotrexate-resistant L1210 cells.
Age-related changes in cell surface antigens of preleukemic AKR thymocytes.
Aggregation of Thy-1 glycoprotein induces tyrosine phosphorylation of different proteins in isolated rat mast cells and rat basophilic leukemia cells.
AKR murine thymic leukemias are from a distinct thymic cell lineage and do not express the beta chain of the T-cell antigen receptor.
Analogues of methotrexate.
Antifolates induce primary inhibition of the de novo purine pathway prior to 5-aminoimidazole-4-carboxamide ribotide transformylase in leukemia cells.
Atypical transient state kinetics of recombinant human dihydrofolate reductase produced by hysteretic behavior. Comparison with dihydrofolate reductases from other sources.
Biochemical and biological studies on 2-desamino-2-methylaminopterin, an antifolate the polyglutamates of which are more potent than the monoglutamate against three key enzymes of folate metabolism.
Cellular pharmacology of MTA: a correlation of MTA-induced cellular toxicity and in vitro enzyme inhibition with its effect on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.
Characterization of Thy-1 (CDw90) expression in CD34+ acute leukemia.
Chemistry and antitumor evaluation of selected classical 2,4-diaminoquinazoline analogues of folic acid.
Coamplification of 3-hydroxy-3-methylglutaryl coenzyme A reductase genes in methotrexate-resistant human leukemia cell lines.
Comparison of quantitative structure-activity relationships of the inhibition of leukemia cells in culture with the inhibition of dihydrofolate reductase from leukemia cells and other cell types.
Comparison of triazines as inhibitors of L1210 dihydrofolate reductase and of L1210 cells sensitive and resistant to methotrexate.
Construction and properties of replication-competent murine retroviral vectors encoding methotrexate resistance.
Cytotoxicity of 5-fluoro-2'-deoxyuridine: requirement for reduced folate cofactors and antagonism by methotrexate.
Decrease in Thy-1 expression on peripheral CD34 positive cells induced by G-CSF mobilization. The Tohoku Children Leukemia Study Group.
Development of a retroviral construct containing a human mutated dihydrofolate reductase cDNA for hematopoietic stem cell transduction.
Development of an amphotropic, high-titer retrovirus vector expressing the dihydrofolate reductase gene and conferring methotrexate resistance.
Development of an assay system for the detection and classification of methotrexate resistance in fresh human leukemic cells.
DHFR/MSH3 amplification in methotrexate-resistant cells alters the hMutSalpha/hMutSbeta ratio and reduces the efficiency of base-base mismatch repair.
Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity.
Differential alterations of dihydrofolate reductase gene in human leukemia cell lines made resistant to various folate analogues.
Differential sensitivity to acute cholesterol lowering of activation mediated via the high-affinity IgE receptor and Thy-1 glycoprotein.
Dihydrofolate reductase activity in adriamycin and methotrexate sensitive and resistant P388 leukemia cells.
Dihydrofolate reductase gene expression characterized by the PCR assay in human leukemia cells.
Dihydrofolate reductase gene intronic 19-bp deletion polymorphisms in a Japanese population.
Effect of bridge region variation on antifolate and antitumor activity of classical 5-substituted 2,4-diaminofuro[2,3-d]pyrimidines.
Effects of germline DHFR and FPGS variants on methotrexate metabolism and relapse of leukemia.
Engagement of Phospholipid Scramblase 1 in Activated Cells: IMPLICATION FOR PHOSPHATIDYLSERINE EXTERNALIZATION AND EXOCYTOSIS.
Enhanced therapeutic effect of methotrexate in experimental rat leukemia after inactivation of cobalamin (vitamin B12) by nitrous oxide.
Evaluation of proliferative disorders in canine bone marrow by use of flow cytometric scatter plots and monoclonal antibodies.
Evidence for a functional defect in the translocation of the methotrexate transport carrier in a methotrexate-resistant murine L1210 leukemia cell line.
Evidence for kinetic and immunologic heterogeneity of dihydrofolate reductase in L1210 leukemia cells.
Evidence for two molecular species of dihydrofolate reductase in amethopterin resistant and sensitive cells of the mouse leukemia L4946.
Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells.
Exogenous administration of gangliosides inhibits Fc epsilon RI-mediated mast cell degranulation by decreasing the activity of phospholipase C gamma.
Expression of dihydrofolate reductase and multidrug resistance genes in trimetrexate-resistant human leukemia cell lines.
Expression of human alpha 1 antitrypsin in murine hematopoietic cells in vivo after retrovirus-mediated gene transfer.
Expression of Thy-1 antigen (CDw90) on adult acute leukemia blast cells.
Expression of variant dihydrofolate reductase with decreased binding affinity to antifolates in MOLT-3 human leukemia cell lines resistant to trimetrexate.
Flow cytometric analysis of Thy-1 expression in CD34-positive acute leukemia.
Folate analogues altered in the C9-N10 bridge region. 18. Synthesis and antitumor evaluation of 11-oxahomoaminopterin and related compounds.
Folate-pool interconversions and inhibition of biosynthetic processes after exposure of L1210 leukemia cells to antifolates. Experimental and network thermodynamic analyses of the role of dihydrofolate polyglutamylates in antifolate action in cells.
Frequent expression of human Thy-1 antigen on pre-B cell acute lymphoblastic leukemia with t(9;22).
Functional expression of the endogenous Thy-1 gene and the transfected murine Thy-1.2 gene in rat basophilic leukemia cells.
Functional heterogeneity of Thy-1 membrane microdomains in rat basophilic leukemia cells.
Further studies on substituted quinazolines and triazines as inhibitors of a methotrexate-insensitive murine dihydrofolate reductase.
Further studies on the interaction of nonpolyglutamatable aminopterin analogs with dihydrofolate reductase and the reduced folate carrier as determinants of in vitro antitumor activity.
Further studies on the pharmacologic effects of the 7-hydroxy catabolite of methotrexate in the L1210 murine leukemia cell.
Gene amplification in a leukemic patient treated with methotrexate.
Genomic imbalances associated with methotrexate resistance in human osteosarcoma cell lines detected by comparative genomic hybridization-based techniques.
Growth properties and alloantigenic expression of murine lymphoblastoid cell lines.
High-throughput drug screening identifies pyrimethamine as a potent and selective inhibitor of acute myeloid leukemia.
Human leukemia and normal leukocytes contain a species of immunoreactive but nonfunctional dihydrofolate reductase.
Identification of a high-molecular-weight nonfunctional protein in L1210 leukemia cells with common antigenic determinants to dihydrofolate reductase.
Identification of a novel bone marrow-derived B-cell progenitor population that coexpresses B220 and Thy-1 and is highly enriched for Abelson leukemia virus targets.
Immunofluorescence and histologic studies of virus-induced murine lymphocytic leukemias.
Immunologic heterogeneity of dihydrofolate reductase from methotrexate sensitive and resistant L1210 leukemia cells.
Improved purification of tetrahydrofolate dehydrogenase from L1210 leukemia by affinity chromatography.
Inhibition of a methotrexate-insensitive dihydrofolate reductase from L5178Y cells by substituted triazines and quinazolines.
Inhibition of dihydrofolate reductase, methotrexate transport, and growth of methotrexate-sensitive and -resistant L1210 leukemia cells in vitro by 5-substituted 2,4-diaminoquinazolines.
Inhibition of thymidylate synthetase and dihydrofolate reductase by naturally occurring oligoglutamate derivatives of folic acid.
Interaction of D, L-erythro- and D,L-threo-gamma-fluoromethotrexate with human leukemia cell dihydrofolate reductase.
Irreversible enzyme inhibitors. 133. Studies on differential irreversible inhibition of dihydrofolic reductase from three strains of L1210 leukemia, liver, spleen, and intestine of the mouse.
Irreversible enzyme inhibitors. 158. Effect of bridge modification on the selective irreversible inhibition of dihydrofolic reductase from L1210 mouse leukemia and liver by 2,4-diamino-5-(3,4-dichlorophenyl)-6-[p-(m-fluorosulfonyl-benzamidomethyl) phenoxymethyl]pyrimidine. II.
Irreversible enzyme inhibitors. 158. Effect of bridge modification on the selective irreversible inhibition of dihydrofolic reductase from L1210 mouse leukemia and liver by 2,4-diamino-5-(3,4-dichlorophenyl)-6-[p-(m-fluorosulfonylbenzamidomethyl)phenoxymethyl]pyrimidine. II.
Irreversible enzyme inhibitors. CLVII. Effect of bridge modification on the selective irreversible inhibition of dihydrofolic reductase from L1210 mouse leukemia and liver by 2,4-diamino-5-(3,4-dichlorophenyl)-6-[p-(m-fluorosulfonylbenzamidomethyl)phenoxymethyl]pyrimidine. I.
Irreversible enzyme inhibitors. CLVII. Effect of bridge modification on the selective irreversible inhibition of dihydrofolic reductase from L1210 mouse leukemia and liver by 2,4-diamino-5-(3,4-dichlorophenyl)-6-[p-(m-fluorosultonyl-benzamidomethyl) phenozymethyl]pyrimidine. I.
Irreversible enzyme inhibitors. CXVII. Hydrophobic bonding to dihydrofolic reductase. XI. Comparison of the enzyme from Walker 256, rat liver, and L1210 mouse leukemia.
Irreversible enzyme inhibitors. CXXXIV. Effect of ring substitution on the selective irreversible inhibition of dihydrofolic reductase from L1210 mouse leukemia and liver by 2,4-diamino-5-(3,4-dichlorophenyl)-6-[p-(m-fluorosulfonyl-phenylureido)phenoxymethyl]pyrimidine.
Irreversible enzyme inhibitors. CXXXV. Effect of ring substitution on the selective irreversible inhibition of dihydrofolic reductase from L1210 mouse leukemia and liver by 2,4-diamino-5-(3,4-dichlorophenyl)-6-[p-(p-fluorosulfonyl-phenylureido)phenoxymethyl]pyrimidine.
L1210 dihydrofolate reductase. Kinetics and mechanism of activation by various agents.
L1210 dihydrofolate reductase: activation and enhancement of methotrexate sensitivity.
Lack of dihydrofolate reductase in human tumor and leukemia cells in vivo.
Lack of intracellular conversion of dihydrohomofolate to tetrahydrohomofolate in leukemia cells with high levels of dihydrofolate reductase.
Limited effectiveness of in vitro high-dose methotrexate and leucovorin to overcome resistance in L1210 leukemia cells with elevations of dihydrofolate reductase.
Long-term protection of recipient mice from lethal doses of methotrexate by marrow infected with a double-copy vector retrovirus containing a mutant dihydrofolate reductase.
Mechanism of the induction of the differentiation of HL-60 leukemia cells by antifolates.
Methotrexate analogues--XVII. Antitumor activity of 4-amino-4-deoxy-N10-methylpteroyl-D,L-homocysteic acid and its dual inhibition of dihydrofolate reductase and folyl polyglutamate synthetase.
Methotrexate analogues. 16. Importance of the side-chain amide carbonyl group as a structural determinant of biological activity.
Methotrexate analogues. 25. Chemical and biological studies on the gamma-tert-butyl esters of methotrexate and aminopterin.
Methotrexate analogues. 26. Inhibition of dihydrofolate reductase and folylpolyglutamate synthetase activity and in vitro tumor cell growth by methotrexate and aminopterin analogues containing a basic amino acid side chain.
Methotrexate analogues. 28. Synthesis and biological evaluation of new gamma-monoamides of aminopterin and methotrexate.
Methotrexate analogues. 31. Meta and ortho isomers of aminopterin, compounds with a double bond in the side chain, and a novel analogue modified at the alpha-carbon: chemical and in vitro biological studies.
Methotrexate analogues. 32. Chain extension, alpha-carboxyl deletion, and gamma-carboxyl replacement by sulfonate and phosphonate: effect on enzyme binding and cell-growth inhibition.
Methotrexate analogues. 33. N delta-acyl-N alpha-(4-amino-4-deoxypteroyl)-L-ornithine derivatives: synthesis and in vitro antitumor activity.
Methotrexate analogues. 34. Replacement of the glutamate moiety in methotrexate and aminopterin by long-chain 2-aminoalkanedioic acids.
Methotrexate-resistant human promyelocytic leukemia (HL-60) cells express a dihydrofolate reductase with altered properties associated with increased enzyme activity.
Microsatellite instability and clonal heterogeneity of MDR1 messenger RNA expression in trimetrexate-resistant human leukemia MOLT-3 cells developed in thymidine.
Modulation of dihydrofolate reductase gene expression in methotrexate-resistant human leukemia CCRF-CEM/E cells by antisense oligonucleotides.
Molecular basis of antifolate resistance.
Multiple forms of L1210 dihydrofolate reductase differing in affinity for methotrexate.
Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis.
Mutations in the gene for human dihydrofolate reductase: an unlikely cause of clinical relapse in pediatric leukemia after therapy with methotrexate.
Overproduction of two antigenically distinct forms of dihydrofolate reductase in a highly methotrexate-resistant mouse leukemia cell line.
Polyglutamyl and polylysyl derivatives of the lysine analogues of folic acid and homofolic acid.
Polyglutamylation of the dihydrofolate reductase inhibitor gamma-methylene-10-deazaaminopterin is not essential for antitumor activity.
Polymorphism of dihydrofolate reductase from a methotrexate-resistant subline of L1210 cells.
Potential anticancer agents. XXIII. 1. Qualitative structure--activity relationship in the "classical" antifolates area.
Production, purification and characterization of biologically active recombinant human nerve growth factor.
Productive murine leukemia virus (MuLV) infection of EL4 T-lymphoblastoid cells: selective elevation of H-2 surface expression and possible association of Thy-1 antigen with viruses.
Protein tyrosine kinase Syk is involved in Thy-1 signaling in rat basophilic leukemia cells.
Quantitative correlations of biological activities of dactinomycin analogs and methotrexate derivatives with van der Waals volume.
Quinazoline antifolates as inhibitors of dihydrofolate reductase from human leukemia cells.
R plasmid dihydrofolate reductase with a dimeric subunit structure.
Rat lymphoid leukemia of T cell type induced by 7,12-dimethylbenz(alpha)anthracene. Immunological and enzymological characterization.
Rate and extent of interconversion of tetrahydrofolate cofactors to dihydrofolate after cessation of dihydrofolate reductase activity in stationary versus log phase L1210 leukemia cells.
Regiospecific gamma-conjugation of methotrexate to poly(L-lysine). Chemical and biological studies.
Regulation of Thy-1 gene expression by the methylation of the 5' region of Thy-1 gene and intracellular regulatory factors in immature B cells.
Resistance to methotrexate due to gene amplification in a patient with acute leukemia.
Somatic hybrid of thymus leukemia (.
Src family-selective tyrosine kinase inhibitor, PP1, inhibits both Fc epsilonRI- and Thy-1-mediated activation of rat basophilic leukemia cells.
Synthesis and antifolate properties of 5,10-methylenetetrahydro-8,10-dideazaminopterin.
Synthesis and biological activity of folic acid and methotrexate analogues containing L-threo-(2S,4S)-4-fluoroglutamic acid and DL-3,3-difluoroglutamic acid.
Synthesis and evaluation of a classical 2,4-diamino-5-substituted-furo[2,3-d]pyrimidine and a 2-amino-4-oxo-6-substituted-pyrrolo[2,3-d]pyrimidine as antifolates.
Synthesis and preliminary in vitro screening of lipophilic alpha, gamma-bis(amides) as potential prodrugs of methotrexate.
Synthesis of N-10-methyl-4-thiofolic acid and related compounds.
The antileukemic efficacy of an immunotoxin composed of a monoclonal anti-Thy-1 antibody disulfide linked to the ribosome-inactivating protein gelonin.
The association of increased dihydrofolate reductase with amethopterin resistance in mouse leukemia.
The cytotoxic activity of 1-acyl- and 1,2-diacyl-4,4-diethyl-3,5-pyrazolidinediones.
The cytotoxicity and mode of action of 2,3,4-trisubstituted pyrroles and related derivatives in human Tmolt4 leukemia cells.
Thy-1 expression on blast cells from adult patients with acute myeloid leukemia.
Thy-1 glycoprotein and src-like protein-tyrosine kinase p53/p56lyn are associated in large detergent-resistant complexes in rat basophilic leukemia cells.
Thy-1-mediated activation of rat basophilic leukemia cells does not require co-expression of the high-affinity IgE receptor.
Thy-1-mediated activation of rat mast cells: the role of Thy-1 membrane microdomains.
Topography of plasma membrane microdomains and its consequences for mast cell signaling.
Transfer of a mutant dihydrofolate reductase gene into pre- and postimplantation mouse embryos by a replication-competent retrovirus vector.
Transitory expression of Thy-1 antigen in immature B cell lines.
Tricyclic 2,4-diaminopyrimidines with broad antifolate activity and the ability to inhibit Pneumocystis carinii growth in cultured human lung fibroblasts in the presence of leucovorin.
Trimethoprim interference in methotrexate assay by an enzyme inhibition assay kit.
[Acute mixed-cell human leukemia]
[CDw90 (Thy-1) expression on CD34 positive cells in peripheral blood stem cell harvest]
[Comparison of inhibitory effects of triazines on dihydrofolate reductase isolated from murine leukemia cells with the inhibition of growth of cells in culture]
[Cynomorium songaricum improves sperm count and motility and serum testosterone level and promotes proliferation of undifferentiated spermatogonia in oligoasthenospermia rats].
[Cytochemical study of tetrahydrofolate dehydrogenase in blast cells in acute leukemia]
[Detection of alterations of dihydrofolate reductase gene in folate-resistant leukemia cells by in vitro enzymatic amplification]
[Determination, properties and significance of dihydrofolic acid reductase in the white blood cells in leukemia.]
Leukemia L1210
Analysis of DNA damage and repair in murine leukemia L1210 cells using a quantitative polymerase chain reaction assay.
ASSOCIATION OF INCREASED DIHYDROFOLATE REDUCTASE LEVELS AND CHROMOSOME ALTERATION IN AMETHOPTERIN-RESISTANT SUBLINES OF LEUKEMIA L1210.
CYTOGENETICS OF MOUSE LEUKEMIA L1210. I. ASSOCIATION OF A SPECIFIC CHROMOSOME WITH DIHYDROFOLATE REDUCTASE ACTIVITY IN AMETHOPTERIN-TREATED SUBLINES.
Dihydrofolate reductase activity and loss of resistance in an antifolate-resistant subline of leukemia L1210 after discontinuation of treatment.
Dihydrofolate reductase activity of leukemia L1210 during development of methotrexate resistance.
SELECTION OF CHROMOSOMAL VARIANT IN AMETHOPTERIN-RESISTANT SUBLINES OF LEUKEMIA L1210 WITH INCREASED LEVELS OF DIHYDROFOLATE REDUCTASE.
Leukemia, Erythroblastic, Acute
c-myc antisense transcripts accelerate differentiation and inhibit G1 progression in murine erythroleukemia cells.
Cell surface molecules of Friend erythroleukemias: decrease in T200 glycoprotein expression after induction.
Evidence for an accessory component that increases the affinity of the erythropoietin receptor.
Murine erythroleukemia cell variants: isolation of cells that have amplified the dihydrofolate reductase gene and retained the ability to be induced to differentiate.
Regulated expression of amplified human beta globin genes.
Leukemia, Lymphocytic, Chronic, B-Cell
Cytochemical study of tetrahydrofolate dehydrogenase in chronic lymphocytic leukemia cells.
Leukemia, Lymphoid
Antitumor agents. XXXIV: Mechanism of action of bruceoside A and brusatol on nucleic acid metabolism of P-388 lymphocytic leukemia cells.
Cytotoxicity of rhenium(I) alkoxo and hydroxo carbonyl complexes in murine and human tumor cells.
The cytotoxicity of copper(II) complexes of heterocyclic thiosemicarbazones and 2-substituted pyridine N-oxides.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Characterization of Thy-1 (CDw90) expression in CD34+ acute leukemia.
Cytoenzymological-cytogenetical correlations concerning chronic granulocytic leukemia leucocytes.
Human leukemia and normal leukocytes contain a species of immunoreactive but nonfunctional dihydrofolate reductase.
Methotrexate exacerbates tumor progression in a murine model of chronic myeloid leukemia.
Trimetrexate inhibits progression of the murine 32Dp210 model of chronic myeloid leukemia in animals expressing drug-resistant dihydrofolate reductase.
[Expression of primitive stem cell antigens on the blast cells of patients with chronic myeloid leukemia]
Leukemia, Myeloid
Cellular and molecular mechanisms of resistance to antifolate drugs: new analogues and approaches to overcome the resistance.
Coamplification of 3-hydroxy-3-methylglutaryl coenzyme A reductase genes in methotrexate-resistant human leukemia cell lines.
Evaluation of proliferative disorders in canine bone marrow by use of flow cytometric scatter plots and monoclonal antibodies.
Thy-1 epitopes are expressed on murine myeloid leukemia and reticulum sarcoma cells.
Leukemia, Myeloid, Acute
Acute myeloid leukemia is associated with retroviral gene transfer to hematopoietic progenitor cells in a rhesus macaque.
Characterization of Thy-1 (CDw90) expression in CD34+ acute leukemia.
Heterogeneity in the specific activity and methotrexate sensitivity of dihydrofolate reductase from blast cells of acute myelogenous leukemia patients.
Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo.
Thy-1 expression on blast cells from adult patients with acute myeloid leukemia.
[CDw90 (Thy-1) expression on CD34 positive cells in peripheral blood stem cell harvest]
Leukemia, T-Cell
Cytotoxicity of trimetrexate against antifolate-resistant human T-cell leukemia cell lines developed in oxidized or reduced folate.
Modulation of specific protein expression levels by PTEN: identification of AKAP121, DHFR, G3BP, Rap1, and RCC1 as potential targets of PTEN.
Liver Cirrhosis
Mesothelin/mucin 16 signaling in activated portal fibroblasts regulates cholestatic liver fibrosis.
Thy-1 is expressed in hepatic myofibroblasts and not oval cells in stem cell-mediated liver regeneration.
Liver Diseases
Hepatic progenitor cells from adult human livers for cell transplantation.
Liver Failure, Acute
Thy-1 is expressed in hepatic myofibroblasts and not oval cells in stem cell-mediated liver regeneration.
Liver Neoplasms
The RFC1 80G>A, among Common One-Carbon Polymorphisms, Relates to Survival Rate According to DNA Global Methylation in Primary Liver Cancers.
Up-regulation of thy-1 promotes invasion and metastasis of hepatocarcinomas.
Wnt/?-catenin aids in regulating the proliferation of hepG2 cells mediated by thy-1.
Lung Injury
?v?3 Integrin drives fibroblast contraction and strain stiffening of soft provisional matrix during progressive fibrosis.
Aging promotes pro-fibrotic matrix production and increases fibrocyte recruitment during acute lung injury.
Thy-1 interaction with Fas in lipid rafts regulates fibroblast apoptosis and lung injury resolution.
Lung Neoplasms
Antimalarial drug pyrimethamine plays a dual role in anti-tumor proliferation and metastasis through targeting DHFR and TP.
Association between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancer.
Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer.
MicroRNA-1301-3p promotes the progression of non-small cell lung cancer by targeting Thy-1 and predicts poor prognosis of patients.
Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma.
Plasma thymidylate synthase and dihydrofolate reductase mRNA levels as potential predictive biomarkers of pemetrexed sensitivity in patients with advanced non-small cell lung cancer.
Randomized phase 2b study of pralatrexate versus erlotinib in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) after failure of prior platinum-based therapy.
Thy-1(+) Cancer-associated Fibroblasts Adversely Impact Lung Cancer Prognosis.
Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: The association with treatment efficacy of pemetrexed.
[Abnormal expression of Thy-1 as a novel tumor marker in lung cancer and its prognostic significance]
Lupus Nephritis
Therapeutic effects of prostacyclin analog on crescentic glomerulonephritis of rat.
Lymphadenopathy
Characterization of lymphoproliferation induced by interactions between lprcg and gld genes.
Lymphocytic Choriomeningitis
Dynamics of memory T cell proliferation under conditions of heterologous immunity and bystander stimulation.
Lymphoma
5,10-Methylenetetrahydro-5-deazafolic acid and analogues: synthesis and biological activities.
A mutant lymphoma cell line with a defective Thy-1 glycoprotein gene.
A Thy-1 negative lymphoma cell variant defective in the formation of glycosyl-phosphatidylinositol membrane protein anchors.
A Thy-1- mutant defining a gene acting in trans position to regulate cell-surface Thy-1 glycoprotein expression and Thy-1 messenger RNA content.
Absence of Thy-1 antigen in L-cell X mouse lymphoma hybrids.
Alterations in expression and glycosylation pattern of the Thy-1 glycoprotein during maturation and transformation of mouse T lymphocytes.
Analysis of thy-1 variants of murine lymphoma cells.
Anchoring of membrane proteins via phosphatidylinositol is deficient in two classes of Thy-1 negative mutant lymphoma cells.
Anti-thymocyte autoimmunity in BALB/C mice accompanying immunization to a syngeneic lymphoma.
Antibody to dihydrofolate reductase from a methotrexate-resistant subline of the L1210 lymphoma.
Atypical mannolipids characterize Thy-1-negative lymphoma mutants.
Biochemical analysis of glycophospholipids from wild-type mouse lymphoma cells and from Thy-1 negative mutants which do not add glycolipid-anchored proteins.
Characterization of glycophospholipid intermediate in the biosynthesis of glycophosphatidylinositol anchors accumulating in the Thy-1-negative lymphoma line SIA-b.
Characterization of putative glycoinositol phospholipid anchor precursors in mammalian cells. Localization of phosphoethanolamine.
Chi-Ju-Di-Huang-Wan protects rats against retinal ischemia by downregulating matrix metalloproteinase-9 and inhibiting p38 mitogen-activated protein kinase.
Class E Thy-1 negative mouse lymphoma cells utilize an alternate pathway of oligosaccharide processing to synthesize complex-type oligosaccharides.
Class F Thy-1-negative murine lymphoma cells are deficient in ether lipid biosynthesis.
Clinical resistance to antimetabolites.
Defective glycosyl phosphatidylinositol biosynthesis in extracts of three Thy-1 negative lymphoma cell mutants.
Derivation and characterization of glycoinositol-phospholipid anchor-defective human K562 cell clones.
Detection of a Thy-1 precursor in human T lymphoma cell lines.
Dihydrofolate reductase from a resistant subline of the L1210 lymphoma. Purification and properties.
Dihydrofolate reductase from a resistant subline of the L1210 lymphoma. Purification by affinity chromatography and ultraviolet difference spectrophotometric and circular dichroic studies.
Dihydrofolate reductase from the L1210 R murine lymphoma. Further studies on the binding of substrates and inhibitors to the enzyme.
Dihydrofolate reductase from the L1210R murine lymphoma. Fluorometric measurements of the interaction of the enzyme with coenzymes, substrates, and inhibitors.
DNA methylation alters chromatin structure and regulates Thy-1 expression in EL-4 T cells.
Dynamics and longevity of the glycolipid-anchored membrane protein, Thy-1.
E mu-bcl-2 transgene facilitates spontaneous transformation of early pre-B and immunoglobulin-secreting cells but not T cells.
Effect of gene dosage on cell-surface expression of Thy-1 antigen in somatic cell hybrids between Thy-1- Abelson-leukemia-virus induced lymphomas and Thy-1+ mouse lymphomas.
Eradication of spontaneous and experimental adenocarcinoma metastases with chronic indomethacin and intermittent IL-2 therapy.
Evidence from neuron/lymphoma heterokaryons for a common trans-acting factor suppressing Thy-1 expression.
Evidence that murine hematopoietic cell subset marker J11d is attached to a glycosyl-phosphatidylinositol membrane anchor.
Evidence that the Thy-1 molecule is the target for T cell mitogenic antibody against brain-associated antigens.
Expression of the Thy-1 glycoprotein gene by DNA-mediated gene transfer.
Expression of Thy-1 glycoprotein on lectin-resistant lymphoma cell lines.
F1 resistance to AKR lymphoma cells in vivo and in vitro.
Fatty acids regulate Thy-1 antigen mRNA stability in T lymphocyte precursors.
Gene amplification in methotrexate-resistant mouse cells. I. DNA rearrangement accompanies dihydrofolate reductase gene amplification in a T-cell lymphoma.
Glycoinositol phospholipid anchor-defective K562 mutants with biochemical lesions distinct from those in Thy-1- murine lymphoma mutants.
High expression of the Thy-1 antigen on natural killer cells recently derived from bone marrow.
Hydrophilic anchor-deficient Thy-1 is secreted by a class E mutant T lymphoma.
Immunoelectron microscopic localization of Thy-1 glycoprotein in wild type and Thy-1-negative lymphoma cells.
Immunogenetics of a thymus antigen in lymphoma-prone and lymphoma-resistant colonies of wild mice.
Increased gamma/delta T cells and Thy-1 cells in cutaneous T cell lymphoma.
Increased gene amplification in L5178Y mouse lymphoma cells with hydroxyurea-induced chromosomal aberrations.
Lymphoma Thy-1 glycoprotein is linked to the cytoskeleton via a 4.1-like protein.
Lymphomas with acquired mouse mammary tumor virus proviruses resemble distinct prethymic and intrathymic phenotypes defined in vivo.
Mannosamine inhibits the synthesis of putative glycoinositol phospholipid anchor precursors in mammalian cells without incorporating into an accumulated intermediate.
Metabolic correction of defects in the lipid anchoring of Thy-1 in lymphoma mutants.
Methotrexate and cytarabine inhibit progression of human lymphoma in NOD/SCID mice carrying a mutant dihydrofolate reductase and cytidine deaminase fusion gene.
Mitogenicity of anti-Thy-1 monoclonal antibodies attributable to an Fc-dependent mechanism.
Multi-level regulation of Thy-1 antigen expression in mouse T lymphomas.
Multiple activities of a cloned cell line mediating natural killer cell function.
Nonmetastatic tumor cells acquire metastatic properties following somatic hybridization with normal cells.
Properties of a methotrexate-insensitive variant of dihydrofolate reductase derived from methotrexate-resistant L5178Y cells.
Radiolabeling and isolation of Thy-1 active glycolipids from murine brain and lymphoma cell lines.
Regulation of Thy-1 and Pgp-1 glycoproteins in hybrids between T-cell lymphomas and Abelson-leukemia-virus-induced lymphomas.
Saponin-induced release of cell-surface-anchored Thy-1 by serum glycosylphosphatidylinositol-specific phospholipase D.
Sequential activation and loss of the pre-B cell Thy-1 gene in T-cell X pre-B cell somatic hybrids.
Sodium butyrate causes reexpression of three membrane proteins on glycolipid-anchoring mutants.
T-cell lymphomas emerging as epineoplasms in mice bearing transplanted polyoma virus-induced salivary gland tumors.
The amino acid sequence of dihydrofolate reductase from the mouse lymphoma L1210.
The glycophospholipid anchor of Thy-1. Biosynthetic labeling experiments with wild-type and class E Thy-1 negative lymphomas.
The phenotype of five classes of T lymphoma mutants. Defective glycophospholipid anchoring, rapid degradation, and secretion of Thy-1 glycoprotein.
The synthesis and properties of T25 blycoprotein in Thy-1-negative mutant lymphoma cells.
The Thy-1 antigen exhibits rapid lateral diffusion in the plasma membrane of rodent lymphoid cells and fibroblasts.
Thy-1 supports adhesion of mouse thymocytes to thymic epithelial cells through a Ca2(+)-independent mechanism.
Thy-1 variants of mouse lymphomas: biochemical characterization of the genetic defect.
Thy-1: a differentiation marker of potential mammary myoepithelial cells in vitro.
Transplantation of canine malignant lymphomas in the nude and SCID mouse.
Trimethoprim binding to bacterial and mammalian dihydrofolate reductase: a comparison by proton and carbon-13 nuclear magnetic resonance.
Variation of dihydrofolate reductase activity during in vitro and in vivo growth of sublines of L1210 lymphoma.
Lymphoma, B-Cell
Chi-Ju-Di-Huang-Wan protects rats against retinal ischemia by downregulating matrix metalloproteinase-9 and inhibiting p38 mitogen-activated protein kinase.
Pleiotropic loss of activation pathways in a T-cell receptor alpha-chain deletion variant of a cytolytic T-cell clone.
Schedule-Dependent Synergy Between the Histone Deacetylase Inhibitor Belinostat and the Dihydrofolate Reductase Inhibitor Pralatrexate in T-and B-cell Lymphoma Cells in vitro.
Lymphoma, Non-Hodgkin
A second target of benzamide riboside: Dihydrofolate reductase.
Enhanced degradation of dihydrofolate reductase through inhibition of NAD kinase by nicotinamide analogs.
Expression of the adhesion molecules CD49d and CD49e on G-CSF-mobilized CD34+ cells of patients with solid tumors or non-Hodgkin's and Hodgkin's lymphoma and of healthy donors is inversely correlated with the amount of mobilized CD34+ cells.
Nonclassical 2,4-diamino-5-aryl-6-ethylpyrimidine antifolates: activity as inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
Structural studies on bioactive compounds. 8. Synthesis, crystal structure, and biological properties of a new series of 2,4-diamino-5-aryl-6-ethylpyrimidine dihydrofolate reductase inhibitors with in vivo activity against a methotrexate-resistant tumor cell line.
The cytotoxic effect of methotrexate as evaluated by colony-forming activity of hemopoietic and tumor cells.
Lymphoma, T-Cell
A mutant lymphoma cell line with a defective Thy-1 glycoprotein gene.
A Thy-1- mutant defining a gene acting in trans position to regulate cell-surface Thy-1 glycoprotein expression and Thy-1 messenger RNA content.
Demonstration of a hematopoietic stem cell antigen (SC-1) on a murine lymphoma and isolation of variants lacking the antigen.
DNA methylation alters chromatin structure and regulates Thy-1 expression in EL-4 T cells.
Evidence that the Thy-1 molecule is the target for T cell mitogenic antibody against brain-associated antigens.
Gene amplification in methotrexate-resistant mouse cells. I. DNA rearrangement accompanies dihydrofolate reductase gene amplification in a T-cell lymphoma.
MG-1: a specificity identifying members of the macrophage and granulocyte lineages of mice.
Mitogenicity of anti-Thy-1 monoclonal antibodies attributable to an Fc-dependent mechanism.
Phenotypic drift and clonal variation in differentiation antigen expression on AKR T-cell lymphoma lines grown in vitro.
Regulation of Thy-1 and Pgp-1 glycoproteins in hybrids between T-cell lymphomas and Abelson-leukemia-virus-induced lymphomas.
Sequential activation and loss of the pre-B cell Thy-1 gene in T-cell X pre-B cell somatic hybrids.
Lymphoma, T-Cell, Cutaneous
Increased gamma/delta T cells and Thy-1 cells in cutaneous T cell lymphoma.
Lymphoma, T-Cell, Peripheral
The membrane transport and polyglutamation of pralatrexate: a new-generation dihydrofolate reductase inhibitor.
Macular Degeneration
Influence of verteporfin photodynamic therapy on inflammation in human choroidal neovascular membranes secondary to age-related macular degeneration.
Thy-1 Regulates VEGF-Mediated Choroidal Endothelial Cell Activation and Migration: Implications in Neovascular Age-Related Macular Degeneration.
Malaria
3-Methyl-imidazo[2,1-b]thiazole derivatives as a new class of antifolates: Synthesis, in vitro/in vivo bio-evaluation and molecular modeling simulations.
A biochemical and genetic model for parasite resistance to antifolates. Toxoplasma gondii provides insights into pyrimethamine and cycloguanil resistance in Plasmodium falciparum.
A molecular epidemiologic study of point mutations for pyrimethamine-sulfadoxine resistance of Plasmodium falciparum isolates from Lao PDR.
A molecular surveillance system for global patterns of drug resistance in imported malaria.
A mutation-specific PCR system to detect sequence variation in the dihydropteroate synthetase gene of Plasmodium falciparum.
A new tool for the serodiagnosis of acute Plasmodium falciparum malaria in individuals with primary infection.
A shared Asian origin of the triple-mutant dhfr allele in Plasmodium falciparum from sites across Africa.
A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria.
A transgenic Neospora caninum strain based on mutations of the dihydrofolate reductase-thymidylate synthase gene.
Analysis of pfcrt, pfmdr1, dhfr, and dhps mutations and drug sensitivities in Plasmodium falciparum isolates from patients in Vietnam before and after treatment with artemisinin.
Analysis of the Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene sequence.
Anti-folate drug resistance in Africa: meta-analysis of reported dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) mutant genotype frequencies in African Plasmodium falciparum parasite populations.
Antifolate resistance due to new and known Plasmodium falciparum dihydrofolate reductase mutations expressed in yeast.
Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase.
Antimalarial pharmacodynamics and pharmacokinetics of a third-generation antifolate JPC2056 in cynomolgus monkeys using an in vivo in vitro model.
Application of loop-mediated isothermal amplification assay combined with lateral flow dipstick for detection of Plasmodium falciparum and Plasmodium vivax.
Asymptomatic Natural Human Infections With the Simian Malaria Parasites Plasmodium cynomolgi and Plasmodium knowlesi.
Basis for antifolate action and resistance in malaria.
Can pretreatment screening for dhps and dhfr point mutations in Plasmodium falciparum infections be used to predict sulfadoxine-pyrimethamine treatment failure?
Carriage of Mutant Dihydrofolate Reductase and Dihydropteroate Synthase Genes among Plasmodium falciparum Isolates Recovered from Pregnant Women with Asymptomatic Infection in Lagos, Nigeria.
Catalytic and ligand-binding characteristics of Plasmodium falciparum serine hydroxymethyltransferase.
Change in mutation patterns of Plasmodium vivax dihydrofolate reductase (Pvdhfr) and dihydropteroate synthase (Pvdhps) in P. vivax isolates from malaria endemic areas of Thailand.
Characterisation of the dihydrofolate reductase-thymidylate synthetase gene from human malaria parasites highly resistant to pyrimethamine.
Chromosomal rearrangements and point mutations in the DHFR-TS gene of Plasmodium chabaudi under antifolate selection.
Combinations of 4-aminobenzoic acid competitors and dihydrofolate dehydrogenase inhibitors in the chemotherapy of malaria. A commentary.
Comparison of two nested PCR methods for the detection of human malaria.
Concentration-QT modelling of the novel DHFR inhibitor P218 in healthy male volunteers.
Concurrence of Plasmodium falciparum dhfr and crt mutations in northern Ghana.
Cycloguanil and its parent compound proguanil demonstrate distinct activities against Plasmodium falciparum malaria parasites transformed with human dihydrofolate reductase.
Decline in sulfadoxine-pyrimethamine-resistant alleles after change in drug policy in the Amazon region of Peru.
Decreased susceptibility to dihydrofolate reductase inhibitors associated with genetic polymorphisms in Ugandan Plasmodium falciparum isolates.
Determinants of treatment response to sulfadoxine-pyrimethamine and subsequent transmission potential in falciparum malaria.
Development of a lead inhibitor for the A16V+S108T mutant of dihydrofolate reductase from the cycloguanil-resistant strain (T9/94) of Plasmodium falciparum.
dhfr and dhps genotype and sulfadoxine-pyrimethamine treatment failure in children with falciparum malaria in the Democratic Republic of Congo.
DHFR gene point mutation as a predictor of Plasmodium falciparum resistance to cycloguanil in malaria cases from Africa imported to France.
Dihydrofolate reductase and antifolate resistance in malaria.
Dihydrofolate reductase I164L mutations in Plasmodium falciparum isolates: clinical outcome of 14 Kenyan adults infected with parasites harbouring the I164L mutation.
Dihydrofolate reductase inhibitors: developments in antiparasitic chemotherapy.
Dihydrofolate reductase: thymidylate synthase, a bifunctional polypeptide from Crithidia fasciculata.
Discordance in drug resistance-associated mutation patterns in marker genes of Plasmodium falciparum and Plasmodium knowlesi during coinfections.
Discovery of traditional Chinese medicine derived compounds as wild type and mutant Plasmodium falciparum dihydrofolate reductase inhibitors: Induced fit docking and ADME studies.
Divergent regulation of dihydrofolate reductase between malaria parasite and human host.
Effect of trimethoprim-sulphamethoxazole on the risk of malaria in HIV-infected Ugandan children living in an area of widespread antifolate resistance.
Efficacy of artemisinin-based combination therapies for the treatment of falciparum malaria in Pakistan (2007-2015): In vivo response and dhfr and dhps mutations.
Efficacy of artesunate + sulphadoxine/pyrimethamine and artemether + lumefantrine and dhfr and dhps mutations in Somalia: evidence for updating the malaria treatment policy.
Efficacy of sulphadoxine-pyrimethamine for intermittent preventive treatment of malaria in pregnancy, Mansa, Zambia.
Emergence of sulfadoxine-pyrimethamine resistance in Indian isolates of Plasmodium falciparum in the last two decades.
Essential protein-protein interactions between Plasmodium falciparum thymidylate synthase and dihydrofolate reductase domains.
Evaluation of antigen detection tests, microscopy, and polymerase chain reaction for diagnosis of malaria in peripheral blood in asymptomatic pregnant women in nanoro, burkina faso.
Evidence of selective sweeps in genes conferring resistance to chloroquine and pyrimethamine in Plasmodium falciparum isolates in India.
Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria.
Fitness effects of DHFR-TS mutations associated with pyrimethamine resistance in apicomplexan parasites.
Folate metabolism as a source of molecular targets for antimalarials.
Functional expression of the dihydrofolate reductase and thymidylate synthetase activities of the human malaria parasite Plasmodium falciparum in Escherichia coli.
Gametocytocidal and sporontocidal effects of antimalarial drugs on malaria parasites. II. Action of the folic reductase inhibitors, chlorguanide, and pyrimethamine against Plasmodium cynomolgi.
Genetic evidence for Plasmodium falciparum resistance to chloroquine and pyrimethamine in Indochina and the Western Pacific between 1984 and 1998.
Genetic variations of the dihydrofolate reductase gene of Plasmodium vivax in Mandalay Division, Myanmar.
Genotypes and in vivo resistance of Plasmodium falciparum isolates in an endemic region of Iran.
Geographic distribution of amino acid mutations in DHFR and DHPS in Plasmodium vivax isolates from Lao PDR, India and Colombia.
Geographical distribution of amino acid mutations in Plasmodium vivax DHFR and DHPS from malaria endemic areas of Thailand.
Geographical spread and structural basis of sulfadoxine-pyrimethamine drug-resistant malaria parasites.
High chloroquine treatment failure rates and predominance of mutant genotypes associated with chloroquine and antifolate resistance among falciparum malaria patients from the island of Car Nicobar, India.
High multiple mutations of Plasmodium falciparum-resistant genotypes to sulphadoxine-pyrimethamine in Lagos, Nigeria.
High prevalence of drug-resistance mutations in Plasmodium falciparum and Plasmodium vivax in southern Ethiopia.
High-level Plasmodium falciparum sulfadoxine-pyrimethamine resistance with the concomitant occurrence of septuple haplotype in Tanzania.
Homology modeling of dihydrofolate reductase from T. gondii bonded to antagonists: molecular docking and molecular dynamics simulations.
Human dihydrofolate reductase influences the sensitivity of the malaria parasite Plasmodium falciparum to ketotifen - A cautionary tale in screening transgenic parasites.
Hybrid Inhibitors of Malarial Dihydrofolate Reductase with Dual Binding Modes That Can Forestall Resistance.
Identification of novel Mycobacterium tuberculosis dihydrofolate reductase inhibitors through rational drug design.
Identification of P218 as a potent inhibitor of Mycobacterium ulcerans DHFR.
Identification of the optimal third generation antifolate against P. falciparum and P. vivax.
Identifying antimalarial compounds targeting dihydrofolate reductase-thymidylate synthase (DHFR-TS) by chemogenomic profiling.
In vivo efficacy of sulphadoxine-pyrimethamine for the treatment of asymptomatic parasitaemia in pregnant women in Machinga District, Malawi.
Increased prevalence of dhfr and dhps mutants at delivery in Malawian pregnant women receiving intermittent preventive treatment for malaria.
Inhibitors of dihydrofolate reductase in Leishmania and trypanosomes.
Kinetic and molecular properties of the dihydrofolate reductase from pyrimethamine-sensitive and pyrimethamine-resistant clones of the human malaria parasite Plasmodium falciparum.
Linkage disequilibrium between two chromosomally distinct loci associated with increased resistance to chloroquine in Plasmodium falciparum.
Linkage group selection: rapid gene discovery in malaria parasites.
Loop-Mediated Isothermal Amplification and LFD Combination for Detection of Plasmodium falciparum and Plasmodium vivax.
Low infectivity of Plasmodium falciparum gametocytes to Anopheles gambiae following treatment with sulfadoxine-pyrimethamine in Mali.
Malaria antifolate resistance with contrasting Plasmodium falciparum dihydrofolate reductase (DHFR) polymorphisms in humans and Anopheles mosquitoes.
Malaria cure with sulphadoxine/pyrimethamine combination in 12 semi-immune adults from West-Central Africa with high rates of point mutations in Plasmodium falciparum dhfr and dhps genes.
Malaria treatment failure with novel mutation in the Plasmodium falciparum dihydrofolate reductase (pfdhfr) gene in Kolkata, West Bengal, India.
Mapping sulphadoxine-pyrimethamine-resistant Plasmodium falciparum malaria in infected humans and in parasite populations in Africa.
Modelling and informatics in the analysis of P. falciparum DHFR enzyme inhibitors.
Molecular characterization of dihydrofolate reductase in relation to antifolate resistance in Plasmodium vivax.
Molecular docking analysis of phyto-constituents from Cannabis sativa with pfDHFR.
Molecular Docking Analysis of Pyrimethamine Derivatives with Plasmodium falciparum Dihydrofolate Reductase.
Molecular docking and QSAR studies for modeling the antimalarial activity of hybrids 4-anilinoquinoline-triazines derivatives with the wild-type and mutant receptor pf-DHFR.
Molecular epidemiology of malaria in Cameroon. XI. Geographic distribution of Plasmodium falciparum isolates with dihydrofolate reductase gene mutations in southern and central Cameroon.
Molecular epidemiology of malaria in Cameroon. XXII. Geographic mapping and distribution of Plasmodium falciparum dihydrofolate reductase (dhfr) mutant alleles.
Molecular epidemiology of malaria in Cameroon. XXVII. Clinical and parasitological response to sulfadoxine-pyrimethamine treatment and Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase alleles in Cameroonian children.
Molecular epidemiology of malaria in Cameroon. XXX. sequence analysis of Plasmodium falciparum ATPase 6, dihydrofolate reductase, and dihydropteroate synthase resistance markers in clinical isolates from children treated with an artesunate-sulfadoxine-pyrimethamine combination.
Molecular epidemiology of malaria in Yaounde, Cameroon I. Analysis of point mutations in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum.
Molecular epidemiology of malaria in Yaounde, Cameroon. VI. Sequence variations in the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene and in vitro resistance to pyrimethamine and cycloguanil.
Molecular epidemiology of Plasmodium vivax anti-folate resistance in India.
Molecular markers of resistance to sulfadoxine-pyrimethamine during intermittent preventive treatment for malaria in Mozambican infants.
Molecular surveillance of Plasmodium vivax dhfr and dhps mutations in isolates from Afghanistan.
Molecular survey of Plasmodium falciparum resistance in south-eastern Iran.
Mutagenesis of dihydrofolate reductase from Plasmodium falciparum: analysis in Saccharomyces cerevisiae of triple mutant alleles resistant to pyrimethamine or WR99210.
Mutational 'hot-spots' in mammalian, bacterial and protozoal dihydrofolate reductases associated with antifolate resistance: sequence and structural comparison.
Mutations in the antifolate-resistance-associated genes dihydrofolate reductase and dihydropteroate synthase in Plasmodium vivax isolates from malaria-endemic countries.
New developments in malaria diagnostics: Monoclonal antibodies against Plasmodium dihydrofolate reductase-thymidylate synthase, heme detoxification protein and glutamate rich protein.
Novel approaches to tackling malarial drug resistance using yeast.
Occurrence of septuple and elevated Pfdhfr-Pfdhps quintuple mutations in a general population threatens the use of sulfadoxine-pyrimethamine for malaria prevention during pregnancy in eastern-coast of Tanzania.
Pharmacokinetic justification of antiprotozoal therapy. A US perspective.
Plasmodium falciparum multiple infections, disease severity and host characteristics in malaria affected travellers returning from Africa.
Plasmodium falciparum: mutation pattern in the dihydrofolate reductase-thymidylate synthase genes of Vietnamese isolates, a novel mutation, and coexistence of two clones in a Thai patient.
Plasmodium falciparum: selection of serine 108 of dihydrofolate reductase during treatment of uncomplicated malaria with co-trimoxazole in Ugandan children.
Plasmodium vivax: Prevalence of mutations associated with sulfadoxine-pyrimethamine resistance in Plasmodium vivax clinical isolates from Pakistan.
Polyclonal Plasmodium falciparum malaria in travelers and selection of antifolate mutations after proguanil prophylaxis.
Polymorphism in dhfr/dhps genes, parasite density and ex vivo response to pyrimethamine in Plasmodium falciparum malaria parasites in Thies, Senegal.
Polymorphisms in Plasmodium falciparum dhfr and dhps genes and age related in vivo sulfadoxine-pyrimethamine resistance in malaria-infected patients from Nigeria.
Polymorphisms in Plasmodium falciparum dihydropteroate synthetase and dihydrofolate reductase genes in Nigerian children with uncomplicated malaria using high-resolution melting technique.
Population-based validation of dihydrofolate reductase gene mutations for the prediction of sulfadoxine-pyrimethamine resistance in Uganda.
Preclinical evaluation of antifolate QN254 (5-chloro-N*6*-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine) as antimalarial drug candidate.
Prevalence of mutations in dihydrofolate reductase and dihydropteroate synthetase genes of Plasmodium falciparum: analysis of imported cases of malaria in Italy.
Prevalence of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes of Plasmodium falciparum isolates from southern Mauritania.
Prevalence of the dihydrofolate reductase Asn-108 mutation as the basis for pyrimethamine-resistant falciparum malaria in the Brazilian Amazon.
Probing the role of parasite-specific, distant structural regions on communication and catalysis in the bifunctional thymidylate synthase-dihydrofolate reductase from Plasmodium falciparum.
Probing the Structural Dynamics of the Plasmodium falciparum Tunneling-Fold Enzyme 6-Pyruvoyl Tetrahydropterin Synthase to Reveal Allosteric Drug Targeting Sites.
Profiles of Kelch mutations in Plasmodium falciparum across South Asia and their implications for tracking drug resistance.
Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations.
Purification of the bifunctional thymidylate synthase-dihydrofolate reductase complex from the human malaria parasite Plasmodium falciparum.
Pyrimethamine analogs as strong inhibitors of double and quadruple mutants of dihydrofolate reductase in human malaria parasites.
Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa.
Pyrimethamine and WR99210 exert opposing selection on dihydrofolate reductase from Plasmodium vivax.
Pyrimethamine resistant mutations in Plasmodium falciparum.
Pyrimethamine-sulfadoxine efficacy and selection for mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase in Mali.
Quantitative structure-activity relationships for cycloguanil analogs as PfDHFR inhibitors using mathematical molecular descriptors.
Rapid detection of pyrimethamine susceptibility of Plasmodium falciparum by restriction endonuclease digestion of the dihydrofolate reductase gene.
Relationship between age, molecular markers, and response to sulphadoxine-pyrimethamine treatment in Kampala, Uganda.
Resistance to antifolates in Plasmodium falciparum, the causative agent of tropical malaria.
Response of Plasmodium falciparum to cotrimoxazole therapy: relationship with plasma drug concentrations and dihydrofolate reductase and dihydropteroate synthase genotypes.
Selection of antifolate-resistant Plasmodium falciparum by sulfadoxine-pyrimethamine treatment and infectivity to anopheles mosquitoes.
Selection strength and hitchhiking around two anti-malarial resistance genes.
Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine.
Sequence variations in the genes encoding dihydropteroate synthase and dihydrofolate reductase and clinical response to sulfadoxine-pyrimethamine in patients with acute uncomplicated falciparum malaria.
Sequence variations in the Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene and their relationship with pyrimethamine resistance.
Shape- and chemical feature-based 3D-pharmacophore model generation and virtual screening: identification of potential leads for P. falciparum DHFR enzyme inhibition.
Similar trends of pyrimethamine resistance-associated mutations in Plasmodium vivax and P. falciparum.
Stable molecular transformation of Toxoplasma gondii: a selectable dihydrofolate reductase-thymidylate synthase marker based on drug-resistance mutations in malaria.
Stable transfection of malaria parasite blood stages.
Stepwise acquisition of pyrimethamine resistance in the malaria parasite.
Structural studies provide clues for analog design of specific inhibitors of Cryptosporidium hominis thymidylate synthase-dihydrofolate reductase.
Submicroscopic gametocytes and the transmission of antifolate-resistant Plasmodium falciparum in Western Kenya.
Substituted pyrrolo[2,3-d]pyrimidines as Cryptosporidium hominis thymidylate synthase inhibitors.
Targeting DHFR in parasitic protozoa.
The chemotherapy of rodent malaria, 8. The action of some sulphonamides alone or with folic reductase inhibitors against malaria vectors and parasites, part 3: the action of sulphormethoxine and pyrimethamine on the sporogonic stages.
The chemotherapy of rodent malaria. 18. The action of some sulphonamides alone or with folic reductase inhibitors against malaria vectors and parasites. 5. The blood schizontocidal action of some newer sulphonamides.
The chemotherapy of rodent malaria. VI. The action of some sulphonamides alone or with folic reductase inhibitors against malaria vectors and parasites. I. Introduction and anti-vector studies.
The chemotherapy of rodent malaria. VII. The action of some sulphonamides alone or with folic reductase inhibitors against malaria vectors and parasites, 2: schizontocidal action in the albino mouse.
The chemotherapy of rodent malaria. XIV. The action of some sulphonamides alone or with folic reductase inhibitors against malaria vectors and parasites. 4. The response of normal and drug-resistant strains of Plasmodium berghei.
The cytogenetic effects of pyrimethamine on male mouse germ cells.
The effect of point mutations in dihydrofolate reductase genes and multidrug resistance gene 1-86 on treatment of falciparum malaria in Sudan.
The Plasmodium falciparum, Nima-related kinase Pfnek-4: a marker for asexual parasites committed to sexual differentiation.
The selectable marker human dihydrofolate reductase enables sequential genetic manipulation of the Plasmodium berghei genome.
Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations.
Therapeutic efficacy of artesunate in the treatment of uncomplicated Plasmodium falciparum malaria and anti-malarial, drug-resistance marker polymorphisms in populations near the China- Myanmar border.
Therapeutic efficacy of sulfadoxine-pyrimethamine and prevalence of resistance markers in Tanzania prior to revision of malaria treatment policy: Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase mutations in monitoring in vivo resistance.
Towards an understanding of drug resistance in malaria: three-dimensional structure of Plasmodium falciparum dihydrofolate reductase by homology building.
Transformation of Plasmodium falciparum malaria parasites by homologous integration of plasmids that confer resistance to pyrimethamine.
Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil.
Two mutations in dihydrofolate reductase combined with one in the dihydropteroate synthase gene predict sulphadoxine-pyrimethamine parasitological failure in Ugandan children with uncomplicated falciparum malaria.
Understanding the Pyrimethamine Drug Resistance Mechanism via Combined Molecular Dynamics and Dynamic Residue Network Analysis.
Validation of a simplified method for using molecular markers to predict sulfadoxine-pyrimethamine treatment failure in African children with falciparum malaria.
Whole genome re-sequencing identifies a mutation in an ABC transporter (mdr2) in a Plasmodium chabaudi clone with altered susceptibility to antifolate drugs.
[Molecular epidemiological surveillance of markers for antimalarial drugs in Plasmodium falciparum isolates imported to Barcelona, Spain]
[Molecular markers for malaria drug resistance: necessary but not sufficient criteria to decide change in treatment policy]
[Monitoring the chemoresistance of Plasmodium falciparum malaria in Yopougon (Abidjan): in vivo study of chloroquine sensitivity and evaluation of pyrimethamine resistance following the analysis of point mutation in the dihydrofolate reductase gene]
[Point mutations in dihydrofolate reductase and dihydropteroate synthase genes of Plasmodium falciparum from three endemic malaria regions in Colombia]
[Resistance to chloroquine and cycloguanil of Plasmodium falciparum in patients arriving in France after travel in Africa without chemoprophylaxis]
Malaria, Avian
Global phylogeographic limits of Hawaii's avian malaria.
Malaria, Cerebral
Evidence of selective sweeps in genes conferring resistance to chloroquine and pyrimethamine in Plasmodium falciparum isolates in India.
Malaria, Falciparum
A shared Asian origin of the triple-mutant dhfr allele in Plasmodium falciparum from sites across Africa.
Cycloguanil and its parent compound proguanil demonstrate distinct activities against Plasmodium falciparum malaria parasites transformed with human dihydrofolate reductase.
Decline in sulfadoxine-pyrimethamine-resistant alleles after change in drug policy in the Amazon region of Peru.
dhfr and dhps genotype and sulfadoxine-pyrimethamine treatment failure in children with falciparum malaria in the Democratic Republic of Congo.
Divergent regulation of dihydrofolate reductase between malaria parasite and human host.
Hybrid Inhibitors of Malarial Dihydrofolate Reductase with Dual Binding Modes That Can Forestall Resistance.
Polymorphism in dhfr/dhps genes, parasite density and ex vivo response to pyrimethamine in Plasmodium falciparum malaria parasites in Thies, Senegal.
Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa.
Pyrimethamine and WR99210 exert opposing selection on dihydrofolate reductase from Plasmodium vivax.
Therapeutic efficacy of artesunate in the treatment of uncomplicated Plasmodium falciparum malaria and anti-malarial, drug-resistance marker polymorphisms in populations near the China- Myanmar border.
Transformation of Plasmodium falciparum malaria parasites by homologous integration of plasmids that confer resistance to pyrimethamine.
Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil.
[Monitoring the chemoresistance of Plasmodium falciparum malaria in Yopougon (Abidjan): in vivo study of chloroquine sensitivity and evaluation of pyrimethamine resistance following the analysis of point mutation in the dihydrofolate reductase gene]
Malaria, Vivax
Association of genetic mutations in Plasmodium vivax dhfr with resistance to sulfadoxine-pyrimethamine: geographical and clinical correlates.
Evaluation of the activities of pyrimethamine analogs against Plasmodium vivax and Plasmodium falciparum dihydrofolate reductase-thymidylate synthase using in vitro enzyme inhibition and bacterial complementation assays.
Lack of quadruple and quintuple mutant alleles associated with sulfadoxine-pyrimethamine resistance in Plasmodium vivax isolates from Brazilian endemic areas.
Pyrimethamine and WR99210 exert opposing selection on dihydrofolate reductase from Plasmodium vivax.
Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations.
Malnutrition
Effect of malnutrition on methotrexate toxicity and tissue levels of dihydrofolate reductase in the rat.
Effect of protein-intake on dihydrofolate-reductase activity of host and tumor-tissues.
Marek Disease
A gene for dihydrofolate reductase in a herpesvirus.
Mastitis
Effects of endotoxin-induced mastitis on the pharmacokinetic properties of aditoprim in dairy cows.
Mastocytoma
Anti-Thy-1 antibody responses evoked by Thy-1 antigen expressed in transfected mouse mastocytoma cells and rat fibroblast.
Measles
Generation of mammalian cells expressing stably measles virus proteins via bicistronic RNA.
Medulloblastoma
Dihydrofolate reductase activity in primary brain tumors in children.
miR-192 suppresses leptomeningeal dissemination of medulloblastoma by modulating cell proliferation and anchoring through the regulation of DHFR, integrins, and CD47.
Melanoma
Current research on immunopathology of melanoma: analysis of lymphocyte populations in relation to antigen expression and histological features of melanoma.
Detection of human soluble Thy-1 in serum by ELISA. Fibroblasts and activated endothelial cells are a possible source of soluble Thy-1 in serum.
Directed phenotype switching as an effective antimelanoma strategy.
Dynamic catch of a Thy-1-?5?1+syndecan-4 trimolecular complex.
Endogenous gene and amplifiable cDNA construct both produce unstable t-PA mRNA in Bowes melanoma cells.
Expression of Thy-1 antigen on human melanoma cells.
Interaction of human Thy-1 (CD 90) with the integrin alphavbeta3 (CD51/CD61): an important mechanism mediating melanoma cell adhesion to activated endothelium.
Mechanism of dihydrofolate reductase downregulation in melanoma by 3-O-(3,4,5-trimethoxybenzoyl)-(-)-epicatechin.
Melanoma Activation of 3-O-(3,4,5-Trimethoxybenzoyl)-(-)-Epicatechin to a Potent Irreversible Inhibitor of Dihydrofolate Reductase.
Melanoma cells use Thy-1 (CD90) on endothelial cells for metastasis formation.
Natural resistance to methotrexate in human melanomas.
Synthesis and Biological Activity of a 3,4,5-Trimethoxybenzoyl Ester Analogue of Epicatechin-3-gallate.
The Thy-1/Thy-1 ligand interaction is involved in binding of melanoma cells to activated Thy-1- positive microvascular endothelial cells.
Thy-1 (CD90)-Induced Metastatic Cancer Cell Migration and Invasion Are ?3 Integrin-Dependent and Involve a Ca2+/P2X7 Receptor Signaling Axis.
Thymidylate synthase as a target enzyme for the melanoma-specific toxicity of 4-S-cysteaminylphenol and N-acetyl-4-S-cysteaminylphenol.
Melanoma, Experimental
Phase I clinical and pharmacokinetic study of trimetrexate using a daily x5 schedule.
Mesothelioma
Protection of hematopoietic stem cells from pemetrexed toxicity by retroviral gene transfer with a mutant dihydrofolate reductase-mutant thymidylate synthase fusion gene.
TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed.
Mesothelioma, Malignant
TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed.
Monoclonal Gammopathy of Undetermined Significance
Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis.
Mucositis
Effect of local bee honey on dihydrofolate reductase enzyme inhibitor-induced mucositis: A histological study on albino wistar rats.
Multiple Myeloma
Proteomic analysis of oridonin-induced apoptosis in multiple myeloma cells.
The anti-tumor activity of pralatrexate (PDX) correlates with the expression of RFC and DHFR mRNA in preclinical models of multiple myeloma.
Murine Acquired Immunodeficiency Syndrome
A unique subset of normal murine CD4+ T cells lacking Thy-1 is expanded in a murine retrovirus-induced immunodeficiency syndrome, MAIDS.
Muscle Weakness
The Sympathetic Nervous System Regulates Skeletal Muscle Motor Innervation and Acetylcholine Receptor Stability.
Muscular Atrophy
eNOS Uncoupling, A Therapeutic Target For Ischemic Foot of Diabetic Rat.
Muscular Dystrophy, Duchenne
Two expressed human genes sustain slightly more DNA damage after alkylating agent treatment than an inactive gene.
Mycosis Fungoides
Cutaneous expression of Thy-1 in mycosis fungoides.
Thy-1 and T-cell receptor antigen expression in mycosis fungoides and benign inflammatory dermatoses.
Myelodysplastic Syndromes
Cytochemical study of tetrahydrofolate dehydrogenase in myelodysplastic syndromes.
Flow cytometric analysis of Thy-1 expression in myelodysplastic syndrome.
Qualitative and quantitative study of dihydrofolate reductase in myelodysplastic syndromes.
Nasopharyngeal Carcinoma
Overexpression of thymidylate synthetase confers an independent prognostic indicator in nasopharyngeal carcinoma.
Thy-1, a versatile modulator of signaling affecting cellular adhesion, proliferation, survival, and cytokine/growth factor responses.
Neoplasm Metastasis
Antimalarial drug pyrimethamine plays a dual role in anti-tumor proliferation and metastasis through targeting DHFR and TP.
Current research on immunopathology of melanoma: analysis of lymphocyte populations in relation to antigen expression and histological features of melanoma.
Expression of Thy-1 antigen on human melanoma cells.
Genetic determinants of methotrexate responsiveness and resistance in colon cancer cells.
Imaging of dihydrofolate reductase fusion gene expression in xenografts of human liver metastases of colorectal cancer in living rats.
Impact of genetic variants of RFC1, DHFR and MTHFR in osteosarcoma patients treated with high-dose methotrexate.
Levels of E2F-1 expression are higher in lung metastasis of colon cancer as compared with hepatic metastasis and correlate with levels of thymidylate synthase.
Mechanisms of methotrexate resistance in osteosarcoma.
Melanoma cells use Thy-1 (CD90) on endothelial cells for metastasis formation.
Methotrexate and methotrexate polyglutamates in human sarcoma metastases after high-dose methotrexate therapy.
Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression.
Methotrexate induces apoptosis in CaSki and NRK cells and influences the organization of their actin cytoskeleton.
Nonmetastatic tumor cells acquire metastatic properties following somatic hybridization with normal cells.
Overexpression of thymidylate synthetase confers an independent prognostic indicator in nasopharyngeal carcinoma.
Roles Of EAAT1, DHFR, And Fetuin-A In The Pathogenesis, Progression And Prognosis Of Chondrosarcoma.
The Thy-1/Thy-1 ligand interaction is involved in binding of melanoma cells to activated Thy-1- positive microvascular endothelial cells.
Thy-1 (CD90)-Induced Metastatic Cancer Cell Migration and Invasion Are ?3 Integrin-Dependent and Involve a Ca2+/P2X7 Receptor Signaling Axis.
Thy-1 as a regulator of cell-cell and cell-matrix interactions in axon regeneration, apoptosis, adhesion, migration, cancer, and fibrosis.
Thy-1 in Integrin Mediated Mechanotransduction.
Up-regulation of thy-1 promotes invasion and metastasis of hepatocarcinomas.
Neoplasms
10-Ethyl-10-deaza-aminopterin: structural design and biochemical, pharmacologic, and antitumor properties.
2,4-Diamino-5-(2'-arylpropargyl)pyrimidine derivatives as new nonclassical antifolates for human dihydrofolate reductase inhibition.
2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline (tmq), a potent non-classical folate antagonist inhibitor--I effect on dihydrofolate reductase and growth of rodent tumors in vitro and in vivo.
3-Methyl-imidazo[2,1-b]thiazole derivatives as a new class of antifolates: Synthesis, in vitro/in vivo bio-evaluation and molecular modeling simulations.
A comparison of the inhibition of growth of methotrexate-resistant and -sensitive leukemia cells in culture by triazines. Evidence for a new mechanism of cell resistance to methotrexate.
A conjugate of adriamycin and monoclonal antibodies to Thy-1 antigen inhibits human neuroblastoma cells in vitro.
A Daily Dose of 5 mg Folic Acid for 90 Days Is Associated with Increased Serum Unmetabolized Folic Acid and Reduced Natural Killer Cell Cytotoxicity in Healthy Brazilian Adults.
A new form of dihydrofolate reductase in cancer cells.
A one-pot analysis approach to simplify measurements of protein stability and folding kinetics.
A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma.
A polycistronic transcript in transformed cells encodes the dihydrofolate reductase of herpesvirus saimiri.
A rapid method for separating tumour infiltrating cells and tumour cells from colorectal tumours.
A second target of benzamide riboside: Dihydrofolate reductase.
A Tribute to Bruce Chabner.
A-to-I RNA Editing Up-regulates Human Dihydrofolate Reductase in Breast Cancer.
Aberrant Expression of Folate Metabolism Enzymes and Its Diagnosis and Survival Prediction in Ovarian Carcinoma.
Accumulation, intracellular metabolism, and antitumor activity of high- and low-dose methotrexate in human osteosarcoma xenografts.
Acetylshikonin isolated from Lithospermum erythrorhizon roots inhibits dihydrofolate reductase and hampers autochthonous mammary carcinogenesis in ?16HER2 transgenic mice.
Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 gene mutations.
Analogues of methotrexate and aminopterin with gamma-methylene and gamma-cyano substitution of the glutamate side chain: synthesis and in vitro biological activity.
Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells.
Analysis of dihydrofolate reductase gene amplification in a methotrexate-resistant human tumor cell line.
Analysis of the mRNA expression of chemotherapy-related genes in colorectal carcinoma using the danenberg tumor profile method.
Anticancer properties of distinct antimalarial drug classes.
Antifolate agents: a patent review (2010 - 2013).
Antifolate polyglutamylation and competitive drug displacement at dihydrofolate reductase as important elements in leucovorin rescue in L1210 cells.
Antitumor activity of Toxoplasma lysate antigen against methylcholanthrene-induced tumor-bearing rats.
Applying the designed multiple ligands approach to inhibit dihydrofolate reductase and thioredoxin reductase for anti-proliferative activity.
Association between HIC1 and RASSF1A promoter hypermethylation with MTHFD1 G1958A polymorphism and clinicopathological features of breast cancer in Iranian patients.
Binding of natural and synthetic polyphenols to human dihydrofolate reductase.
Biochemical and biological studies on 2-desamino-2-methylaminopterin, an antifolate the polyglutamates of which are more potent than the monoglutamate against three key enzymes of folate metabolism.
Biochemical correlates of responsiveness and collateral sensitivity of some methotrexate-resistant murine tumors to the lipophilic antifolate, metoprine.
Biochemical factors in the selectivity of leucovorin rescue: selective inhibition of leucovorin reactivation of dihydrofolate reductase and leucovorin utilization in purine and pyrimidine biosynthesis by methotrexate and dihydrofolate polyglutamates.
Biosynthetic and structural studies on Thy-1 in a rat neuronal tumor cell line.
Bispecific antibodies target operationally tumor-specific antigens in two leukemia relapse models.
c-Myc dependent initiation of genomic instability during neoplastic transformation.
c-Myc-associated genomic instability of the dihydrofolate reductase locus in vivo.
Cancer research: from folate antagonism to molecular targets.
CD90 and CD24 Co-Expression Is Associated with Pancreatic Intraepithelial Neoplasias.
Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells.
Cell-type-specific markers for distinguishing and studying neurons and the major classes of glial cells in culture.
Cellular and molecular mechanisms of resistance to antifolate drugs: new analogues and approaches to overcome the resistance.
Cellular changes and antitumor responses in the plasmacytoma-bearing mouse following cyclophosphamide treatment.
Central nervous system pharmacology of Baker's antifolate (NSC139105) in man.
Chapter 9 regulation of human dihydrofolate reductase activity and expression.
Characterization of in vivo chemoresistant human hepatocellular carcinoma cells with transendothelial differentiation capacities.
Characterization of tumor-associated lymphocytes in a series of mouse mammary tumor lines with differing biological properties.
Clinical efficacy and mechanism of Pralatrexate combined with Palbociclib Isethionate in treatment of bladder cancer patients.
CNT-based nanocarrier loaded with pyrimethamine for adipose mesenchymal stem cells differentiation and cancer treatment: The computational and experimental methods.
Co-expression and amplification of dihydrofolate reductase cDNA and the Escherichia coli XGPRT gene in Chinese hamster ovary cells.
Combination therapy of colon carcinoma 26 in mice with recombinant human interleukin-2 and interferon-alpha A/D: occurrence of large granular cells in the tumor.
Computer modeling studies of the structural role of NADPH binding to active site mutants of human dihydrofolate reductase in complex with piritrexim.
Construction of a dominant selectable marker using a novel dihydrofolate reductase.
Control of syngeneic tumor growth by activation of CD8+ T cells: efficacy is limited by migration away from the site and induction of nonresponsiveness.
Current research on immunopathology of melanoma: analysis of lymphocyte populations in relation to antigen expression and histological features of melanoma.
Cyclin-dependent kinase inhibitor SU9516 enhances sensitivity to methotrexate in human T-cell leukemia Jurkat cells.
Cytoxicity of [(5,6-dichloro-9a-n-propyl-2,3,9,9a-tetrahydro-3-oxo-1H fluoren-7-yl)oxy]acetic acid, an agent known to reduce brain edema.
Daily supplementation with 5 mg of folic acid in Brazilian patients with hereditary spherocytosis.
Demonstration of complex antigenic heterogeneity in a human glioma cell line and eight derived clones by specific monoclonal antibodies.
Dendrimer-based multivalent methotrexates as dual acting nanoconjugates for cancer cell targeting.
Deregulation of the G1/S phase transition in cancer and squamous intraepithelial lesions of the uterine cervix: a case control study.
Design and In vitro Validation of Multivalent Dendrimer Methotrexates as a Folate-targeting Anticancer Therapeutic.
Design and rationale for novel antifolates.
Design and Synthesis of Classical and Nonclassical 6-Arylthio-2,4-diamino-5-ethylpyrrolo[2,3-d]pyrimidines as Antifolates.
Design of dihydrofolate reductase inhibitors from X-ray crystal structures.
Design, Synthesis, and Biological Evaluation of Coupled Bioactive Scaffolds as Potential Anticancer Agents for Dual Targeting of Dihydrofolate Reductase and Thioredoxin Reductase.
Design, synthesis, and X-ray crystal structure of a potent dual inhibitor of thymidylate synthase and dihydrofolate reductase as an antitumor agent.
Design, synthesis, and X-ray crystal structure of classical and nonclassical 2-amino-4-oxo-5-substituted-6-ethylthieno[2,3-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors and as potential antitumor agents.
Determination of plasma trimetrexate levels using gas chromatography-mass spectrometry with selected-ion monitoring.
Determination of thymidine phosphorylase expression level facilitates recurrence risk stratification in stage II/III colorectal cancer following adjuvant chemotherapy with oral fluoropyrimidines.
Developmental pattern of Thy-1 immunoreactivity in the human kidney and the application to pediatric renal neoplasms.
DHFR and MDR1 upregulation is associated with chemoresistance in osteosarcoma stem-like cells.
DHFR Inhibitors: Reading the Past for Discovering Novel Anticancer Agents.
DHFR/TYMS are positive regulators of glioma cell growth and modulate chemo-sensitivity to temozolomide.
Differential methotrexate toxicity between two human oral squamous carcinoma cell lines.
Differential oncogene amplification in tumor cells from a patient treated with cisplatin and 5-fluorouracil.
Differential regulation of retinoblastoma tumor suppressor protein by G(1) cyclin-dependent kinase complexes in vivo.
Dihydrofolate reductase and cell growth activity inhibition by the beta-carboline-benzoquinolizidine plant alkaloid deoxytubulosine from Alangium lamarckii: its potential as an antimicrobial and anticancer agent.
Dihydrofolate reductase as a predictor for poor response to platinum-based chemotherapy in epithelial ovarian cancer.
Dihydrofolate reductase gene variations in susceptibility to disease and treatment outcomes.
Dihydrofolate reductase in primary brain tumors, cell cultures of central nervous system origin, and normal brain during fetal and neonatal growth.
Disparate Response to Methotrexate in Stem Versus Non-Stem Cells.
DNA damage and repair measured in different genomic regions using the comet assay with fluorescent in situ hybridization.
DNA variants in DHFR gene and response to treatment in children with childhood B ALL: revisited in AIEOP-BFM protocol.
DNA Variants in Region for Noncoding Interfering Transcript of Dihydrofolate Reductase Gene and Outcome in Childhood Acute Lymphoblastic Leukemia.
E mu-bcl-2 transgene facilitates spontaneous transformation of early pre-B and immunoglobulin-secreting cells but not T cells.
Effect of C9-methyl substitution and C8-C9 conformational restriction on antifolate and antitumor activity of classical 5-substituted 2,4-diaminofuro[2,3-d]pyrimidines.
Effect of in vivo administration of Lyt antibodies. Lyt phenotype of T cells in lymphoid tissues and blocking of tumor rejection.
Effect of methotrexate-monoclonal anti-prostatic acid phosphatase antibody conjugate on human prostate tumor.
Effect of protein-intake on dihydrofolate-reductase activity of host and tumor-tissues.
Effects of anti-sense oligonucleotides directed toward dihydrofolate reductase RNA in mammalian cultured cells.
Effects of PSK, an antitumor protein-bound polysaccharide, on the surface charge of lymphocytes in X5563-bearing mice.
Effects of trimethoprim on leukaemic cells in vitro.
Efficient utilization of the reduced folate carrier in CCRF-CEM human leukemic lymphoblasts by the potent antifolate N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L- ornithine (PT523) and its B-ring analogues.
Emodin Inhibits Breast Cancer Growth by Blocking the Tumor-Promoting Feedforward Loop between Cancer Cells and Macrophages.
Enhanced degradation of dihydrofolate reductase through inhibition of NAD kinase by nicotinamide analogs.
Enzymes of the one-carbon folate metabolism as anticancer targets predicted by survival rate analysis.
Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma.
Evaluation of UDP-glucuronosyltransferase 2B17 (UGT2B17) and dihydrofolate reductase (DHFR) genes deletion and the expression level of NGX6 mRNA in breast cancer.
Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas.
Expression of a new human THY-1 related antigen in Ewing's sarcoma and peripheral neuroectodermal tumors.
Expression of Ly-6, a marker for highly malignant murine tumor cells, is regulated by growth conditions and stress.
Expression of Ly-6.2 and Thy-1 antigens on NIH 3T3 cells suppressed after transformation with activated human ras-oncogenes.
Expression of p16(INK4A) but not hypoxia markers or poly adenosine diphosphate-ribose polymerase is associated with improved survival in patients with pancreatic adenocarcinoma.
Expression of the adhesion molecules CD49d and CD49e on G-CSF-mobilized CD34+ cells of patients with solid tumors or non-Hodgkin's and Hodgkin's lymphoma and of healthy donors is inversely correlated with the amount of mobilized CD34+ cells.
Expression of Thy-1 and effect of phosphatidylinositol-specific phospholipase C on primate and murine cell lines.
Expression of Thy-1 antigen on human melanoma cells.
Folate analogues. 21. Synthesis and antifolate and antitumor activities of N10-(cyanomethyl)-5,8-dideazafolic acid.
Formation, turnover, and sensitivity to phosphatidylinositol-specific phospholipase C of Thy-1 of a rat neuronal tumor cell line.
Further studies on substituted quinazolines and triazines as inhibitors of a methotrexate-insensitive murine dihydrofolate reductase.
Gene amplification: an example of accelerated evolution in tumorigenic cells.
Gene Polymorphisms Involved in Folate Metabolism and DNA Methylation with the Risk of Head and Neck Cancer.
Gene-specific DNA repair and steady state transcription of the MDR1 gene in human tumor cell lines.
Gene-specific DNA repair of pyrimidine dimers does not decline during cellular aging in vitro.
Genotoxicity of pemetrexed in human peripheral blood lymphocytes.
Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in human breast cancer.
Glucocorticoids regulate expression of dihydrofolate reductase cDNA in mouse mammary tumour virus chimaeric plasmids.
Halogenated derivatives of methotrexate as human dihydrofolate reductase inhibitors in cancer chemotherapy.
Heterogeneity of methotrexate binding in human colon tumor cells.
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
High-dose methotrexate therapy with leucovorin rescue: in vitro investigations on human osteosarcoma cell lines.
Highly inducible synthesis of heterologous proteins in epithelial cells carrying a glucocorticoid-responsive vector.
Histone deacetylase inhibition enhances the therapeutic effects of methotrexate on primary central nervous system lymphoma.
Human dihydrofolate reductase and thymidylate synthase form a complex in vitro and co-localize in normal and cancer cells.
Human embryonic and neuronal stem cell markers in retinoblastoma.
Hydrolysis of methotrexate-immunoglobulin conjugates by liver homogenates and characterization of catabolites.
Identification of a cis-acting element of human dihydrofolate reductase mRNA.
Identification of dihydrofolate reductase in human central-nervous-system tumours.
Identification of highly potent and selective inhibitors of Toxoplasma gondii dihydrofolate reductase.
Identification of novel Mycobacterium tuberculosis dihydrofolate reductase inhibitors through rational drug design.
Identification of three new compounds that directly target human serine hydroxymethyltransferase 2.
Immunogenetics of a thymus antigen in lymphoma-prone and lymphoma-resistant colonies of wild mice.
Immunoglobulin superfamily expression in primary retinoblastoma and retinoblastoma cell lines.
Immunologic basis of resistance to RL male 1 induced by immunoselected Thy-1.2 negative variants.
Immunophenotype profile of childhood medulloblastomas and supratentorial primitive neuroectodermal tumors using 16 monoclonal antibodies.
Immunophenotyping of childhood astrocytomas with a library of monoclonal antibodies.
In Silico Study Identified Methotrexate Analog as Potential Inhibitor of Drug Resistant Human Dihydrofolate Reductase for Cancer Therapeutics.
In Silico Study Probes Potential Inhibitors of Human Dihydrofolate Reductase for Cancer Therapeutics.
In vitro and in vivo interaction between murine fibrosarcoma cells and natural killer cells.
In vitro effects of Plasmodium falciparum dihydrofolate reductase inhibitors on normal and cancer cell proliferation.
In vivo methotrexate transport in murine Lewis lung tumor.
Increased levels of multiple forms of dihydrofolate reductase in peripheral blood leucocytes of cancer patients receiving haematopoietic colony-stimulating factors: interim analysis.
Increasing Methotrexate Resistance by Combination of Active-site Mutations in Human Dihydrofolate Reductase.
Induction of CD4(+)CD25(+)Foxp3(-) regulatory T cells by Thy-1 stimulation of CD4(+) T cells.
Induction of white cell proliferation due to haematopoietic growth factors is associated with an increase in multiple forms of dihydrofolate reductase in non-neutropenic cancer patients.
Influence of reduced folate carrier and dihydrofolate reductase genes on methotrexate-induced cytotoxicity.
Inhibition of DHFR targets the self-renewing potential of brain tumor initiating cells.
Inhibition of dihydrofolate reductase. 3. 4.6-Diamino-1,2-dihydro-2,2-dimethyl-1-(2-substituted-phenyl)-s-triazine inhibition of bovine liver and mouse tumor enzymes.
Inhibition of histone deacetylase activity is a novel function of the antifolate drug methotrexate.
Inhibition of human dihydrofolate reductase by 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(substituted-phenyl)-s-triazine s. A quantitative structure-activity relationship analysis.
Inhibition of in vitro generation of cytotoxicity against tumor cells by monoclonal antibody to Thy-1.
Inhibitors of dihydrofolate reductase in Leishmania and trypanosomes.
Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma.
Intracellular Ca2+ Increases and Connexin 43 Hemichannel Opening Are Necessary but Not Sufficient for Thy-1-Induced Astrocyte Migration.
Intracellular pharmacokinetics of methotrexate polyglutamates in human breast cancer cells. Selective retention and less dissociable binding of 4-NH2-10-CH3-pteroylglutamate4 and 4-NH2-10-CH3-pteroylglutamate5 to dihydrofolate reductase.
Investigations on the biological properties of the lipophilic DHFR-inhibitory benzoprims reveal non-folate modes of action and opportunities for anti-cancer drug design.
Irreversible enzyme inhibitors. 118. Hydrophobic bonding to dihydrofolic reductase. XII. Further comparisons with the enzyme from Walker 256 rat tumor and rat liver.
K20 and ICO-10 monoclonal antibodies (gp120/200; Thy-1): immunophenotyping of human solid tumours.
Lack of dihydrofolate reductase in human tumor and leukemia cells in vivo.
Levels of E2F-1 expression are higher in lung metastasis of colon cancer as compared with hepatic metastasis and correlate with levels of thymidylate synthase.
Light activates reduction of methotrexate by NADPH in the ternary complex with Escherichia coli dihydrofolate reductase.
Lipid-soluble diaminopyrimidine inhibitors of dihydrofolate reductase.
Lipophilic conjugates of methotrexate with short-chain alkylamino acids as DHFR inhibitors. Synthesis, biological evaluation, and molecular modeling.
Localized and disseminated histiocytic sarcoma of dendritic cell origin in dogs.
Long-term survival of adoptively transferred tumor-infiltrating lymphocytes in mice.
Loss of fibroblast Thy-1 expression correlates with lung fibrogenesis.
Low doses of colony-stimulating factors lead to resolution of neutropenia in cancer patients through increased levels of dihydrofolate reductase.
Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer.
Lymphomas with acquired mouse mammary tumor virus proviruses resemble distinct prethymic and intrathymic phenotypes defined in vivo.
Mechanism inspired development of rationally designed dihydrofolate reductase inhibitors as anticancer agents.
Mechanism of inhibition of wt-dihydrofolate reductase from E. coli by tea epigallocatechin-gallate.
Mechanism-based design, synthesis and biological studies of N?-substituted tetrahydrofolate analogs as inhibitors of cobalamin-dependent methionine synthase and potential anticancer agents.
Mechanisms and implications of dual-acting methotrexate in folate-targeted nanotherapeutic delivery.
Mechanisms of methotrexate resistance in osteosarcoma.
Melanoma cells use Thy-1 (CD90) on endothelial cells for metastasis formation.
Membrane phenotype of the rat cytotoxic T lymphocyte.
Methotrexate analogues. 26. Inhibition of dihydrofolate reductase and folylpolyglutamate synthetase activity and in vitro tumor cell growth by methotrexate and aminopterin analogues containing a basic amino acid side chain.
Methotrexate analogues. 29. Effect of gamma-aminobutyric acid spacers between the pteroyl and glutamate moieties on enzyme binding and cell growth inhibition.
Methotrexate analogues. 30. Dihydrofolate reductase inhibition and in vitro tumor cell growth inhibition by N epsilon-(haloacetyl)-L-lysine and N delta-(haloacetyl)-L-ornithine analogues and an acivicin analogue of methotrexate.
Methotrexate analogues. 31. Meta and ortho isomers of aminopterin, compounds with a double bond in the side chain, and a novel analogue modified at the alpha-carbon: chemical and in vitro biological studies.
Methotrexate and folic reductase in human cancer.
Methotrexate conjugated to gold nanoparticles inhibits tumor growth in a syngeneic lung tumor model.
Methotrexate content in squamous cell carcinoma of the head and neck after low-dose methotrexate.
Methotrexate exacerbates tumor progression in a murine model of chronic myeloid leukemia.
Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs.
Methotrexate induces apoptosis in CaSki and NRK cells and influences the organization of their actin cytoskeleton.
Methotrexate induces apoptosis through p53/p21-dependent pathway and increases E-cadherin expression through downregulation of HDAC/EZH2.
Methotrexate polyglutamate synthesis by cultured human breast cancer cells.
Methotrexate resistance in an in vivo mouse tumor due to a non-active-site dihydrofolate reductase mutation.
Methotrexate significantly induces apoptosis by inhibiting STAT3 activation in NPM-ALK-positive ALCL cells.
Methotrexate-conjugated L-lysine coated iron oxide magnetic nanoparticles for inhibition of MCF-7 breast cancer cells.
MicroRNA-1301-3p promotes the progression of non-small cell lung cancer by targeting Thy-1 and predicts poor prognosis of patients.
Mitochondrial One-Carbon Pathway Supports Cytosolic Folate Integrity in Cancer Cells.
Mitogenic hormones and tumor promoters greatly increase the incidence of colony-forming cells bearing amplified dihydrofolate reductase genes.
Modulation and biological effects of Ly-6.2 expression on EL4 tumour cells.
Modulation of CD4 expression on lymphoma cells transplanted to mice fed (n - 3) polyunsaturated fatty acids.
Modulation of dihydrofolate reductase gene expression in methotrexate-resistant human leukemia CCRF-CEM/E cells by antisense oligonucleotides.
mRNA expression levels of E2F transcription factors correlate with dihydrofolate reductase, reduced folate carrier, and thymidylate synthase mRNA expression in osteosarcoma.
Much more than you expected: The non-DHFR-mediated effects of methotrexate.
Multidrug resistance and its reversal.
Mutational 'hot-spots' in mammalian, bacterial and protozoal dihydrofolate reductases associated with antifolate resistance: sequence and structural comparison.
Natural resistance to methotrexate in human melanomas.
New agents for colon and breast cancer.
New antifolates in clinical development.
Non-glutamate type pyrrolo[2,3-d]pyrimidine antifolates. II. Synthesis and antitumor activity of N5-substituted glutamine analogs.
Novel 6-5 fused ring heterocycle antifolates with potent antitumor activity: bridge modifications and heterocyclic benzoyl isosters of 2,4-diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidine antifolate.
Novel 8-deaza-5,6,7,8-tetrahydroaminopterin derivatives as dihydrofolate inhibitor: Design, synthesis and antifolate activity.
Novel folate-hydroxamate based antimetabolites: synthesis and biological evaluation.
Novel high-performance liquid chromatographic assay using fluorescence detection for the quantitation of plasma gamma-methylene-10-deazaaminopterin and its major metabolite, 7-hydroxy-gamma-methylene-10-deazaaminopterin, in patients with solid cancers in a phase I trial.
Occurrence and significance of D-methotrexate as a contaminant of commercial methotrexate.
One-carbon genetic variants and the role of MTHFD1 1958G>A in liver and colon cancer risk according to global DNA methylation.
Optimized peptide based inhibitors targeting the dihydrofolate reductase pathway in cancer.
Oral piritrexim, an effective treatment for metastatic urothelial cancer.
Overexpression of thymidylate synthetase confers an independent prognostic indicator in nasopharyngeal carcinoma.
Pemetrexed: mRNA expression of the target genes TS, GARFT and DHFR correlates with the in vitro chemosensitivity of human solid tumors.
Pharmacokinetics of Aryldihydro-s-triazines with antifolate activity II: Blood levels and their relevance to antineoplastic activity in rats.
Phase I clinical and pharmacokinetic study of trimetrexate using a daily x5 schedule.
Phase I studies of trimetrexate using single and weekly dose schedules.
Phase I studies with Baker's Antifol (BAF) (NSC 139105).
Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis.
Phase I trial of 10-deaza-aminopterin in patients with advanced cancer.
Phenotypic heterogeneity of antisyngeneic tumor killer cells (ASTK) generated in allogeneic mixed lymphocyte reactions.
Phorbol ester dramatically increases incidence of methotrexate-resistant mouse cells: possible mechanisms and relevance to tumor promotion.
Photochemical release of methotrexate from folate receptor-targeting PAMAM dendrimer nanoconjugate.
Photoswitchable Antimetabolite for Targeted Photoactivated Chemotherapy.
Piritrexim (ILEX Oncology).
Pivotal role of dihydrofolate reductase knockdown in the anticancer activity of 2-hydroxyoleic acid.
Plasma B-vitamins and one-carbon metabolites and the risk of breast cancer in younger women.
Plasma thymidylate synthase and dihydrofolate reductase mRNA levels as potential predictive biomarkers of pemetrexed sensitivity in patients with advanced non-small cell lung cancer.
Post-transplant methotrexate administration leads to improved curability of mice bearing a mammary tumor transplanted with marrow transduced with a mutant human dihydrofolate reductase cDNA.
Potential anticancer agents. XXIII. 1. Qualitative structure--activity relationship in the "classical" antifolates area.
Pralatrexate, a dihydrofolate reductase inhibitor for the potential treatment of several malignancies.
Prognostic Significance of miR-215 in Colon Cancer.
Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer.
Progression elevated gene-3, PEG-3, induces genomic instability in rodent and human tumor cells.
Protection of hematopoietic stem cells from pemetrexed toxicity by retroviral gene transfer with a mutant dihydrofolate reductase-mutant thymidylate synthase fusion gene.
Quantitation of dihydrofolate reductase and thymidylate synthase mRNAs in vivo and in vitro by polymerase chain reaction.
Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction.
Quantitative structure-activity relationships of the inhibition of Pneumocystis carinii dihydrofolate reductase by 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(X-phenyl)-s-triazines.
Rapid formation of poly-gamma-glutamyl derivatives of methotrexate and their association with dihydrofolate reductase as assessed by high pressure liquid chromatography in the Ehrlich ascites tumor cell in vitro.
Reduced folate carrier and dihydrofolate reductase expression in acute lymphocytic leukemia may predict outcome: a Children's Cancer Group Study.
Relationships between resistance to cisplatin and antifolates in sensitive and resistant tumour cell lines.
Resistance proteins in human kidney, breast, ovarian and lung-carcinoma - a comparative-analysis.
Risk Stratification in Multinodular Goiter: A Retrospective Review of Sonographic Features, Histopathological Results, and Cancer Risk.
Role of antimetabolites of purine and pyrimidine nucleotide metabolism in tumor cell differentiation.
Role of E2F-1 in chemosensitivity.
Role of methotrexate polyglutamylation and cellular energy metabolism in inhibition of methotrexate binding to dihydrofolate reductase by 5-formyltetrahydrofolate in Ehrlich ascites tumor cells in vitro.
Role of the cellular oxidation-reduction state in methotrexate binding to dihydrofolate reductase and dissociation induced by reduced folates.
Roles Of EAAT1, DHFR, And Fetuin-A In The Pathogenesis, Progression And Prognosis Of Chondrosarcoma.
Schedule-dependent synergism and antagonism between raltitrexed ("Tomudex") and methotrexate in human colon cancer cell lines in vitro.
Screening of DHFR-binding drugs by MALDI-TOFMS.
Second generation sequencing of the mesothelioma tumor genome.
Sensitization of hematopoietic stem and progenitor cells to trimetrexate using nucleoside transport inhibitors.
Sensitization of human erythroleukemia K562 cells resistant to methotrexate by inhibiting IMPDH.
Sequence analysis of a human gene responsible for drug resistance: a rapid method for manual and automated direct sequencing of products generated by the polymerase chain reaction.
Simple and Reliable HPLC Method for the Monitoring of Methotrexate in Osteosarcoma Patients.
Single agent and combination studies of pralatrexate and molecular correlates of sensitivity.
Species-specific differences in translational regulation of dihydrofolate reductase.
Spontaneous nonthymic T cell lymphomas in young Wistar rats.
Stimulation of methotrexate resistance and dihydrofolate reductase gene amplification by c-myc.
Structural analysis of dihydrofolate reductases enables rationalization of antifolate binding affinities and suggests repurposing possibilities.
Structural comparison of chromosomal and exogenous dihydrofolate reductase from Staphylococcus aureus in complex with the potent inhibitor trimethoprim.
Structural design, biochemical properties, and evidence for improved therapeutic activity of 5-alkyl derivatives of 5-deazaaminopterin and 5-deazamethotrexate compared to methotrexate in murine tumor models.
Structural Exploration and Conformational Transitions in MDM2 upon DHFR Interaction from Homo sapiens: A Computational Outlook for Malignancy via Epigenetic Disruption.
Structural studies on bioactive compounds. 8. Synthesis, crystal structure, and biological properties of a new series of 2,4-diamino-5-aryl-6-ethylpyrimidine dihydrofolate reductase inhibitors with in vivo activity against a methotrexate-resistant tumor cell line.
Structural studies provide clues for analog design of specific inhibitors of Cryptosporidium hominis thymidylate synthase-dihydrofolate reductase.
Structural tuning of acridones for developing anticancer agents targeting dihydrofolate reductase.
Structure-based analysis of Bacilli and plasmid dihydrofolate reductase evolution.
Structure-based design and synthesis of lipophilic 2,4-diamino-6-substituted quinazolines and their evaluation as inhibitors of dihydrofolate reductases and potential antitumor agents.
Studies on folic reductase. 3. The level of enzyme activity and response to methotrexate of transplantable mouse tumors.
Substituted pyrrolo[2,3-d]pyrimidines as Cryptosporidium hominis thymidylate synthase inhibitors.
Synergistic computational and experimental proteomics approaches for more accurate detection of active serine hydrolases in yeast.
Synthesis and antifolate evaluation of the aminopterin analogue with a bicyclo.
Synthesis and biological activities of tricyclic conformationally restricted tetrahydropyrido annulated furo[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases.
Synthesis and biological activity of the 2-desamino and 2-desamino-2-methyl analogues of aminopterin and methotrexate.
Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents.
Synthesis and evaluation of 2,4-diaminoquinazoline antifolates with activity against methotrexate-resistant human tumor cells.
Synthesis and in vitro biological activity of new deaza analogues of folic acid, aminopterin, and methotrexate with an L-ornithine side chain.
Synthesis and potent antifolate activity and cytotoxicity of B-ring deaza analogues of the nonpolyglutamatable dihydrofolate reductase inhibitor Nalpha-(4-amino-4-deoxypteroyl)-Ndelta-hemiphthaloyl- L-ornithine (PT523).
Synthesis of N-[4-[1-ethyl-2-(2,4-diaminofuro[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid as an antifolate.
Synthesis of N-{4-[(2,4-diamino-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid and N-{4-[(2-amino-4-oxo-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid as dual inhibitors of dihydrofolate reductase and thymidylate synthase and as potential antitumor agents.
Synthesis, Antifolate and Anticancer Activities of N(5) -Substituted 8,10-Dideazatetrahydrofolate Analogues.
T-cell differentiative capacity of haematopoietic stem cells immortalized in vitro with radiation leukemia virus.
Targeted Mitochondrial Fluorescence Imaging-Guided Tumor Antimetabolic Therapy with the Imprinted Polymer Nanomedicine Capable of Specifically Recognizing Dihydrofolate Reductase.
The 19-bp deletion of dihydrofolate reductase (DHFR), methylenetetrahydrofolate reductase (MTHFR) C677T, Factor V Leiden, prothrombin G20210A polymorphisms in cancer patients with and without thrombosis.
The 2-desamino and 2-desamino-2-methyl analogues of aminopterin do not inhibit dihydrofolate reductase but are potently toxic to tumor cells in culture.
The antifolate activity of tea catechins.
The effect of folate-related SNPs on clinicopathological features, response to neoadjuvant treatment and survival in pre- and postmenopausal breast cancer patients.
The effect of side-chain, para-aminobenzoyl region, and B-ring modifications on dihydrofolate reductase binding, influx via the reduced folate carrier, and cytotoxicity of the potent nonpolyglutamatable antifolate N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L- ornithine.
The methotrexate story: a paradigm for development of cancer chemotherapeutic agents.
The multiple roles of Thy-1 in cell differentiation and regeneration.
The Transgenic Zebrafish Display Fluorescence Reflecting the Expressional Dynamics of Dihydrofolate Reductase.
Theory and normal-mode analysis of change in protein vibrational dynamics on ligand binding.
Therapeutic Targeting of Mitochondrial One-Carbon Metabolism in Cancer.
THY-1 (CD90) expression promotes the growth of gastric cancer cells.
Thy-1 (CD90)-Induced Metastatic Cancer Cell Migration and Invasion Are ?3 Integrin-Dependent and Involve a Ca2+/P2X7 Receptor Signaling Axis.
Thy-1 antigen on normal and neoplastic rat mammary tissues: changes in location and amount of antigen during differentiation of cultured stem cells.
Thy-1 as a negative growth regulator in ras-transformed mouse fibroblasts.
Thy-1 as a potential novel diagnostic marker for gastrointestinal stromal tumors.
Thy-1 as a regulator of cell-cell and cell-matrix interactions in axon regeneration, apoptosis, adhesion, migration, cancer, and fibrosis.
THY-1 induction is associated with up-regulation of fibronectin and thrombospondin-1 in human ovarian cancer.
Thy-1 inhibits mitogen-induced Ca2+ oscillation in ras-transformed mouse fibroblasts.
Thy-1 predicts poor prognosis and is associated with self-renewal in ovarian cancer.
Thy-1 promoter hypermethylation: a novel epigenetic pathogenic mechanism in pulmonary fibrosis.
Thy-1(+) Cancer-associated Fibroblasts Adversely Impact Lung Cancer Prognosis.
Thy-1, a novel marker for angiogenesis upregulated by inflammatory cytokines.
Thy-1, a versatile modulator of signaling affecting cellular adhesion, proliferation, survival, and cytokine/growth factor responses.
Thymic involution and thymocyte phenotypic alterations induced by murine mammary adenocarcinomas.
Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: The association with treatment efficacy of pemetrexed.
Transgenic rescue of methotrexate-induced teratogenicity in Drosophila melanogaster.
Translational research with pemetrexed in breast cancer.
Transplantable polyomavirus-induced salivary gland epitheliomas are populated by immature T cells derived from the host.
Transplantation of canine malignant lymphomas in the nude and SCID mouse.
Trimetrexate glucuronate associated with anti-Kaposi sarcoma effect.
Trimetrexate inhibits progression of the murine 32Dp210 model of chronic myeloid leukemia in animals expressing drug-resistant dihydrofolate reductase.
Trimetrexate: clinical development of a nonclassical antifolate.
Ultrastructural evaluation of the effect of N-acetylcysteine on methotrexate nephrotoxicity in rats.
Up-regulation of thy-1 promotes invasion and metastasis of hepatocarcinomas.
Use of a human tumor cloning system to evaluate analogs of methotrexate and mitoxantrone.
Using a Fragment-Based Approach to Identify Alternative Chemical Scaffolds Targeting Dihydrofolate Reductase from Mycobacterium tuberculosis.
Variance in the expression of 5-Fluorouracil pathway genes in colorectal cancer.
Vibrational softening of a protein on ligand binding.
Vitamin B17 Ameliorates Methotrexate-Induced Reproductive Toxicity, Oxidative Stress, and Testicular Injury in Male Rats.
[A preliminary study on molecular target identification of drugs in individualized treatment of malignant solid tumors in children].
[Abnormal expression of Thy-1 as a novel tumor marker in lung cancer and its prognostic significance]
[Antitumor effect of PSK (2): effector mechanism of the antimetastatic effect in the "double grafted tumor system"]
[Cotransduction of Human mdr-1 and Dihydrofolate Reductase Genes into Murine Hematopoietic Cells]
[Evaluation of biochemical criteria for sensitivity of tumor cells to methotrexate by means of mathematic simulation]
[Preliminary research of hepatocarcinoma stem cell markers.]
[The biological behavior of hepatocarcinoma stem cells in rats]
Neoplasms, Glandular and Epithelial
[Tetrahydrofolic-dependent enzymes and dihydrofolic reductase in normal and psoriasic human epidermis and in cutaneous epithelial neoplasms]
Nephritis
Activating transcription factor 3 (ATF3) promotes sublytic C5b-9-induced glomerular mesangial cells apoptosis through up-regulation of Gadd45? and KLF6 gene expression.
Agmatine inhibits cell proliferation and improves renal function in anti-thy-1 glomerulonephritis.
Anti-inflammatory role of DPP-4 inhibitors in a non-diabetic model of glomerular injury.
Anti-mouse mesangial cell serum induces acute glomerulonephropathy in mice.
Anti-Thy-1 monoclonal antibody with specific reactivity with vascular endothelial cells in rat glomeruli.
Apoptosis of cultured rat glomerular mesangial cells induced by IgG2a monoclonal anti-Thy-1 antibodies.
Apoptosis of glomerular mesangial cells induced by sublytic C5b-9 complexes in rats with Thy-1 nephritis is dependent on Gadd45 gamma upregulation.
C1q, a subunit of the first component of complement, enhances antibody-mediated apoptosis of cultured rat glomerular mesangial cells.
C5a Induces the Synthesis of IL-6 and TNF-? in Rat Glomerular Mesangial Cells through MAPK Signaling Pathways.
Chronic anti-Thy-1 nephritis is aggravated in the nonclipped but not in the clipped kidney of Goldblatt hypertensive rats.
Contrasting effects of steroids and mizoribine on macrophage activation and glomerular lesions in rat thy-1 mesangial proliferative glomerulonephritis.
Efficient induction of apoptosis in cultured rat glomerular mesangial cells by dimeric monoclonal IgA anti-Thy-1 antibodies.
Eicosapentaenoic acid regulates I?B? and prevents tubulointerstitial injury in kidney.
Exogenous 5'-nucleotidase improves glomerular autoregulation in Thy-1 nephritic rats.
Expression of smooth muscle cell phenotype by rat mesangial cells in immune complex nephritis. Alpha-smooth muscle actin is a marker of mesangial cell proliferation.
Gene expression profile and overexpression of apoptosis-related genes (NGFI-B and Gadd 45 gamma) in early phase of Thy-1 nephritis model.
Glomerular damage in experimental proliferative glomerulonephritis under glomerular capillary hypertension.
Glomerulosclerosis develops in Thy-1 nephritis under persistent accumulation of macrophages.
Inhibition of Inducible Nitric Oxide Synthase Alters Thy-1 Glomeruonephritis in Rats.
Interferon-beta Reduces Proteinuria in Experimental Glomerulonephritis.
Ion-Channel modulator TH1177 reduces glomerular injury and serum creatinine in chronic mesangial proliferative disease in rats.
KLF6 Acetylation Promotes Sublytic C5b-9-Induced Production of MCP-1 and RANTES in Experimental Mesangial Proliferative Glomerulonephritis.
Local actions of endogenous angiotensin II in injured glomeruli.
Mycophenolate mofetil and roscovitine decrease cyclin expression and increase p27(kip1) expression in anti Thy1 mesangial proliferative nephritis.
Nitric oxide inhibition enhances platelet aggregation in experimental anti-Thy-1 nephritis.
Overexpression of cyclooxygenase-2 predisposes to podocyte injury.
Oxidant stress in hyperlipidemia-induced renal damage.
Participation of endothelial cells and transformed mesangial cells in remodeling of glomerular capillary loops in Thy-1 nephritis.
Participation of the matrix metalloproteinase inhibitor in Thy-1 nephritis.
Protective effects of Shichimotsu-koka-To on irreversible Thy-1 nephritis.
Ras antagonist farnesylthiosalicylic acid (FTS) reduces glomerular cellular proliferation and macrophage number in rat thy-1 nephritis.
Roles of coagulation pathway and factor Xa in the progression of diabetic nephropathy in db/db mice.
SMP-534 ameliorates progression of glomerular fibrosis and urinary albumin in diabetic db/db mice.
Sublytic C5b-9 complexes induce apoptosis of glomerular mesangial cells in rats with Thy-1 nephritis through role of interferon regulatory factor-1-dependent caspase 8 activation.
Sublytic C5b-9 complexes induce proliferative changes of glomerular mesangial cells in rat Thy-1 nephritis through TRAF6-mediated PI3K-dependent Akt1 activation.
Sublytic C5b-9 Induces Glomerular Mesangial Cell Apoptosis Through miR-3546/SOX4/Survivin Axis in Rat Thy-1 Nephritis.
Sublytic C5b-9 Induces Glomerular Mesangial Cell Apoptosis through the Cascade Pathway of MEKK2-p38 MAPK-IRF-1-TRADD-Caspase 8 in Rat Thy-1 Nephritis.
Sublytic C5b-9 induces glomerular mesangial cell proliferation via ERK1/2-dependent SOX9 phosphorylation and acetylation by enhancing Cyclin D1 in rat Thy-1 nephritis.
Sublytic C5b-9 Induces IL-23 and IL-36a Production by Glomerular Mesangial Cells via PCAF-Mediated KLF4 Acetylation in Rat Thy-1 Nephritis.
Sublytic C5b-9 induces IL-6 and TGF-?1 production by glomerular mesangial cells in rat Thy-1 nephritis through p300-mediated C/EBP? acetylation.
Sublytic C5b-9 induces proliferation of glomerular mesangial cells via ERK5/MZF1/RGC-32 axis activated by FBXO28-TRAF6 complex.
Sublytic C5b-9 triggers glomerular mesangial cell apoptosis in rat Thy-1 nephritis via Gadd45 activation mediated by Egr-1 and p300-dependent ATF3 acetylation.
Sublytic C5b-9 triggers glomerular mesangial cell apoptosis via XAF1 gene activation mediated by p300-dependent IRF-1 acetylation.
Sublytic C5b-9 triggers glomerular mesangial cell proliferation via enhancing FGF1 and PDGF? gene transcription mediated by GCN5-dependent SOX9 acetylation in rat Thy-1 nephritis.
The complement C5b-9 complexes induced injury of glomerular mesangial cells in rats with Thy-1 nephritis by increasing nitric oxide synthesis.
The profile of gene expression and role of nuclear factor kappa B on glomerular injury in rats with Thy-1 nephritis.
Therapeutic effects of prostacyclin analog on crescentic glomerulonephritis of rat.
Thy-1-mediated phosphatidylinositol turnover in cultured rat glomerular mesangial cell.
TSP-1 promotes glomerular mesangial cell proliferation and extracellular matrix secretion in Thy-1 nephritis rats.
Tubulointerstitial injury of Thy-1 nephritis in uninephrectomized stroke-prone spontaneously hypertensive rats.
[Roles of coagulation pathway and factor Xa in chronic kidney disease (CKD)].
Nephroma, Mesoblastic
Developmental pattern of Thy-1 immunoreactivity in the human kidney and the application to pediatric renal neoplasms.
Neural Tube Defects
A dihydrofolate reductase 2 (DHFR2) variant is associated with risk of neural tube defects in an Irish cohort but not in a United Kingdom cohort.
Association of FOLH1, DHFR, and MTHFR gene polymorphisms with susceptibility of Neural Tube Defects: A case control study from Eastern India.
Maternal association and influence of DHFR 19?bp deletion variant predisposes foetus to anencephaly susceptibility: a family-based triad study.
Neurilemmoma
Distribution of Thy-1 differentiation alloantigen in the rat nervous system and in a cell line derived from a rat peripheral neurinoma.
Neuroblastoma
A conjugate of adriamycin and monoclonal antibodies to Thy-1 antigen inhibits human neuroblastoma cells in vitro.
Biosynthesis of tetrahydrobiopterin in the presence of dihydrofolate reductase inhibitors.
Definition of a Thy-1 determinant on human neuroblastoma, glioma, sarcoma, and teratoma cells with a monoclonal antibody.
Differential expression of the human Thy-1 gene in rodent-human somatic cell hybrids [corrected]
Distribution of the thy-1 antigen in cellular and subcellular fractions of adult mouse brain.
Immunohistochemical performance testing of monoclonal antibodies to neuroblastoma cells on normal adrenals, spinal and sympathetic ganglia, and neural crest tumours.
Quinazoline antifolates as inhibitors of growth, dihydrofolate reductase, and thymidylate synthetase of mouse neuroblastoma cells in culture.
Role of human chromosome 11 in determining surface antigenic phenotype of normal and malignant cells. Somatic cell genetic analysis of eight antigens, including putative human Thy-1.
Second messenger-induced modulation of Thy-1 antigen expression: an ELISA study using murine thymic and neuroblastoma cells.
Neurodegenerative Diseases
20S proteasome mediated degradation of DHFR: implications in neurodegenerative disorders.
Genetics and Epigenetics of One-Carbon Metabolism Pathway in Autism Spectrum Disorder: A Sex-Specific Brain Epigenome?
Neuroectodermal Tumors, Primitive
Expression of a new human THY-1 related antigen in Ewing's sarcoma and peripheral neuroectodermal tumors.
Neuroectodermal Tumors, Primitive, Peripheral
Expression of a new human THY-1 related antigen in Ewing's sarcoma and peripheral neuroectodermal tumors.
Neutropenia
Folate pathway genetic polymorphisms modulate methotrexate-induced toxicity in childhood acute lymphoblastic leukemia.
Low doses of colony-stimulating factors lead to resolution of neutropenia in cancer patients through increased levels of dihydrofolate reductase.
Obesity
Low folate intake and serum levels are associated with higher body mass index and abdominal fat accumulation: a case control study.
Thy-1 (CD90) promotes bone formation and protects against obesity.
Thy-1 Deficiency Augments Bone Loss in Obesity by Affecting Bone Formation and Resorption.
Opportunistic Infections
2,4-Diaminothieno[2,3-d]pyrimidine analogues of trimetrexate and piritrexim as potential inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
6-Substituted 2,4-diaminopyrido[3,2-d]pyrimidine analogues of piritrexim as inhibitors of dihydrofolate reductase from rat liver, Pneumocystis carinii, and Toxoplasma gondii and as antitumor agents.
Conformationally restricted analogues of trimethoprim: 2,6-diamino-8-substituted purines as potential dihydrofolate reductase inhibitors from Pneumocystis carinii and Toxoplasma gondii.
Design and Synthesis of Classical and Nonclassical 6-Arylthio-2,4-diamino-5-ethylpyrrolo[2,3-d]pyrimidines as Antifolates.
Design, synthesis, and molecular modeling of novel pyrido[2,3-d]pyrimidine analogues as antifolates; application of Buchwald-Hartwig aminations of heterocycles.
In vitro generation of novel pyrimethamine resistance mutations in the Toxoplasma gondii dihydrofolate reductase.
Prediction of residues involved in inhibitor specificity in the dihydrofolate reductase family.
Synthesis and antiparasitic and antitumor activity of 2, 4-diamino-6-(arylmethyl)-5,6,7,8-tetrahydroquinazoline analogues of piritrexim.
Synthesis and dihydrofolate reductase inhibitory activities of 2,4-diamino-5-deaza and 2,4-diamino-5,10-dideaza lipophilic antifolates.
Optic Nerve Injuries
Brimonidine protects against loss of Thy-1 promoter activation following optic nerve crush.
Inhibition of histone deacetylases 1 and 3 protects injured retinal ganglion cells.
Protection by an Oral Disubstituted Hydroxylamine Derivative against Loss of Retinal Ganglion Cell Differentiation following Optic Nerve Crush.
Orbital Diseases
Evidence for enhanced Thy-1 (CD90) expression in orbital fibroblasts of patients with Graves' ophthalmopathy.
Osteoporosis
Thy-1 (CD90) promotes bone formation and protects against obesity.
Osteosarcoma
A second target of benzamide riboside: Dihydrofolate reductase.
Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells.
ATIC Gene Polymorphism and Histologic Response to Chemotherapy in Pediatric Osteosarcoma.
Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma.
DHFR and MDR1 upregulation is associated with chemoresistance in osteosarcoma stem-like cells.
Enhanced degradation of dihydrofolate reductase through inhibition of NAD kinase by nicotinamide analogs.
High-dose methotrexate therapy with leucovorin rescue: in vitro investigations on human osteosarcoma cell lines.
Impact of genetic variants of RFC1, DHFR and MTHFR in osteosarcoma patients treated with high-dose methotrexate.
Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression.
Modulation of Sp1-dependent transcription by a cis-acting E2F element in dhfr promoter.
mRNA expression levels of E2F transcription factors correlate with dihydrofolate reductase, reduced folate carrier, and thymidylate synthase mRNA expression in osteosarcoma.
Ovarian Neoplasms
Dihydrofolate reductase as a predictor for poor response to platinum-based chemotherapy in epithelial ovarian cancer.
Ex vivo expansion and selection of human CD34+ peripheral blood progenitor cells after introduction of a mutated dihydrofolate reductase cDNA via retroviral gene transfer.
Optimization of peptides that target human thymidylate synthase to inhibit ovarian cancer cell growth.
THY-1 induction is associated with up-regulation of fibronectin and thrombospondin-1 in human ovarian cancer.
Thy-1 predicts poor prognosis and is associated with self-renewal in ovarian cancer.
Thy-1, a versatile modulator of signaling affecting cellular adhesion, proliferation, survival, and cytokine/growth factor responses.
[Cisplatin resistant effects of dihydrofolate reductase gene expression up-regulation in epithelial ovarian cancer].
Pancytopenia
Identification and characterization of an inborn error of metabolism caused by dihydrofolate reductase deficiency.
[Acute pancytopenia induced by pyrimethamine during treatment of cerebral toxoplasmosis associated with AIDS. Role of dihydrofolate reductase inhibitors]
Papilloma
Selective amplification in methotrexate-resistant mouse cells of an artificial dihydrofolate reductase transcription unit making use of cryptic splicing and polyadenylation sites.
Paraproteinemias
Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis.
Parasitemia
High prevalence of dihydrofolate reductase gene mutations in Plasmodium falciparum parasites among pregnant women in Nigeria after reported use of sulfadoxine-pyrimethamine.
Plasmodium falciparum dihydrofolate reductase and dihyropteroate synthase mutations and the use of trimethoprim-sulfamethoxazole prophylaxis among persons infected with human immunodeficiency virus.
Sulfadoxine-pyrimethamine efficacy and selection of Plasmodium falciparum DHFR mutations in Burkina Faso before its introduction as intermittent preventive treatment for pregnant women.
Validation of microsatellite markers for use in genotyping polyclonal Plasmodium falciparum infections.
Parkinson Disease
Age-related increase of alpha-synuclein oligomers is associated with motor disturbances in L61 transgenic mice.
Pemphigoid, Bullous
A ligand of human thy-1 is localized on polymorphonuclear leukocytes and monocytes and mediates the binding to activated thy-1-positive microvascular endothelial cells and fibroblasts.
Peripheral Nerve Injuries
Adhesion molecule L1 overexpressed under the control of the neuronal Thy-1 promoter improves myelination after peripheral nerve injury in adult mice.
Persistent Infection
Rapid selection of Plasmodium falciparum dihydrofolate reductase mutants by pyrimethamine prophylaxis.
Phenylketonurias
Adverse effects of trimethoprim-sulfamethoxazole in a child with dihydropteridine reductase deficiency.
Dihydrofolate reductase protects endothelial nitric oxide synthase from uncoupling in tetrahydrobiopterin deficiency.
Identification and characterization of an inborn error of metabolism caused by dihydrofolate reductase deficiency.
Pheochromocytoma
Nerve growth factor activates Thy-1 and neurofilament gene transcription in rat PC12 cells.
Plague
Molecular Modeling Studies of Yersinia pestis Dihydrofolate Reductase.
Plasmacytoma
A Thy-1 negative lymphoma cell variant defective in the formation of glycosyl-phosphatidylinositol membrane protein anchors.
c-Myc-associated genomic instability of the dihydrofolate reductase locus in vivo.
E mu-bcl-2 transgene facilitates spontaneous transformation of early pre-B and immunoglobulin-secreting cells but not T cells.
Pneumocystis Infections
Lipophilic antifolate trimetrexate is a potent inhibitor of Trypanosoma cruzi: prospect for chemotherapy of Chagas' disease.
Pneumocystis jirovecii infection and the associated dihydropteroate synthase (DHPS) and dihydrofolate reductase (DHFR) mutations in HIV-positive individuals from Pune, India.
Pneumonia
A molecular model of the folate binding site of Pneumocystis carinii dihydrofolate reductase.
Application of DNA amplification to pneumocystosis: presence of serum Pneumocystis carinii DNA during human and experimentally induced Pneumocystis carinii pneumonia.
Correlations of Inhibitor Kinetics for Pneumocystis jirovecii and Human Dihydrofolate Reductase with Structural Data for Human Active Site Mutant Enzyme Complexes (dagger) (double dagger).
Design, synthesis, and computational affinity prediction of ester soft drugs as inhibitors of dihydrofolate reductase from Pneumocystis carinii.
Detection of Pneumocystis carinii in serum of AIDS patients with Pneumocystis pneumonia by the polymerase chain reaction.
Diagnosis of Pneumocystis carinii pneumonia in AIDS patients by using polymerase chain reactions on serum specimens.
Dihydrofolate reductase gene polymorphisms in Pneumocystis carinii f. sp. hominis in Japan.
Expression and characterization of recombinant human-derived Pneumocystis carinii dihydrofolate reductase.
Genetic characterization of the dihydrofolate reductase gene of Pneumocystis jirovecii isolates from Portugal.
Genetic diversity of drug targets including dihydropteroate synthase, dihydrofolate reductase and cytochrome b, in Pneumocystis carinii f. sp. hominis isolates in Japan.
Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections.
Low prevalence of Pneumocystis pneumonia (PCP) but high prevalence of pneumocystis dihydropteroate synthase (dhps) gene mutations in HIV-infected persons in Uganda.
Mutations of Pneumocystis jirovecii dihydrofolate reductase associated with failure of prophylaxis.
Non specific PCR products using rat-derived Pneumocystis carinii dihydrofolate reductase gene-specific primers in DNA amplification of human respiratory samples.
Polymorphisms involving the Pneumocystis jirovecii-related genes in AIDS patients in eastern China.
Structural studies on bioactive compounds. Part 36: design, synthesis and biological evaluation of pyrimethamine-based antifolates against Pneumocystis carinii.
Synergistic combinations of Ro 11-8958 and other dihydrofolate reductase inhibitors with sulfamethoxazole and dapsone for therapy of experimental pneumocystosis.
Pneumonia, Bacterial
Pneumonia, Pneumocystis
A molecular model of the folate binding site of Pneumocystis carinii dihydrofolate reductase.
Application of DNA amplification to pneumocystosis: presence of serum Pneumocystis carinii DNA during human and experimentally induced Pneumocystis carinii pneumonia.
Combination of PS-15, epiroprim, or pyrimethamine with dapsone in prophylaxis of Toxoplasma gondii and Pneumocystis carinii dual infection in a rat model.
Crystallographic analysis reveals a novel second binding site for trimethoprim in active site double mutants of human dihydrofolate reductase.
Design, synthesis, and computational affinity prediction of ester soft drugs as inhibitors of dihydrofolate reductase from Pneumocystis carinii.
Detection of Pneumocystis carinii in serum of AIDS patients with Pneumocystis pneumonia by the polymerase chain reaction.
Development of substituted pyrido[3,2-d]pyrimidines as potent and selective dihydrofolate reductase inhibitors for pneumocystis pneumonia infection.
Diagnosis of Pneumocystis carinii pneumonia in AIDS patients by using polymerase chain reactions on serum specimens.
Dihydrofolate reductase gene polymorphisms in Pneumocystis carinii f. sp. hominis in Japan.
Expression and characterization of recombinant human-derived Pneumocystis carinii dihydrofolate reductase.
Genetic characterization of the dihydrofolate reductase gene of Pneumocystis jirovecii isolates from Portugal.
Genetic diversity of drug targets including dihydropteroate synthase, dihydrofolate reductase and cytochrome b, in Pneumocystis carinii f. sp. hominis isolates in Japan.
Mutations of Pneumocystis jirovecii dihydrofolate reductase associated with failure of prophylaxis.
Polymorphisms involving the Pneumocystis jirovecii-related genes in AIDS patients in eastern China.
Structural analysis of a holoenzyme complex of mouse dihydrofolate reductase with NADPH and a ternary complex with the potent and selective inhibitor 2,4-diamino-6-(2'-hydroxydibenz[b,f]azepin-5-yl)methylpteridine.
Structural studies on bioactive compounds. Part 36: design, synthesis and biological evaluation of pyrimethamine-based antifolates against Pneumocystis carinii.
Synergistic combinations of Ro 11-8958 and other dihydrofolate reductase inhibitors with sulfamethoxazole and dapsone for therapy of experimental pneumocystosis.
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Frequent expression of human Thy-1 antigen on pre-B cell acute lymphoblastic leukemia with t(9;22).
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A second target of benzamide riboside: Dihydrofolate reductase.
Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 gene mutations.
Association between polymorphisms of dihydrofolate reductase and gamma glutamyl hydrolase genes and toxicity of high dose methotrexate in children with acute lymphoblastic leukemia.
Characterization of Thy-1 (CDw90) expression in CD34+ acute leukemia.
Current research on immunopathology of melanoma: analysis of lymphocyte populations in relation to antigen expression and histological features of melanoma.
Dihydrofolate Reductase Genetic Polymorphisms Affect Methotrexate Dose Requirements in Pediatric Patients With Acute Lymphoblastic Leukemia on Maintenance Therapy.
DNA variants in DHFR gene and response to treatment in children with childhood B ALL: revisited in AIEOP-BFM protocol.
DNA Variants in Region for Noncoding Interfering Transcript of Dihydrofolate Reductase Gene and Outcome in Childhood Acute Lymphoblastic Leukemia.
DNA variants in the dihydrofolate reductase gene and outcome in childhood ALL.
Elevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resistance in childhood acute lymphoblastic leukemia.
Enhanced degradation of dihydrofolate reductase through inhibition of NAD kinase by nicotinamide analogs.
Frequent expression of human Thy-1 antigen on pre-B cell acute lymphoblastic leukemia with t(9;22).
Genomic and transcriptomic analyses reveal a tandem amplification unit of 11 genes and mutations in mismatch repair genes in methotrexate-resistant HT-29 cells.
Immunophenotypic differences between putative hematopoietic stem cells and childhood B-cell precursor acute lymphoblastic leukemia cells.
Increased frequency of expression of elevated dihydrofolate reductase in T-cell versus B-precursor acute lymphoblastic leukemia in children.
Influence of dihydrofolate reductase gene polymorphisms rs408626 (-317A>G) and rs442767 (-680C>A) on the outcome of methotrexate-based maintenance therapy in South Indian patients with acute lymphoblastic leukemia.
Influence of variants in folate metabolism genes on 6-mercaptopurine induced toxicity during treatment for childhood acute lymphocytic leukemia.
Maternal Haplotypes in DHFR Promoter and MTHFR Gene in Tuning Childhood Acute Lymphoblastic Leukemia Onset-Latency: Genetic/Epigenetic Mother/Child Dyad Study (GEMCDS).
Methotrexate causes persistent deficits in memory and executive function in a juvenile animal model.
mRNA expression levels of methotrexate resistance-related proteins in childhood leukemia as determined by a standardized competitive template-based RT-PCR method.
Multivariate analysis and quantitative structure-activity relationships. Inhibition of dihydrofolate reductase and thymidylate synthetase by quinazolines.
Overexpression of dihydrofolate reductase is a factor of poor survival in acute lymphoblastic leukemia.
Quantitative correlations of biological activities of dactinomycin analogs and methotrexate derivatives with van der Waals volume.
Reduced folate carrier and dihydrofolate reductase expression in acute lymphocytic leukemia may predict outcome: a Children's Cancer Group Study.
Resistance mechanisms to methotrexate in tumors.
Resistance Mechanisms to Methotrexate in Tumors.
Simultaneous Inhibition of Protein Kinase CK2 and Dihydrofolate Reductase Results in Synergistic Effect on Acute Lymphoblastic Leukemia Cells.
Survival and risk of relapse of acute lymphoblastic leukemia in a Mexican population is affected by dihydrofolate reductase gene polymorphisms.
Synthesis, antifolate, and antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines.
Tetrahydrofolate dehydrogenase cytochemistry in acute lymphoblastic leukemia.
Utilization of an immunostaining technique to demonstrate heterogeneity in the content of dihydrofolate reductase in peripheral blast cells from a patient with acute lymphocytic leukemia.
[Expression and clinical significance of resistance proteins in initial acute lymphatic leukemia (ALL) in childhood]
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Increased frequency of expression of elevated dihydrofolate reductase in T-cell versus B-precursor acute lymphoblastic leukemia in children.
Pregnancy, Tubal
Contribution of genetic polymorphism of methylene tetrahydrofolate reductase on the effect of methotrexate in ectopic pregnancy patients.
Primary Myelofibrosis
Blood leucocyte enzymes. II. Activities at 8-9 a.m. in cells of normal subjects, chronic lymphatic leukaemia and chronic myeloid leukaemia patients.
Prion Diseases
Decreased cell surface prion protein in mouse models of prion disease.
GPI-anchor signal sequence influences PrPC sorting, shedding and signalling, and impacts on different pathomechanistic aspects of prion disease in mice.
Proteinuria
Interferon-beta Reduces Proteinuria in Experimental Glomerulonephritis.
Long-term observation of glomerulonephritis induced by multiple injections with anti-Thy-1 antibody in rats.
The profile of gene expression and role of nuclear factor kappa B on glomerular injury in rats with Thy-1 nephritis.
Psoriasis
A multicentre 12-week open study of a lipid-soluble folate antagonist, piritrexim in severe psoriasis.
Generalized pustular psoriasis induced by potassium iodide. A postulated role for dihydrofolic reductase.
Increased neutrophil adherence in psoriasis: role of the human endothelial cell receptor Thy-1 (CD90).
Photoswitchable Antimetabolite for Targeted Photoactivated Chemotherapy.
The antifolate activity of tea catechins.
[A Case of Crohn's Disease Showing Favorable Response to Induction and Maintenance Therapy with Methotrexate after Failure of Anti-tumor Necrosis Factor Therapy].
Pulmonary Fibrosis
Lipopolysaccharide promotes pulmonary fibrosis in acute respiratory distress syndrome (ARDS) via lincRNA-p21 induced inhibition of Thy-1 expression.
The multiple roles of Thy-1 in cell differentiation and regeneration.
Thy-1 depletion and integrin ?3 upregulation-mediated PI3K-Akt-mTOR pathway activation inhibits lung fibroblast autophagy in lipopolysaccharide-induced pulmonary fibrosis.
Thy-1 promoter hypermethylation: a novel epigenetic pathogenic mechanism in pulmonary fibrosis.
[Effect and mechanism of inhibition of lipopolysaccharide-induced pulmonary fibrosis by butyric acid].
Rabies
Interscience conference on antimicrobial agents and chemotherapy - 50th annual meeting - research on promising new agents: part 1.
Respiratory Distress Syndrome
Lipopolysaccharide promotes pulmonary fibrosis in acute respiratory distress syndrome (ARDS) via lincRNA-p21 induced inhibition of Thy-1 expression.
Respiratory Tract Infections
Pneumocystis jirovecii infection and the associated dihydropteroate synthase (DHPS) and dihydrofolate reductase (DHFR) mutations in HIV-positive individuals from Pune, India.
Restless Legs Syndrome
Gender-specific regulation of tyrosine hydroxylase in thymocyte differentiation antigen-1 knockout mice.
Retinoblastoma
Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells.
Excessive folic acid intake and relation to adverse health outcome.
Gene expression changes induced by estrogen and selective estrogen receptor modulators in primary-cultured human endometrial cells: signals that distinguish the human carcinogen tamoxifen.
Overexpression of Cdk6 and Ccnd1 in chondrocytes inhibited chondrocyte maturation and caused p53-dependent apoptosis without enhancing proliferation.
Quantitative evaluation of the cell cycle-related retinoblastoma protein and localization of Thy-1 differentiation protein and macrophages during follicular development and atresia, and in human corpora lutea.
Regulation of the cancer cell membrane lipid composition by NaCHOleate: Effects on cell signaling and therapeutical relevance in glioma.
Relationship of p15 and p16 gene alterations to elevated dihydrofolate reductase in childhood acute lymphoblastic leukaemia.
Resistance mechanisms to methotrexate in tumors.
Resistance Mechanisms to Methotrexate in Tumors.
Retinoblastoma protein associates with SP1 and activates the hamster dihydrofolate reductase promoter.
Risk of retinoblastoma is associated with a maternal polymorphism in dihydrofolatereductase (DHFR) and prenatal folic acid intake.
Rhinitis, Allergic
Analysis of expression of ILC2 cells in nasal mucosa based on animal model of allergic bacterial infection rhinitis.
Riboflavin Deficiency
The effect of riboflavin deficiency on methylenetetrahydrofolate reductase (NADPH) (EC 1.5.1.20) and folate metabolism in the rat.
Sarcoma
Antitumor activity of antifolate inhibitors of thymidylate and purine synthesis in human soft tissue sarcoma cell lines with intrinsic resistance to methotrexate.
Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells.
Construction and use of a dominant, selectable marker: a Harvey sarcoma virus-dihydrofolate reductase chimera.
Correlation of double-minute chromosomes with unstable multidrug cross-resistance in uptake mutants of neuroblastoma cells.
Definition of a Thy-1 determinant on human neuroblastoma, glioma, sarcoma, and teratoma cells with a monoclonal antibody.
Developmental pattern of Thy-1 immunoreactivity in the human kidney and the application to pediatric renal neoplasms.
Dihydrofolate reductase in primary brain tumors, cell cultures of central nervous system origin, and normal brain during fetal and neonatal growth.
Loss and stabilization of amplified dihydrofolate reductase genes in mouse sarcoma S-180 cell lines.
Mechanisms of sensitivity and natural resistance to antifolates in a methylcholanthrene-induced rat sarcoma.
Micro-Edman degradation: the use of high pressure liquid chromatography and gas chromatography in the amino terminal sequence determination of 8 nanomoles of dihydrofolate reductase from a mouse sarcoma.
Structure of amplified normal and variant dihydrofolate reductase genes in mouse sarcoma S180 cells.
Thy-1 as a negative growth regulator in ras-transformed mouse fibroblasts.
Thy-1 epitopes are expressed on murine myeloid leukemia and reticulum sarcoma cells.
Trimetrexate glucuronate associated with anti-Kaposi sarcoma effect.
Sarcoma, Avian
An intragenic region downstream from the dihydrofolate reductase promoter is required for replication-dependent expression.
Cosmid vectors for high efficiency DNA-mediated transformation and gene amplification in mammalian cells: studies with the human growth hormone gene.
Dihydrofolate reductase in primary brain tumors, cell cultures of central nervous system origin, and normal brain during fetal and neonatal growth.
Protection from herpes simplex virus type 1 lethal and latent infections by secreted recombinant glycoprotein B constitutively expressed in human cells with a BK virus episomal vector.
Proximal upstream flanking sequences direct calcium regulation of the rat prolactin gene.
Sarcoma, Clear Cell
Developmental pattern of Thy-1 immunoreactivity in the human kidney and the application to pediatric renal neoplasms.
Sarcoma, Ewing
Expression of a new human THY-1 related antigen in Ewing's sarcoma and peripheral neuroectodermal tumors.
Sarcoma, Myeloid
Acute myeloid leukemia is associated with retroviral gene transfer to hematopoietic progenitor cells in a rhesus macaque.
Scrapie
A variable concept for the preparation of branched glycosyl phosphatidyl inositol anchors.
Seizures
Expression in brain of amyloid precursor protein mutated in the alpha-secretase site causes disturbed behavior, neuronal degeneration and premature death in transgenic mice.
Morphological changes among hippocampal dentate granule cells exposed to early kindling-epileptogenesis.
Severe Combined Immunodeficiency
Similarities between human ataxia fibroblasts and murine SCID cells: high sensitivity to gamma rays and high frequency of methotrexate-induced DHFR gene amplification, but normal radiosensitivity to densely ionizing alpha particles.
Sustained proliferation, multi-lineage differentiation and maintenance of primitive human haemopoietic cells in NOD/SCID mice transplanted with human cord blood.
Skin Diseases
Differentiation of human T lymphocytes: II. Phenotypic difference in skin and blood malignant T-cells in cutaneous T-cell lymphoma.
Thy-1 and T-cell receptor antigen expression in mycosis fungoides and benign inflammatory dermatoses.
Soft Tissue Infections
Iclaprim: a novel dihydrofolate reductase inhibitor for skin and soft tissue infections.
Spinal Cord Compression
Transgenic overexpression of the cell adhesion molecule L1 in neurons facilitates recovery after mouse spinal cord injury.
Spinal Dysraphism
Dihydrofolate reductase gene intronic 19-bp deletion polymorphisms in a Japanese population.
Dihydrofolate reductase gene variations in susceptibility to disease and treatment outcomes.
New 19 bp deletion polymorphism in intron-1 of dihydrofolate reductase (DHFR): a risk factor for spina bifida acting in mothers during pregnancy?
The 19-bp deletion polymorphism in intron-1 of dihydrofolate reductase (DHFR) may decrease rather than increase risk for spina bifida in the Irish population.
Variation and expression of dihydrofolate reductase (DHFR) in relation to spina bifida.
Squamous Cell Carcinoma of Head and Neck
Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas.
Gene Polymorphisms Involved in Folate Metabolism and DNA Methylation with the Risk of Head and Neck Cancer.
In vitro activity of novel antifolates against human squamous carcinoma cell lines of the head and neck with inherent resistance to methotrexate.
Synthesis, antifolate, and antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines.
Staphylococcal Infections
Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections.
Starvation
Cooperation of E2F-p130 and Sp1-pRb complexes in repression of the Chinese hamster dhfr gene.
Delayed processing of dihydrofolate reductase heterogeneous nuclear RNA in amino acid-starved mouse fibroblasts.
Folate deficiency followed by ionizing radiation perturbs hepatic dihydrofolate reducatse activity.
Multiple transcription start sites, DNase I-hypersensitive sites, and an opposite-strand exon in the 5' region of the CHO dhfr gene.
Relationship between the expression of estrogen-regulated genes and estrogen-stimulated proliferation of MCF-7 mammary tumor cells.
The role of thymine starvation in the expression of type IV plasmid-encoded trimethoprim-resistant dihydrofolate reductase.
Stomach Neoplasms
Heterogeneity of methotrexate binding in human colon tumor cells.
THY-1 (CD90) expression promotes the growth of gastric cancer cells.
Stomatitis
Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma.
Stroke
A comprehensive association analysis between homocysteine metabolic pathway gene methylation and ischemic stroke in a Chinese hypertensive population.
Common mutations at the homocysteine metabolism pathway and pediatric stroke.
Translocation of a long amino-terminal domain through ER membrane by following signal-anchor sequence.
Synucleinopathies
Alpha-Synuclein-induced DNA Methylation and Gene Expression in Microglia.
Impact of DHA intake in a mouse model of synucleinopathy.
Teratocarcinoma
Suppression of the hypomethylated Moloney leukemia virus genome in undifferentiated teratocarcinoma cells and inefficiency of transformation by a bacterial gene under control of the long terminal repeat.
[Transformation of the cells of transplantable teratocarcinoma CBA9H6 by a bacterial dihydrofolate reductase gene]
Teratoma
Definition of a Thy-1 determinant on human neuroblastoma, glioma, sarcoma, and teratoma cells with a monoclonal antibody.
Testicular Neoplasms
Expression of the adhesion molecules CD49d and CD49e on G-CSF-mobilized CD34+ cells of patients with solid tumors or non-Hodgkin's and Hodgkin's lymphoma and of healthy donors is inversely correlated with the amount of mobilized CD34+ cells.
Tetanus
Characterization of isolated mouse cerebellar cell populations in vitro.
Expression of Thy-1, H-2, and NS-4 cell surface antigens and tetanus toxin receptors in early postnatal and adult mouse cerebellum.
Further evidence for the presence of subepithelial nerve cells in the rat ileum--an immunohistochemical study.
Maintenance of immunocytologically identified Purkinje cells from mouse cerebellum in monolayer culture.
Neuronal differentiation of cloned human teratoma cells in response to retinoic acid in vitro.
Thrombosis
The 19-bp deletion of dihydrofolate reductase (DHFR), methylenetetrahydrofolate reductase (MTHFR) C677T, Factor V Leiden, prothrombin G20210A polymorphisms in cancer patients with and without thrombosis.
Thymoma
A cDNA construct of tissue inhibitor of metalloproteinases (TIMP) linked to the last exon of Thy-1 confers glycophospholipid anchorage on this naturally secreted protein.
Alloantigenic phenotype of radiation-induced thymomas in the mouse.
Cell-specific heterogeneity in sensitivity of phosphatidylinositol-anchored membrane antigens to release by phospholipase C.
Glycolipid anchors are attached to Thy-1 glycoprotein rapidly after translation.
Identification of defects in glycosylphosphatidylinositol anchor biosynthesis in the Thy-1 expression mutants.
Indomethacin-induced sialic acid-mediated changes in surface markers from "cortical type" to "medullary type" in murine thymoma line EL-4.
Mechanism of catecholamine-mediated destabilization of messenger RNA encoding Thy-1 protein in T-lineage cells.
No glycolipid anchors are added to Thy-1 glycoprotein in Thy-1-negative mutant thymoma cells of four different complementation classes.
Recombinant glycosyl-phosphatidylinositol-anchored proteins are not associated with protein kinases in transfected thymoma cells.
Removal of lymphocyte surface molecules with phosphatidylinositol-specific phospholipase C: effects on mitogen responses and evidence that ThB and certain Qa antigens are membrane-anchored via phosphatidylinositol.
Susceptibility to cell death is a dominant phenotype: triggering of activation-driven T-cell death independent of the T-cell antigen receptor complex.
Thy-1 binds to integrin beta(3) on astrocytes and triggers formation of focal contact sites.
Thy-1 mRNA destabilization by norepinephrine requires a 3' UTR cAMP responsive decay element and involves RNA binding proteins.
Thy-1-negative and Ly-1-negative variants of T cells produce interleukin 2 in response to mitogens.
Thy-L antigen expression on rat brain cell lines.
Transformation of undifferentiated Thy-1lo B220+ thymic lymphoid cells by the Abelson murine leukemia virus.
Two different mutants blocked in synthesis of dolichol-phosphoryl-mannose do not add glycophospholipid anchors to membrane proteins: quantitative correction of the phenotype of a CHO cell mutant with tunicamycin.
Thymus Neoplasms
Stage-specific induction of terminal deoxynucleotidyl transferase in a T-lymphoid line upon coculture with a thymic stromal line.
The programmed cell death of an immature thymocyte cell line transgenic for an alpha beta TCR and the c-myc proto-oncogene.
Thyrotoxicosis
Cytoenzymologic activities of some oxidroeductases and alkaline phosphatase of leucocytes in Basedow, Cushing and Addison diseases.
Immunoexpressions of embryonic and nonembryonic stem cell markers (Nanog, Thy-1, c-kit) and cellular connections (connexin 43 and occludin) on testicular tissue in thyrotoxicosis rat model.
Toxoplasmosis
Combination of PS-15, epiroprim, or pyrimethamine with dapsone in prophylaxis of Toxoplasma gondii and Pneumocystis carinii dual infection in a rat model.
Discovery of Potent and Selective Leads against Toxoplasma gondii Dihydrofolate Reductase via Structure-Based Design.
Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis.
Highly efficient ligands for dihydrofolate reductase from Cryptosporidium hominis and Toxoplasma gondii inspired by structural analysis.
Homology modeling of dihydrofolate reductase from T. gondii bonded to antagonists: molecular docking and molecular dynamics simulations.
Knocking down of the DHFR-TS gene in Toxoplasma gondii using siRNA and assessing the subsequences on toxoplasmosis in mice.
Molecular docking to Toxoplasma gondii thymidylate synthase-dihydrofolate reductase and efficacy of raltitrexed in infected mice.
Perspective on current and emerging drugs in the treatment of acute and chronic toxoplasmosis.
Pharmacokinetic justification of antiprotozoal therapy. A US perspective.
Primary structure of the dihydrofolate reductase-thymidylate synthase gene from Toxoplasma gondii.
Selective peptide inhibitors of bifunctional thymidylate synthase-dihydrofolate reductase from Toxoplasma gondii provide insights into domain-domain communication and allosteric regulation.
Targeting DHFR in parasitic protozoa.
The cytogenetic effects of pyrimethamine on male mouse germ cells.
Toxoplasmosis, Cerebral
Salvage trial of trimetrexate-leucovorin for the treatment of cerebral toxoplasmosis in patients with AIDS.
[Acute pancytopenia induced by pyrimethamine during treatment of cerebral toxoplasmosis associated with AIDS. Role of dihydrofolate reductase inhibitors]
Toxoplasmosis, Congenital
Fitness of Toxoplasma gondii is not related to DHFR single-nucleotide polymorphism during congenital toxoplasmosis.
Trypanosomiasis
Structure and reactivity of Trypanosoma brucei pteridine reductase: inhibition by the archetypal antifolate methotrexate.
Trypanosomiasis, African
Structural Insights into the Development of Cycloguanil Derivatives as Trypanosoma brucei Pteridine-Reductase-1 Inhibitors.
Trypanosoma brucei DHFR-TS Revisited: Characterisation of a Bifunctional and Highly Unstable Recombinant Dihydrofolate Reductase-Thymidylate Synthase.
Trypanosomal Dihydrofolate Reductase Reveals Natural Antifolate Resistance.
Tuberculosis
1,3,5-triazaspiro[5.5]undeca-2,4-dienes as selective Mycobacterium tuberculosis dihydrofolate reductase inhibitors with potent whole cell activity.
A proposed model of Mycobacterium avium complex dihydrofolate reductase and its utility for drug design.
Antifolate Activity of Plant Polyphenols against Mycobacterium tuberculosis.
Binding mode analysis of 2,4-diamino-5-methyl-5-deaza-6-substituted pteridines with Mycobacterium tuberculosis and human dihydrofolate reductases.
Cloning, expression, and characterization of Mycobacterium tuberculosis dihydrofolate reductase.
Crystal structures of the closed form of Mycobacterium tuberculosis dihydrofolate reductase in complex with dihydrofolate and antifolates.
Design and Synthesis of a Focused Library of Diamino Triazines as Potential Mycobacterium tuberculosis DHFR Inhibitors.
Design, synthesis and biological activity of novel substituted 3-benzoic acid derivatives as MtDHFR inhibitors.
Detection of Pneumocystis carinii in a rat model of infection by polymerase chain reaction.
E84G mutation in dihydrofolate reductase from drug resistant strains of Mycobacterium tuberculosis (Mumbai, India) leads to increased interaction with Trimethoprim.
Expansion of a novel lead targeting M. tuberculosis DHFR as antitubercular agents.
Fragment Discovery for the Design of Nitrogen Heterocycles as Mycobacterium tuberculosis Dihydrofolate Reductase Inhibitors.
High-throughput screening and sensitized bacteria identify an M. tuberculosis dihydrofolate reductase inhibitor with whole cell activity.
Identification of novel DHFR inhibitors for treatment of tuberculosis by combining virtual screening with in vitro activity assay.
Identification of novel Mycobacterium tuberculosis dihydrofolate reductase inhibitors through rational drug design.
Identification of novel selective Mtb-DHFR inhibitors as antitubercular agents through structure-based computational techniques.
In silico structure-based design of a novel class of potent and selective small peptide inhibitor of Mycobacterium tuberculosis Dihydrofolate reductase, a potential target for anti-TB drug discovery.
Interactions of 5-deazapteridine derivatives with Mycobacterium tuberculosis and with human dihydrofolate reductases.
Kinetic and Chemical Mechanism of the Dihydrofolate Reductase from Mycobacterium tuberculosis.
Linking High-Throughput Screens to Identify MoAs and Novel Inhibitors of Mycobacterium tuberculosis Dihydrofolate Reductase.
Mycobacterium tuberculosis dihydrofolate reductase is a target for isoniazid.
Mycobacterium tuberculosis dihydrofolate reductase is not a target relevant to the antitubercular activity of isoniazid.
Mycobacterium tuberculosis dihydrofolate reductase reveals two conformational states and a possible low affinity mechanism to antifolate drugs.
Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase.
para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis.
Potency boost of a Mycobacterium tuberculosis dihydrofolate reductase inhibitor by multienzyme F420H2-dependent reduction.
Preparation, biological evaluation and molecular docking study of imidazolyl dihydropyrimidines as potential Mycobacterium tuberculosis dihydrofolate reductase inhibitors.
Prioritizing multiple therapeutic targets in parallel using automated DNA-encoded library screening.
Propargyl-Linked Antifolates Are Potent Inhibitors of Drug-Sensitive and Drug-Resistant Mycobacterium tuberculosis.
Rational drug design, synthesis and biological evaluation of dihydrofolate reductase inhibitors as antituberculosis agents.
Role of mutations in dihydrofolate reductase DfrA (Rv2763c) and thymidylate synthase ThyA (Rv2764c) in Mycobacterium tuberculosis drug resistance.
Role of the dihydrofolate reductase DfrA (Rv2763c) in trimethoprim-sulfamethoxazole (co-trimoxazole) resistance in Mycobacterium tuberculosis.
Structural and Dynamics Perspectives on the Binding of Substrate and Inhibitors in Mycobacterium tuberculosis DHFR.
Structural Insights into Mycobacterium tuberculosis Rv2671 Protein as a Dihydrofolate Reductase Functional Analogue Contributing to para-Aminosalicylic Acid Resistance.
Structure-based design, synthesis and preliminary evaluation of selective inhibitors of dihydrofolate reductase from Mycobacterium tuberculosis.
Sulfonamide derivatives as Mycobacterium tuberculosis inhibitors: in silico approach.
Susceptibilities of Mycobacterium tuberculosis and Mycobacterium avium complex to lipophilic deazapteridine derivatives, inhibitors of dihydrofolate reductase.
Synthesis of 6-(4-(4-propoxyphenyl) piperazin-1-yl)-9H-purine derivatives as antimycobacterial and antifungal agents: In-vitro evaluation and in-silico study.
The identification of novel Mycobacterium tuberculosis DHFR inhibitors and the investigation of their binding preferences by using molecular modelling.
Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs.
Trade-offs with stability modulate innate and mutationally acquired drug resistance in bacterial dihydrofolate reductase enzymes.
Two Parallel Pathways in the Kinetic Sequence of the Dihydrofolate Reductase from Mycobacterium tuberculosis.
Using a Fragment-Based Approach to Identify Alternative Chemical Scaffolds Targeting Dihydrofolate Reductase from Mycobacterium tuberculosis.
Virtual screening against Mycobacterium tuberculosis dihydrofolate reductase: suggested workflow for compound prioritization using structure interaction fingerprints.
[Characterization of Mycobacterium tuberculosis dihydrofolate reductase immobilized on magnetic nanoparticles].
Urinary Bladder Neoplasms
Clinical efficacy and mechanism of Pralatrexate combined with Palbociclib Isethionate in treatment of bladder cancer patients.
Comparative study of sequential combinations of paclitaxel and methotrexate on a human bladder cancer cell line.
MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets.
[Expression of human-mouse chimeric antibody ch-BD1 and its affinity to human bladder cancer in vitro and in vivo]
[Significantly improvement of antibody expression level in CHO cells through downregulation of the DHFR gene in expression vector]
Urinary Tract Infections
Characterization of trimethoprim resistant E. coli dihydrofolate reductase mutants by mass spectrometry and inhibition by propargyl-linked antifolates.
Trimethoprim and other nonclassical antifolates an excellent template for searching modifications of dihydrofolate reductase enzyme inhibitors.
Uterine Cervical Neoplasms
Designing Dihydrofolate Reductase Inhibitors as X-ray Radiosensitizers to Reverse Radioresistance of Cervical Cancer.
Vaccinia
Induction and persistence of a cytotoxic T lymphocyte (CTL) response against a herpes simplex virus-specific CTL epitope expressed in a cellular protein.
Lethal vaccinia infection in cyclophosphamide-suppressed mice is associated with decreased expression of Thy-1, Lyt-2 and L3T4 and diminished IL-2 production in surviving T cells.
Varicose Ulcer
Effect of the GPI anchor of human Thy-1 on antibody recognition and function.
Vesicular Stomatitis
Specific selection of host cell glycoproteins during assembly of murine leukaemia virus and vesicular stomatitis virus: presence of Thy-1 glycoprotein and absence of H-2, Pgp-1 and T-200 glycoproteins on the envelopes of these virus particles.
Tolerance by selective in vivo expansion of foreign major histocompatibility complex-transduced autologous bone marrow.
Virus Diseases
Control of cellular gene expression during adenovirus infection: induction and shut-off of dihydrofolate reductase gene expression by adenovirus type 2.
Functional expression of influenza A viral nucleoprotein in cells transformed with cloned DNA.
Peyer's patches in murine AIDS: dissociation between lymphoproliferation and anergy.
THY-1 Cell Surface Antigen (CD90) Has an Important Role in the Initial Stage of Human Cytomegalovirus Infection.
Vitamin B 12 Deficiency
Folate, folic acid and 5-methyltetrahydrofolate are not the same thing.
Vitamin B12--folate interrelations.
Whooping Cough
Rapid induction of Thy-1 antigenic markers on keratinocytes and epidermal immune cells in the skin of mice following topical treatment with common preservatives used in topical medications and in foods.
Wilms Tumor
Developmental pattern of Thy-1 immunoreactivity in the human kidney and the application to pediatric renal neoplasms.
Xeroderma Pigmentosum
Deficient gene specific repair of cisplatin-induced lesions in Xeroderma pigmentosum and Fanconi's anemia cell lines.
DNA repair in man.
Mutational analysis of a function of xeroderma pigmentosum group A (XPA) protein in strand-specific DNA repair.
Xeroderma pigmentosum complementation group C cells remove pyrimidine dimers selectively from the transcribed strand of active genes.